

COVID-19 Immunogenicity Analysis Report  
mock Study

USG COVID-19 Response Biostatistics Team

April 14, 2021



# Contents

<b>1</b>	<b>Tabular Description of Immunogenicity Data</b>	<b>15</b>
<b>2</b>	<b>Graphical Description of Immunogenicity Data</b>	<b>411</b>
2.1	Pairs plots of antibody markers for overall per-protocol cohort . . . . .	411
2.2	RCDF plots of antibody markers for overall per-protocol cohort . . . . .	428
2.3	Scatter plots of antibody markers versus age for overall per-protocol cohort . . . . .	444
2.4	Box plots of antibody markers for overall per-protocol cohort . . . . .	448
2.5	Spaghetti plots of antibody markers over time for the overall per-protocol cohort . . . . .	464
2.6	RCDF plots of antibody markers by demographics for per-protocol cohort . . . . .	466
2.7	Boxplots of antibody markers by demographics for per-protocol cohort . . . . .	538



# List of Tables

1.1	Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort . . . . .	15
1.2	Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort . . . . .	17
1.3	Table 3a. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by All participants . . . . .	18
1.4	Table 3b. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age . . . . .	20
1.5	Table 3c. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Risk for Severe Covid-19 . . . . .	24
1.6	Table 3d. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Risk for Severe Covid-19 . . . . .	28
1.7	Table 3e. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Sex . . . . .	37
1.8	Table 3f. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, sex . . . . .	41
1.9	Table 3g. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Hispanic or Latino ethnicity . . . . .	49
1.10	Table 3h. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Race . . . . .	56
1.11	Table 3i. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Underrepresented minority status . . . . .	74
1.12	Table 3j. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Underrepresented minority status . . . . .	79
1.13	Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants	90
1.14	Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age . . .	91
1.15	Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19 . . . . .	93
1.16	Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19 . . . . .	95

1.17 Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex . . . . .	98
1.18 Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex . . . . .	100
1.19 Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity . . . . .	103
1.20 Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race . . . . .	106
1.21 Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status . . . . .	112
1.22 Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status . . . . .	114
1.23 Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants . . . . .	118
1.24 Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age	122
1.25 Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19 . . . . .	130
1.26 Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19 . . . . .	138
1.27 Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex	154
1.28 Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex . . . . .	162
1.29 Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity . . . . .	178
1.30 Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race	190
1.31 Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status . . . . .	222
1.32 Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status . . . . .	230
1.33 Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants . . . . .	246
1.34 Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age . . . . .	249
1.35 Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19 . . . . .	255
1.36 Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19 . . . . .	261
1.37 Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex . . . . .	272
1.38 Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex . . . . .	278

1.39 Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity . . . . .	289
1.40 Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race . . . . .	298
1.41 Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status . .	322
1.42 Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status	328
1.43 Table 7a. The ratios of GMTs/GMCs between groups by Age . . . . .	342
1.44 Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19 . . . . .	346
1.45 Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19	350
1.46 Table 7d. The ratios of GMTs/GMCs between groups by Age >= 65, Risk for Severe Covid-19	356
1.47 Table 7e. The ratios of GMTs/GMCs between groups by Sex . . . . .	362
1.48 Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity . . . . .	366
1.49 Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status .	372
1.50 Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm . . . . .	378
1.51 Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2 . . . . .	380
1.52 Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age . . . . .	382
1.53 Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19 . . . . .	385
1.54 Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19 . . . . .	388
1.55 Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age >= 65, Risk for Severe Covid-19 . . . . .	392
1.56 Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex . . . . .	396
1.57 Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity . . . . .	399
1.58 Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status . . . . .	403
1.59 Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo) . . . . .	407
1.60 Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo) . . . . .	408
1.61 Table 11. Antibody levels in the per-protocol cohort (vaccine recipients) . . . . .	409
1.62 Table 12. Antibody levels in the per-protocol cohort (placebo recipients) . . . . .	410



# List of Figures

2.1	Pair plots of D29 Ab markers: baseline negative vaccine arm . . . . .	412
2.2	Pair plots of D57 Ab markers: baseline negative vaccine arm . . . . .	413
2.3	Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm . . . . .	414
2.4	Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm . . . . .	415
2.5	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm . .	416
2.6	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm . .	417
2.7	Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm	418
2.8	Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm	419
2.9	Pair plots of D29 Ab markers: baseline positive vaccine arm . . . . .	420
2.10	Pair plots of D57 Ab markers: baseline positive vaccine arm . . . . .	421
2.11	Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm . . . . .	422
2.12	Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm . . . . .	423
2.13	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm . .	424
2.14	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm . .	425
2.15	Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline positive vaccine arm	426
2.16	Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline positive vaccine arm	427
2.17	RCDF plots for D29 Ab markers: by baseline status x randomization arm . . . . .	428
2.18	RCDF plots for D57 Ab markers: by baseline status x randomization arm . . . . .	429
2.19	RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm .	430
2.20	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm .	431
2.21	RCDF plots for D29 Ab markers: by baseline status for the vaccine arm . . . . .	432
2.22	RCDF plots for D57 Ab markers: by baseline status for the vaccine arm . . . . .	433
2.23	RCDF plots for D29 over D1 fold-rise Ab markers: by baseline status for the vaccine arm .	434
2.24	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status for the vaccine arm .	435
2.25	RCDF plots for D29 Ab markers: baseline negative vaccine arm . . . . .	436
2.26	RCDF plots for D57 Ab markers: baseline negative vaccine arm . . . . .	437
2.27	RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm . . . . .	438
2.28	RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm . . . . .	439

2.29 RCDF plots for D29 Ab markers: baseline positive vaccine arm . . . . .	440
2.30 RCDF plots for D57 Ab markers: baseline positive vaccine arm . . . . .	441
2.31 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm . . . . .	442
2.32 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm . . . . .	443
2.33 Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm . . . . .	444
2.34 Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm . . . . .	445
2.35 Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm . . . . .	446
2.36 Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm . . . . .	447
2.37 Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms . . . . .	448
2.38 Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms . . . . .	449
2.39 Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms . . .	450
2.40 Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms . . .	451
2.41 Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms . . . . .	452
2.42 Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms . . . . .	453
2.43 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms . . .	454
2.44 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms . . .	455
2.45 Boxplots of D29 Ab markers: baseline positive + negative vaccine arm . . . . .	456
2.46 Boxplots of D57 Ab markers: baseline positive + negative vaccine arm . . . . .	457
2.47 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm . . .	458
2.48 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm . . .	459
2.49 Boxplots of D29 Ab markers: baseline positive + negative placebo arm . . . . .	460
2.50 Boxplots of D57 Ab markers: baseline positive + negative placebo arm . . . . .	461
2.51 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm . . .	462
2.52 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm . . .	463
2.53 Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm . . . . .	464
2.54 Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm . . . . .	465
2.55 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups. . . . .	466
2.56 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups. . . . .	467
2.57 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	468
2.58 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	469
2.59 RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition. . . .	470
2.60 RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition. . . .	471
2.61 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition. . . . .	472
2.62 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition. . . . .	473
2.63 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.	474

2.64 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.	475
2.65 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition. . . . .	476
2.66 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition. . . . .	477
2.67 RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth. . . . .	478
2.68 RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth. . . . .	479
2.69 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth. . . . .	480
2.70 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth. . . . .	481
2.71 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. . . . .	482
2.72 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. . . . .	483
2.73 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. . . . .	484
2.74 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth. . . . .	485
2.75 RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity. . . . .	486
2.76 RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity. . . . .	487
2.77 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity. .	488
2.78 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity. .	489
2.79 RCDF plots for D29 Ab markers: baseline negative vaccine arm by race. . . . .	490
2.80 RCDF plots for D57 Ab markers: baseline negative vaccine arm by race. . . . .	491
2.81 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. .	492
2.82 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. .	493
2.83 RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	494
2.84 RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	495
2.85 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	496
2.86 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	497
2.87 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	498
2.88 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	499
2.89 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	500

2.90 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	501
2.91 RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups. . . . .	502
2.92 RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups. . . . .	503
2.93 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups. . . . .	504
2.94 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups. . . . .	505
2.95 RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	506
2.96 RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	507
2.97 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	508
2.98 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	509
2.99 RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	510
2.100RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	511
2.101RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	512
2.102RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	513
2.103RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	514
2.104RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	515
2.105RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	516
2.106RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	517
2.107RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	518
2.108RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	519
2.109RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	520
2.110RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	521
2.111RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity. . . . .	522
2.112RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity. . . . .	523
2.113RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . . . .	524
2.114RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . . . .	525
2.115RCDF plots for D29 Ab markers: baseline positive vaccine arm by race. . . . .	526
2.116RCDF plots for D57 Ab markers: baseline positive vaccine arm by race. . . . .	527
2.117RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. . . . .	528
2.118RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. . . . .	529

2.119RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	530
2.120RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	531
2.121RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	532
2.122RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	533
2.123RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	534
2.124RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	535
2.125RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	536
2.126RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	537
2.127Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group. . . . .	538
2.128Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group. . . . .	539
2.129Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth. . . . .	540
2.130Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth. . . . .	541
2.131Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. . .	542
2.132Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. .	543
2.133Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . .	544
2.134Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . .	545
2.135Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	546
2.136Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	547
2.137Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	548
2.138Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	549
2.139Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. .	551
2.140Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. .	552
2.141Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	553
2.142Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	554
2.143Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	555

2.144Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	556
2.145Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	557
2.146Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	558
2.147Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	559
2.148Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	560
2.149Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	561
2.150Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	562
2.151Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. . . . .	563
2.152Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. . . . .	564
2.153Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	565
2.154Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	566
2.155Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	567
2.156Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	568

# Chapter 1

## Tabular Description of Immunogenicity Data

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Characteristics	Vaccine (N = 898)	Placebo (N = 159)	Total (N = 1057)
<b>Age</b>			
Age < 65	433 (48.2%)	75 (47.2%)	508 (48.1%)
Age ≥ 65	465 (51.8%)	84 (52.8%)	549 (51.9%)
Mean (Range)	58.5 (18.0, 85.0)	60.0 (18.0, 85.0)	58.7 (18.0, 85.0)
<b>BMI</b>			
Mean ± SD	29.8 ± 6.8	29.7 ± 7.1	29.8 ± 6.9
<b>Risk for Severe Covid-19</b>			
At-risk	457 (50.9%)	81 (50.9%)	538 (50.9%)
Not at-risk	441 (49.1%)	78 (49.1%)	519 (49.1%)
<b>Age, Risk for Severe Covid-19</b>			
Age < 65 At-risk	215 (23.9%)	37 (23.3%)	252 (23.8%)
Age < 65 Not at-risk	218 (24.3%)	38 (23.9%)	256 (24.2%)
Age ≥ 65	465 (51.8%)	84 (52.8%)	549 (51.9%)
<b>Sex</b>			
Female	485 (54.0%)	80 (50.3%)	565 (53.5%)
Male	413 (46.0%)	79 (49.7%)	492 (46.5%)
<b>Hispanic or Latino ethnicity</b>			
Hispanic or Latino	127 (14.1%)	23 (14.5%)	150 (14.2%)
Not Hispanic or Latino	704 (78.4%)	125 (78.6%)	829 (78.4%)
Not reported and unknown	67 (7.5%)	11 (6.9%)	78 (7.4%)
<b>Race</b>			
White Non-Hispanic	382 (42.5%)	67 (42.1%)	449 (42.5%)
Black or African American	171 (19.0%)	35 (22.0%)	206 (19.5%)
Asian	66 (7.3%)	5 (3.1%)	71 (6.7%)
American Indian or Alaska Native	18 (2.0%)	4 (2.5%)	22 (2.1%)
Native Hawaiian or Other Pacific Islander	14 (1.6%)	3 (1.9%)	17 (1.6%)
Multiracial	59 (6.6%)	12 (7.5%)	71 (6.7%)
Other	26 (2.9%)	4 (2.5%)	30 (2.8%)

(continued)

Characteristics	Vaccine (N = 898)	Placebo (N = 159)	Total (N = 1057)
Not reported and unknown	99 (11.0%)	19 (11.9%)	118 (11.2%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Characteristics	Vaccine (N = 282)	Placebo (N = 265)	Total (N = 547)
<b>Age</b>			
Age < 65	150 (53.2%)	146 (55.1%)	296 (54.1%)
Age ≥ 65	132 (46.8%)	119 (44.9%)	251 (45.9%)
Mean (Range)	56.6 (18.0, 85.0)	56.3 (18.0, 85.0)	56.5 (18.0, 85.0)
<b>BMI</b>			
Mean ± SD	30.2 ± 7.0	29.8 ± 6.7	30.0 ± 6.9
<b>Risk for Severe Covid-19</b>			
At-risk	131 (46.5%)	115 (43.4%)	246 (45.0%)
Not at-risk	151 (53.5%)	150 (56.6%)	301 (55.0%)
<b>Age, Risk for Severe Covid-19</b>			
Age < 65 At-risk	75 (26.6%)	72 (27.2%)	147 (26.9%)
Age < 65 Not at-risk	75 (26.6%)	74 (27.9%)	149 (27.2%)
Age ≥ 65	132 (46.8%)	119 (44.9%)	251 (45.9%)
<b>Sex</b>			
Female	161 (57.1%)	142 (53.6%)	303 (55.4%)
Male	121 (42.9%)	123 (46.4%)	244 (44.6%)
<b>Hispanic or Latino ethnicity</b>			
Hispanic or Latino	26 (9.2%)	28 (10.6%)	54 (9.9%)
Not Hispanic or Latino	236 (83.7%)	216 (81.5%)	452 (82.6%)
Not reported and unknown	20 (7.1%)	21 (7.9%)	41 (7.5%)
<b>Race</b>			
White Non-Hispanic	129 (45.7%)	115 (43.4%)	244 (44.6%)
Black or African American	53 (18.8%)	57 (21.5%)	110 (20.1%)
Asian	29 (10.3%)	24 (9.1%)	53 (9.7%)
American Indian or Alaska Native	6 (2.1%)	3 (1.1%)	9 (1.6%)
Native Hawaiian or Other Pacific Islander	2 (0.7%)	5 (1.9%)	7 (1.3%)
Multiracial	12 (4.3%)	13 (4.9%)	25 (4.6%)
Other	6 (2.1%)	4 (1.5%)	10 (1.8%)
Not reported and unknown	25 (8.9%)	21 (7.9%)	46 (8.4%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

Table 3a. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>All participants</b>								
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	898	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	898	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	898	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	159	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	159	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	159	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	265	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	265	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	265	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	898	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	898	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	898	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)	13258/13258 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)	1436/1436 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	159	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	159	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	159	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)	0/13373 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	265	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	265	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	265	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)	1286/1286 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3b. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Age</b>								
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	433	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	433	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	433	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	150	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	150	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	150	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	75	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	146	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	146	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	146	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	433	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	433	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	433	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)	10440/10440 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	150	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	150	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	150	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)	1154/1154 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	75	0/10226 = 0% (0.0%, 0.0%)	0/10226 = 0% (0.0%, 0.0%)	0/10226 = 0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0/10226 = 0% (0.0%, 0.0%)	0/10226 = 0% (0.0%, 0.0%)	0/10226 = 0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0/10226 = 0% (0.0%, 0.0%)	0/10226 = 0% (0.0%, 0.0%)	0/10226 = 0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	146	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	146	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	146	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)	1034/1034 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	465	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	465	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	465	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	132	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	84	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	84	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	84	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	119	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	119	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	119	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	465	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	465	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	465	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	132	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	84	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	84	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	84	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)	0/3147 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age $\geq$ 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	119	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)
Age $\geq$ 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	119	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)
Age $\geq$ 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	119	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)	252/252 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3c. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Risk for Severe Covid-19</b>								
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	457	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	457	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	457	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	131	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	131	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	131	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	81	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	115	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	115	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	115	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	457	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	457	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	457	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)	3724.3/3724.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	131	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	131	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	131	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	81	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	115	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	115	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)	316.9/316.9 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	441	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	441	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	441	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	151	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	78	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	150	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	150	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	150	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	441	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	441	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	441	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)	9533.7/9533.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	151	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)	1108.2/1108.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	78	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)	0/9233.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	150	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	150	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	150	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)	969.1/969.1 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3d. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Age, Risk for Severe Covid-19</b>								
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	215	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	215	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	215	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	75	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	72	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	72	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	72	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	215	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	215	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	215	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)	2260/2260 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	75	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	72	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	72	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	72	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)	223/223 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	218	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	75	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	38	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	74	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	74	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	74	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	218	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)	8180/8180 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	75	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)	947/947 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	38	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	74	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	74	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	74	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)	811/811 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	242	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	242	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	242	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	56	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	44	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	43	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	43	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	43	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	242	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	242	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	242	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	56	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	44	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	43	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	43	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	43	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	223	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	223	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	223	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	76	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	76	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	76	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	223	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	223	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	223	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	76	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)	0/1467.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	76	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	76	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	76	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)	158.1/158.1 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3e. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Sex</b>								
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	413	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	413	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	413	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	121	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	123	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	123	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	123	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	413	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	413	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	413	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)	5803/5803 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	121	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	123	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	123	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	123	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)	547.9/547.9 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	485	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	485	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	485	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	161	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	161	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	161	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	80	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	142	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	142	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	142	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	485	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	485	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	485	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)	7455/7455 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	161	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	161	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	161	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)	766.7/766.7 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	80	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)	0/6909.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	142	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	142	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	142	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)	738.1/738.1 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3f. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Age, sex</b>								
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	241	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	241	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	241	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	81	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	81	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	81	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	82	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	82	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	82	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	241	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	241	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	241	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)	5979/5979 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	81	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	81	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	81	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)	596.2/596.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	82	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	82	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	82	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)	614.3/614.3 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	192	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	69	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	192	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)	4461/4461 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	69	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/4845 = 0% (0.0%, 0.0%)	0/4845 = 0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/4845 = 0% (0.0%, 0.0%)	0/4845 = 0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/4845 = 0% (0.0%, 0.0%)	0/4845 = 0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)	419.7/419.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	221	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	43	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	43	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	43	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	59	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	59	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	59	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	221	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	52	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	43	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	43	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	43	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	59	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	59	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	59	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	244	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	244	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	244	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	80	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	80	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	80	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	41	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	244	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	244	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	244	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	80	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	80	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	80	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	41	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)	123.8/123.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3g. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Hispanic or Latino ethnicity</b>								
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	127	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	26	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	26	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	26	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	23	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	28	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	28	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	28	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	127	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	26	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	26	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	26	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	23	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	28	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	28	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	28	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	704	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	704	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	704	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	236	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	236	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	236	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	125	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	125	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	125	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	216	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	216	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	216	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	704	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	704	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	704	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)	10779.9/10779.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	236	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	236	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	236	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)	1206.6/1206.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	125	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	125	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	125	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)	0/11017.6 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	216	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	216	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	216	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)	1093.9/1093.9 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	67	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	20	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	11	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	21	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	21	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	21	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	67	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	20	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	11	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	21	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	21	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	21	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.



Table 3h. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Race</b>								
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	171	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	53	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	35	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	57	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	57	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	57	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	171	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	53	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	35	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	57	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	57	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	57	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)	211.1/211.1 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	66	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	66	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	66	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	29	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	5	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	24	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	24	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	24	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	66	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	66	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	66	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)	679.8/679.8 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	29	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	5	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	24	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	24	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	24	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)	80.9/80.9 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	18	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	18	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	18	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	3	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	3	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	3	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	18	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	18	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	18	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	3	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	3	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	3	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	14	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	14	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	14	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	2	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	3	0/222.5 = 0.0%	0/222.5 = 0.0%	0/222.5 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0/222.5 = 0.0%	0/222.5 = 0.0%	0/222.5 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0/222.5 = 0.0%	0/222.5 = 0.0%	0/222.5 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	5	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	5	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	5	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	14	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	14	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	14	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	3	0/222.5 = 0.0%	0/222.5 = 0.0%	0/222.5 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0/222.5 = 0.0%	0/222.5 = 0.0%	0/222.5 = 0.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0/222.5 = 0.0%	0/222.5 = 0.0%	0/222.5 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	5	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	5	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	5	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	59	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	12	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	12	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	13	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	13	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	13	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	59	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	12	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	12	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	13	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	13	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	13	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	26	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	26	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	26	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	4	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	4	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	4	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	26	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	26	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	26	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	4	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	99	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	99	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	99	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	25	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	19	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	21	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	21	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	21	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	99	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	99	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	99	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	25	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	19	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	21	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	21	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	21	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3i. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Underrepresented minority status</b>								
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	393	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	393	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	393	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	114	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	114	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	114	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	69	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	69	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	69	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	116	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	116	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	116	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	393	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	393	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	393	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)	4332/4332 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	114	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	114	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	114	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	69	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	69	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	69	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)	0/4351 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	116	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	116	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	116	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)	400/400 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)	6852/6852 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)	682.3/682.3 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	115	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)	662/662 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3j. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Age, Underrepresented minority status</b>								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	193	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	193	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	193	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	61	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	68	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	68	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	68	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	193	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	193	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	193	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)	3409/3409 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	61	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	68	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	68	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	68	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)	323/323 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	191	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	62	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	59	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	59	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	59	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	191	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)	5486.2/5486.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	62	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)	527.1/527.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	59	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	59	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	59	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)	524/524 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	200	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	200	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	200	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	53	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	48	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	48	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	48	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	200	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	200	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	200	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	53	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)	0/1006 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	48	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	48	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	48	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)	77/77 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	191	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	67	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	56	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	56	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	56	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	191	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	67	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	56	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	56	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	56	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>All participants</b>								
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	898	12154/13258 = 91.7% (88.6%, 94.0%)	12154/13258 = 91.7% (88.6%, 94.0%)	11364.3/13258 = 85.7% (82.1%, 88.7%)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	282	1359.8/1436 = 94.7% (89.2%, 97.5%)	1359.8/1436 = 94.7% (89.2%, 97.5%)	1242.8/1436 = 86.5% (79.5%, 91.4%)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	159	55.9/13373 = 0.4% (0.1%, 1.6%)	55.9/13373 = 0.4% (0.1%, 1.6%)	0/13373 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	265	990.9/1286 = 77.1% (69.3%, 83.3%)	998.8/1286 = 77.7% (70.0%, 83.9%)	858/1286 = 66.7% (58.6%, 73.9%)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	898	13151.9/13258 = 99.2% (97.7%, 99.7%)	13151.9/13258 = 99.2% (97.7%, 99.7%)	12970.6/13258 = 97.8% (96.1%, 98.8%)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	282	1422.1/1436 = 99.0% (93.4%, 99.9%)	1422.1/1436 = 99.0% (93.4%, 99.9%)	1422.1/1436 = 99.0% (93.4%, 99.9%)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	159	27.9/13373 = 0.2% (0.0%, 1.5%)	27.9/13373 = 0.2% (0.0%, 1.5%)	0/13373 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	265	1236/1286 = 96.1% (91.0%, 98.4%)	1236/1286 = 96.1% (91.0%, 98.4%)	1175.6/1286 = 91.4% (85.3%, 95.1%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Age</b>								
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	433	9433.1/10440 = 90.4% (86.5%, 93.2%)	9433.1/10440 = 90.4% (86.5%, 93.2%)	8772.9/10440 = 84.0% (79.5%, 87.7%)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	150	1080.1/1154 = 93.6% (86.7%, 97.0%)	1080.1/1154 = 93.6% (86.7%, 97.0%)	972.4/1154 = 84.3% (75.6%, 90.3%)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	75	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	146	760.7/1034 = 73.6% (64.1%, 81.3%)	768.6/1034 = 74.3% (64.9%, 82.0%)	638.4/1034 = 61.7% (51.9%, 70.7%)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	433	10333.9/10440 = 99.0% (97.1%, 99.6%)	10333.9/10440 = 99.0% (97.1%, 99.6%)	10197.6/10440 = 97.7% (95.4%, 98.8%)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	150	1140.1/1154 = 98.8% (91.8%, 99.8%)	1140.1/1154 = 98.8% (91.8%, 99.8%)	1140.1/1154 = 98.8% (91.8%, 99.8%)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	75	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)	0/10226 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	146	985.6/1034 = 95.3% (88.8%, 98.1%)	985.6/1034 = 95.3% (88.8%, 98.1%)	929.2/1034 = 89.9% (82.3%, 94.4%)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	465	2720.9/2818 = 96.6% (94.3%, 97.9%)	2720.9/2818 = 96.6% (94.3%, 97.9%)	2591.5/2818 = 92.0% (89.0%, 94.2%)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	132	279.7/282 = 99.2% (94.3%, 99.9%)	279.7/282 = 99.2% (94.3%, 99.9%)	270.4/282 = 95.9% (90.5%, 98.3%)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	84	55.9/3147 = 1.8% (0.4%, 6.9%)	55.9/3147 = 1.8% (0.4%, 6.9%)	0/3147 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	119	230.2/252 = 91.3% (85.1%, 95.1%)	230.2/252 = 91.3% (85.1%, 95.1%)	219.7/252 = 87.2% (80.4%, 91.9%)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	465	2818/2818 = 100.0% (100.0%, 100.0%)	2818/2818 = 100.0% (100.0%, 100.0%)	2773/2818 = 98.4% (96.6%, 99.2%)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	132	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)	282/282 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	84	27.9/3147 = 0.9% (0.1%, 6.2%)	27.9/3147 = 0.9% (0.1%, 6.2%)	0/3147 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age $\geq$ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	119	250.4/252 = 99.4% (95.5%, 99.9%)	250.4/252 = 99.4% (95.5%, 99.9%)	246.3/252 = 97.7% (93.0%, 99.3%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Risk for Severe Covid-19</b>								
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	457	3424/3724.3 = 91.9% (88.7%, 94.3%)	3424/3724.3 = 91.9% (88.7%, 94.3%)	3174.3/3724.3 = 85.2% (81.4%, 88.4%)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	131	314.7/327.8 = 96.0% (90.6%, 98.4%)	314.7/327.8 = 96.0% (90.6%, 98.4%)	297/327.8 = 90.6% (84.0%, 94.7%)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	81	27.9/4139.4 = 0.7% (0.1%, 4.8%)	27.9/4139.4 = 0.7% (0.1%, 4.8%)	0/4139.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115	267.1/316.9 = 84.3% (76.3%, 89.9%)	267.1/316.9 = 84.3% (76.3%, 89.9%)	227.6/316.9 = 71.8% (62.4%, 79.7%)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	457	3691.6/3724.3 = 99.1% (97.3%, 99.7%)	3691.6/3724.3 = 99.1% (97.3%, 99.7%)	3610.1/3724.3 = 96.9% (94.6%, 98.3%)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	131	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)	327.8/327.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	81	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)	0/4139.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	115	310.7/316.9 = 98.0% (91.8%, 99.6%)	310.7/316.9 = 98.0% (91.8%, 99.6%)	304.3/316.9 = 96.0% (90.3%, 98.4%)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	441	8730/9533.7 = 91.6% (87.3%, 94.5%)	8730/9533.7 = 91.6% (87.3%, 94.5%)	8190.1/9533.7 = 85.9% (81.0%, 89.7%)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	151	1045.1/1108.2 = 94.3% (86.8%, 97.7%)	1045.1/1108.2 = 94.3% (86.8%, 97.7%)	945.7/1108.2 = 85.3% (76.2%, 91.4%)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	78	27.9/9233.6 = 0.3% (0.0%, 2.2%)	27.9/9233.6 = 0.3% (0.0%, 2.2%)	0/9233.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	150	723.8/969.1 = 74.7% (64.6%, 82.7%)	731.7/969.1 = 75.5% (65.5%, 83.4%)	630.4/969.1 = 65.1% (54.7%, 74.2%)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	441	9460.2/9533.7 = 99.2% (96.8%, 99.8%)	9460.2/9533.7 = 99.2% (96.8%, 99.8%)	9360.5/9533.7 = 98.2% (95.5%, 99.3%)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	151	1094.4/1108.2 = 98.7% (91.4%, 99.8%)	1094.4/1108.2 = 98.7% (91.4%, 99.8%)	1094.4/1108.2 = 98.7% (91.4%, 99.8%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	78	27.9/9233.6 = 0.3% (0.0%, 2.2%)	27.9/9233.6 = 0.3% (0.0%, 2.2%)	0/9233.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	150	925.3/969.1 = 95.5% (88.5%, 98.3%)	925.3/969.1 = 95.5% (88.5%, 98.3%)	871.3/969.1 = 89.9% (81.8%, 94.6%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Age, Risk for Severe Covid-19</b>								
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	215	2035.4/2260 = 90.1% (85.1%, 93.5%)	2035.4/2260 = 90.1% (85.1%, 93.5%)	1863.4/2260 = 82.5% (76.6%, 87.1%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	75	196.3/207 = 94.8% (86.5%, 98.1%)	196.3/207 = 94.8% (86.5%, 98.1%)	185.6/207 = 89.6% (80.2%, 94.9%)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	72	178.8/223 = 80.2% (69.5%, 87.7%)	178.8/223 = 80.2% (69.5%, 87.7%)	143.4/223 = 64.3% (52.1%, 74.9%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	215	2227.4/2260 = 98.6% (95.5%, 99.5%)	2227.4/2260 = 98.6% (95.5%, 99.5%)	2190.8/2260 = 96.9% (93.3%, 98.6%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	75	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)	207/207 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)	0/2460 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	72	216.8/223 = 97.2% (88.4%, 99.4%)	216.8/223 = 97.2% (88.4%, 99.4%)	210.3/223 = 94.3% (86.3%, 97.8%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218	7397.7/8180 = 90.4% (85.5%, 93.8%)	7397.7/8180 = 90.4% (85.5%, 93.8%)	6909.4/8180 = 84.5% (78.7%, 88.9%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	75	883.9/947 = 93.3% (84.5%, 97.3%)	883.9/947 = 93.3% (84.5%, 97.3%)	786.8/947 = 83.1% (72.4%, 90.2%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	38	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	74	581.9/811 = 71.8% (59.8%, 81.3%)	589.8/811 = 72.7% (60.8%, 82.1%)	494.9/811 = 61.0% (48.8%, 72.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	218	8106.5/8180 = 99.1% (96.2%, 99.8%)	8106.5/8180 = 99.1% (96.2%, 99.8%)	8006.8/8180 = 97.9% (94.8%, 99.2%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	75	933.1/947 = 98.5% (89.9%, 99.8%)	933.1/947 = 98.5% (89.9%, 99.8%)	933.1/947 = 98.5% (89.9%, 99.8%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	38	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)	0/7766 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	74	768.9/811 = 94.8% (86.2%, 98.2%)	768.9/811 = 94.8% (86.2%, 98.2%)	718.9/811 = 88.6% (78.9%, 94.2%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	242	1388.6/1464.3 = 94.8% (91.0%, 97.1%)	1388.6/1464.3 = 94.8% (91.0%, 97.1%)	1310.8/1464.3 = 89.5% (84.8%, 92.9%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	56	118.4/120.8 = 98.1% (87.0%, 99.7%)	118.4/120.8 = 98.1% (87.0%, 99.7%)	111.5/120.8 = 92.3% (80.9%, 97.1%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	44	27.9/1679.4 = 1.7% (0.2%, 11.6%)	27.9/1679.4 = 1.7% (0.2%, 11.6%)	0/1679.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	43	88.3/93.9 = 94.0% (81.9%, 98.2%)	88.3/93.9 = 94.0% (81.9%, 98.2%)	84.2/93.9 = 89.6% (76.4%, 95.9%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	242	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1464.3/1464.3 = 100.0% (100.0%, 100.0%)	1419.3/1464.3 = 96.9% (93.6%, 98.6%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	56	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	44	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)	0/1679.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	43	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)	93.9/93.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	223	1332.3/1353.7 = 98.4% (95.2%, 99.5%)	1332.3/1353.7 = 98.4% (95.2%, 99.5%)	1280.6/1353.7 = 94.6% (90.6%, 97.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	76	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)	158.9/161.2 = 98.6% (90.2%, 99.8%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	27.9/1467.6 = 1.9% (0.2%, 13.2%)	27.9/1467.6 = 1.9% (0.2%, 13.2%)	0/1467.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	76	141.9/158.1 = 89.8% (81.1%, 94.7%)	141.9/158.1 = 89.8% (81.1%, 94.7%)	135.5/158.1 = 85.7% (76.6%, 91.7%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	223	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)	1353.7/1353.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	76	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)	161.2/161.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	27.9/1467.6 = 1.9% (0.2%, 13.2%)	27.9/1467.6 = 1.9% (0.2%, 13.2%)	0/1467.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	76	156.5/158.1 = 99.0% (92.9%, 99.9%)	156.5/158.1 = 99.0% (92.9%, 99.9%)	152.4/158.1 = 96.4% (89.0%, 98.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Sex</b>								
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	413	5405.8/5803 = 93.2% (88.8%, 95.9%)	5405.8/5803 = 93.2% (88.8%, 95.9%)	5139.3/5803 = 88.6% (83.5%, 92.2%)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	121	615.5/669.3 = 92.0% (81.4%, 96.8%)	615.5/669.3 = 92.0% (81.4%, 96.8%)	580.2/669.3 = 86.7% (75.2%, 93.3%)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	123	460.1/547.9 = 84.0% (73.7%, 90.8%)	460.1/547.9 = 84.0% (73.7%, 90.8%)	391.9/547.9 = 71.5% (59.5%, 81.1%)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	413	5778.6/5803 = 99.6% (98.3%, 99.9%)	5778.6/5803 = 99.6% (98.3%, 99.9%)	5716.7/5803 = 98.5% (96.7%, 99.3%)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	121	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)	669.3/669.3 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)	0/6463.1 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	123	530.6/547.9 = 96.8% (86.0%, 99.4%)	530.6/547.9 = 96.8% (86.0%, 99.4%)	511/547.9 = 93.3% (82.5%, 97.6%)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	485	6748.2/7455 = 90.5% (85.9%, 93.7%)	6748.2/7455 = 90.5% (85.9%, 93.7%)	6225.1/7455 = 83.5% (78.2%, 87.7%)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	161	744.3/766.7 = 97.1% (89.8%, 99.2%)	744.3/766.7 = 97.1% (89.8%, 99.2%)	662.6/766.7 = 86.4% (76.2%, 92.7%)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	80	55.9/6909.9 = 0.8% (0.2%, 3.2%)	55.9/6909.9 = 0.8% (0.2%, 3.2%)	0/6909.9 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	142	530.7/738.1 = 71.9% (60.6%, 81.0%)	538.6/738.1 = 73.0% (61.7%, 81.9%)	466.2/738.1 = 63.2% (51.9%, 73.1%)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	485	7373.3/7455 = 98.9% (96.0%, 99.7%)	7373.3/7455 = 98.9% (96.0%, 99.7%)	7254/7455 = 97.3% (94.2%, 98.8%)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	161	752.8/766.7 = 98.2% (88.0%, 99.8%)	752.8/766.7 = 98.2% (88.0%, 99.8%)	752.8/766.7 = 98.2% (88.0%, 99.8%)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	80	27.9/6909.9 = 0.4% (0.1%, 2.9%)	27.9/6909.9 = 0.4% (0.1%, 2.9%)	0/6909.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	142	705.4/738.1 = 95.6% (87.9%, 98.5%)	705.4/738.1 = 95.6% (87.9%, 98.5%)	664.6/738.1 = 90.0% (81.3%, 94.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Age, sex</b>								
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	241	5329/5979 = 89.1% (83.4%, 93.1%)	5329/5979 = 89.1% (83.4%, 93.1%)	4878.9/5979 = 81.6% (75.1%, 86.7%)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	81	573.8/596.2 = 96.2% (86.9%, 99.0%)	573.8/596.2 = 96.2% (86.9%, 99.0%)	501.4/596.2 = 84.1% (70.9%, 92.0%)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	82	418.3/614.3 = 68.1% (54.8%, 78.9%)	426.2/614.3 = 69.4% (56.1%, 80.0%)	360.1/614.3 = 58.6% (45.6%, 70.6%)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	241	5897.2/5979 = 98.6% (95.0%, 99.6%)	5897.2/5979 = 98.6% (95.0%, 99.6%)	5799.4/5979 = 97.0% (93.0%, 98.7%)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	81	582.3/596.2 = 97.7% (84.7%, 99.7%)	582.3/596.2 = 97.7% (84.7%, 99.7%)	582.3/596.2 = 97.7% (84.7%, 99.7%)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)	0/5381 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	82	583.2/614.3 = 94.9% (85.6%, 98.3%)	583.2/614.3 = 94.9% (85.6%, 98.3%)	546.4/614.3 = 89.0% (78.4%, 94.7%)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	192	4104.2/4461 = 92.0% (86.3%, 95.5%)	4104.2/4461 = 92.0% (86.3%, 95.5%)	3893.9/4461 = 87.3% (80.7%, 91.9%)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	69	506.3/557.8 = 90.8% (78.0%, 96.5%)	506.3/557.8 = 90.8% (78.0%, 96.5%)	471/557.8 = 84.4% (70.8%, 92.4%)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	342.4/419.7 = 81.6% (68.1%, 90.2%)	342.4/419.7 = 81.6% (68.1%, 90.2%)	278.2/419.7 = 66.3% (51.1%, 78.7%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	192	4436.6/4461 = 99.5% (97.8%, 99.9%)	4436.6/4461 = 99.5% (97.8%, 99.9%)	4398.2/4461 = 98.6% (96.0%, 99.5%)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	69	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)	557.8/557.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)	0/4845 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	402.4/419.7 = 95.9% (81.9%, 99.2%)	402.4/419.7 = 95.9% (81.9%, 99.2%)	382.8/419.7 = 91.2% (77.4%, 96.9%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	221	1301.6/1342 = 97.0% (93.4%, 98.7%)	1301.6/1342 = 97.0% (93.4%, 98.7%)	1245.3/1342 = 92.8% (88.4%, 95.6%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	52	109.2/111.5 = 97.9% (86.0%, 99.7%)	109.2/111.5 = 97.9% (86.0%, 99.7%)	109.2/111.5 = 97.9% (86.0%, 99.7%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	43	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	59	117.7/128.2 = 91.8% (82.5%, 96.4%)	117.7/128.2 = 91.8% (82.5%, 96.4%)	113.7/128.2 = 88.6% (78.3%, 94.4%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	221	1342/1342 = 100.0% (100.0%, 100.0%)	1342/1342 = 100.0% (100.0%, 100.0%)	1318.4/1342 = 98.2% (95.3%, 99.4%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	52	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)	111.5/111.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	43	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)	0/1618.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	59	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)	128.2/128.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	244	1419.3/1476 = 96.2% (92.7%, 98.0%)	1419.3/1476 = 96.2% (92.7%, 98.0%)	1346.1/1476 = 91.2% (86.8%, 94.3%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	80	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)	161.2/170.5 = 94.6% (86.2%, 98.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	41	55.9/1528.9 = 3.7% (0.9%, 14.0%)	55.9/1528.9 = 3.7% (0.9%, 14.0%)	0/1528.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age $\geq$ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	112.4/123.8 = 90.8% (80.4%, 96.0%)	112.4/123.8 = 90.8% (80.4%, 96.0%)	106/123.8 = 85.7% (74.8%, 92.3%)
Age $\geq$ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	244	1476/1476 = 100.0% (100.0%, 100.0%)	1476/1476 = 100.0% (100.0%, 100.0%)	1454.6/1476 = 98.5% (95.6%, 99.5%)
Age $\geq$ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	80	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)	170.5/170.5 = 100.0% (100.0%, 100.0%)
Age $\geq$ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	41	27.9/1528.9 = 1.8% (0.2%, 12.7%)	27.9/1528.9 = 1.8% (0.2%, 12.7%)	0/1528.9 = 0.0% (0.0%, 0.0%)
Age $\geq$ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	122.2/123.8 = 98.7% (91.0%, 99.8%)	122.2/123.8 = 98.7% (91.0%, 99.8%)	118.1/123.8 = 95.4% (86.1%, 98.6%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Hispanic or Latino ethnicity</b>								
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	127	1357.1/1505.7 = 90.1% (79.9%, 95.4%)	1357.1/1505.7 = 90.1% (79.9%, 95.4%)	1266/1505.7 = 84.1% (73.5%, 91.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	26	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	23	27.9/1613.4 = 1.7% (0.2%, 13.0%)	27.9/1613.4 = 1.7% (0.2%, 13.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	28	70.3/94.6 = 74.3% (47.3%, 90.3%)	70.3/94.6 = 74.3% (47.3%, 90.3%)	68.7/94.6 = 72.6% (46.2%, 89.1%)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	127	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)	1505.7/1505.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	26	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)	130.4/130.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	23	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)	0/1613.4 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	28	94.6/94.6 = 100.0% (100.0%, 100.0%)	94.6/94.6 = 100.0% (100.0%, 100.0%)	84.6/94.6 = 89.4% (58.8%, 98.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	704	9891.8/10779.9 = 91.8% (88.3%, 94.3%)	9891.8/10779.9 = 91.8% (88.3%, 94.3%)	9264.2/10779.9 = 85.9% (81.9%, 89.2%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	236	1130.4/1206.6 = 93.7% (87.2%, 97.0%)	1130.4/1206.6 = 93.7% (87.2%, 97.0%)	1027.2/1206.6 = 85.1% (77.1%, 90.7%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	125	27.9/11017.6 = 0.3% (0.0%, 1.8%)	27.9/11017.6 = 0.3% (0.0%, 1.8%)	0/11017.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	216	833/1093.9 = 76.2% (67.4%, 83.1%)	840.9/1093.9 = 76.9% (68.2%, 83.8%)	720.9/1093.9 = 65.9% (56.9%, 73.9%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	704	10673.7/10779.9 = 99.0% (97.2%, 99.7%)	10673.7/10779.9 = 99.0% (97.2%, 99.7%)	10492.5/10779.9 = 97.3% (95.2%, 98.5%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	236	1192.7/1206.6 = 98.9% (92.2%, 99.8%)	1192.7/1206.6 = 98.9% (92.2%, 99.8%)	1192.7/1206.6 = 98.9% (92.2%, 99.8%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	125	27.9/11017.6 = 0.3% (0.0%, 1.8%)	27.9/11017.6 = 0.3% (0.0%, 1.8%)	0/11017.6 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	216	1043.9/1093.9 = 95.4% (89.4%, 98.1%)	1043.9/1093.9 = 95.4% (89.4%, 98.1%)	995.6/1093.9 = 91.0% (84.0%, 95.1%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	67	905.1/972.5 = 93.1% (75.0%, 98.4%)	905.1/972.5 = 93.1% (75.0%, 98.4%)	834.1/972.5 = 85.8% (67.3%, 94.6%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	20	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	85.1/99 = 86.0% (39.6%, 98.3%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	11	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	21	87.5/97.5 = 89.7% (57.8%, 98.2%)	87.5/97.5 = 89.7% (57.8%, 98.2%)	68.4/97.5 = 70.2% (37.4%, 90.3%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	67	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)	972.5/972.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	20	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	11	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)	0/742 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	21	97.5/97.5 = 100.0% (100.0%, 100.0%)	97.5/97.5 = 100.0% (100.0%, 100.0%)	95.4/97.5 = 97.8% (82.9%, 99.8%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

MOCK

Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Race</b>								
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	382	6347/6852 = 92.6% (88.0%, 95.5%)	6347/6852 = 92.6% (88.0%, 95.5%)	6020.5/6852 = 87.9% (82.6%, 91.7%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	129	646/682.3 = 94.7% (85.1%, 98.2%)	646/682.3 = 94.7% (85.1%, 98.2%)	578.1/682.3 = 84.7% (73.1%, 91.9%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115	556.5/662 = 84.1% (72.1%, 91.5%)	556.5/662 = 84.1% (72.1%, 91.5%)	493.9/662 = 74.6% (62.3%, 83.9%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	382	6780.4/6852 = 99.0% (95.9%, 99.7%)	6780.4/6852 = 99.0% (95.9%, 99.7%)	6680.1/6852 = 97.5% (94.3%, 98.9%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	129	668.4/682.3 = 98.0% (86.6%, 99.7%)	668.4/682.3 = 98.0% (86.6%, 99.7%)	668.4/682.3 = 98.0% (86.6%, 99.7%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	115	631.5/662 = 95.4% (85.3%, 98.7%)	631.5/662 = 95.4% (85.3%, 98.7%)	618.3/662 = 93.4% (82.7%, 97.7%)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	171	1802.2/1879 = 95.9% (90.8%, 98.2%)	1802.2/1879 = 95.9% (90.8%, 98.2%)	1666.4/1879 = 88.7% (81.3%, 93.4%)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	53	196.3/220.1 = 89.2% (67.7%, 97.0%)	196.3/220.1 = 89.2% (67.7%, 97.0%)	194.1/220.1 = 88.2% (67.5%, 96.4%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	35	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	57	153.1/211.1 = 72.5% (55.2%, 85.0%)	161/211.1 = 76.2% (59.4%, 87.6%)	144/211.1 = 68.2% (51.3%, 81.4%)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	171	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)	1879/1879 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	53	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)	220.1/220.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	35	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)	0/2038.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	57	199.5/211.1 = 94.5% (79.4%, 98.7%)	199.5/211.1 = 94.5% (79.4%, 98.7%)	180.1/211.1 = 85.3% (68.2%, 94.0%)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	66	614.5/679.8 = 90.4% (73.5%, 97.0%)	614.5/679.8 = 90.4% (73.5%, 97.0%)	598/679.8 = 88.0% (72.1%, 95.4%)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	29	143.8/146 = 98.5% (88.7%, 99.8%)	143.8/146 = 98.5% (88.7%, 99.8%)	141.6/146 = 97.0% (87.6%, 99.3%)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5	27.9/392.7 = 7.1% (0.1%, 91.4%)	27.9/392.7 = 7.1% (0.1%, 91.4%)	0/392.7 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	24	52.3/80.9 = 64.7% (37.2%, 85.0%)	52.3/80.9 = 64.7% (37.2%, 85.0%)	38.6/80.9 = 47.7% (23.5%, 73.1%)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	66	671.5/679.8 = 98.8% (91.5%, 99.8%)	671.5/679.8 = 98.8% (91.5%, 99.8%)	636.1/679.8 = 93.6% (79.2%, 98.2%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	29	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)	146/146 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)	0/392.7 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	24	73/80.9 = 90.3% (51.3%, 98.8%)	73/80.9 = 90.3% (51.3%, 98.8%)	70.9/80.9 = 87.6% (53.7%, 97.7%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	18	157.9/166.2 = 95.0% (67.0%, 99.4%)	157.9/166.2 = 95.0% (67.0%, 99.4%)	123.4/166.2 = 74.3% (36.5%, 93.5%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)	0/111.8 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	3	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	18	140/166.2 = 84.2% (36.3%, 98.0%)	140/166.2 = 84.2% (36.3%, 98.0%)	140/166.2 = 84.2% (36.3%, 98.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)	11.9/11.9 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	27.9/111.8 = 25.0% (0.8%, 93.3%)	27.9/111.8 = 25.0% (0.8%, 93.3%)	0/111.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)	6.4/6.4 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	14	153.7/179.9 = 85.4% (35.9%, 98.4%)	153.7/179.9 = 85.4% (35.9%, 98.4%)	149.1/179.9 = 82.9% (37.8%, 97.5%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	2	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	3	0/222.5 = 0.0%	0/222.5 = 0.0%	0/222.5 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	5	5.3/15.3 = 34.8% (0.7%, 97.6%)	5.3/15.3 = 34.8% (0.7%, 97.6%)	3.2/15.3 = 20.9% (0.4%, 94.9%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	14	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)	179.9/179.9 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%	4.1/4.1 = 100.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	3	0/222.5 = 0.0%	0/222.5 = 0.0%	0/222.5 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	5	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)	15.3/15.3 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	59	511.9/629.6 = 81.3% (62.1%, 92.0%)	511.9/629.6 = 81.3% (62.1%, 92.0%)	459.9/629.6 = 73.0% (54.6%, 85.9%)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	12	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	12	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	13	29.6/41.8 = 70.9% (28.4%, 93.8%)	29.6/41.8 = 70.9% (28.4%, 93.8%)	29.6/41.8 = 70.9% (28.4%, 93.8%)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	59	629.6/629.6 = 100.0% (100.0%, 100.0%)	629.6/629.6 = 100.0% (100.0%, 100.0%)	603.4/629.6 = 95.8% (75.0%, 99.4%)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	12	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)	50.5/50.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	12	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)	0/751.3 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	13	41.8/41.8 = 100.0% (100.0%, 100.0%)	41.8/41.8 = 100.0% (100.0%, 100.0%)	39.6/41.8 = 94.9% (63.4%, 99.5%)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	26	310.1/336.3 = 92.2% (58.1%, 99.0%)	310.1/336.3 = 92.2% (58.1%, 99.0%)	279.3/336.3 = 83.0% (53.1%, 95.5%)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	4	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	26	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)	336.3/336.3 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)	29/29 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)	0/389.1 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)	7.5/7.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	99	1319.7/1517.4 = 87.0% (72.8%, 94.3%)	1319.7/1517.4 = 87.0% (72.8%, 94.3%)	1193.6/1517.4 = 78.7% (63.7%, 88.6%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	25	165.3/179.2 = 92.3% (57.8%, 99.0%)	165.3/179.2 = 92.3% (57.8%, 99.0%)	134.4/179.2 = 75.0% (45.6%, 91.5%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	19	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	21	78.2/154.8 = 50.5% (24.9%, 75.8%)	78.2/154.8 = 50.5% (24.9%, 75.8%)	47.7/154.8 = 30.8% (12.5%, 58.1%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	99	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1517.4/1517.4 = 100.0% (100.0%, 100.0%)	1498.1/1517.4 = 98.7% (94.6%, 99.7%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	25	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)	179.2/179.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	19	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)	0/1660 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	21	154.8/154.8 = 100.0% (100.0%, 100.0%)	154.8/154.8 = 100.0% (100.0%, 100.0%)	139.2/154.8 = 89.9% (56.8%, 98.4%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Underrepresented minority status</b>								
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	393	3985.2/4332 = 92.0% (87.3%, 95.0%)	3985.2/4332 = 92.0% (87.3%, 95.0%)	3702.6/4332 = 85.5% (80.2%, 89.6%)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	114	465/491 = 94.7% (84.0%, 98.4%)	465/491 = 94.7% (84.0%, 98.4%)	460.6/491 = 93.8% (83.7%, 97.8%)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	69	55.9/4351 = 1.3% (0.3%, 5.1%)	55.9/4351 = 1.3% (0.3%, 5.1%)	0/4351 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	116	287/400 = 71.7% (60.0%, 81.1%)	294.8/400 = 73.7% (62.2%, 82.7%)	260.4/400 = 65.1% (53.4%, 75.3%)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	393	4297.5/4332 = 99.2% (96.3%, 99.8%)	4297.5/4332 = 99.2% (96.3%, 99.8%)	4235.9/4332 = 97.8% (94.4%, 99.1%)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	114	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)	491/491 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	69	27.9/4351 = 0.6% (0.1%, 4.6%)	27.9/4351 = 0.6% (0.1%, 4.6%)	0/4351 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	116	380.5/400 = 95.1% (85.4%, 98.5%)	380.5/400 = 95.1% (85.4%, 98.5%)	348.9/400 = 87.2% (76.2%, 93.6%)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	382	6347/6852 = 92.6% (88.0%, 95.5%)	6347/6852 = 92.6% (88.0%, 95.5%)	6020.5/6852 = 87.9% (82.6%, 91.7%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	129	646/682.3 = 94.7% (85.1%, 98.2%)	646/682.3 = 94.7% (85.1%, 98.2%)	578.1/682.3 = 84.7% (73.1%, 91.9%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115	556.5/662 = 84.1% (72.1%, 91.5%)	556.5/662 = 84.1% (72.1%, 91.5%)	493.9/662 = 74.6% (62.3%, 83.9%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	382	6780.4/6852 = 99.0% (95.9%, 99.7%)	6780.4/6852 = 99.0% (95.9%, 99.7%)	6680.1/6852 = 97.5% (94.3%, 98.9%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	129	668.4/682.3 = 98.0% (86.6%, 99.7%)	668.4/682.3 = 98.0% (86.6%, 99.7%)	668.4/682.3 = 98.0% (86.6%, 99.7%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)	0/6912.6 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	115	631.5/662 = 95.4% (85.3%, 98.7%)	631.5/662 = 95.4% (85.3%, 98.7%)	618.3/662 = 93.4% (82.7%, 97.7%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Age, Underrepresented minority status</b>								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	193	3080.7/3409 = 90.4% (84.5%, 94.2%)	3080.7/3409 = 90.4% (84.5%, 94.2%)	2848.9/3409 = 83.6% (76.8%, 88.6%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	61	366/392 = 93.4% (80.0%, 98.0%)	366/392 = 93.4% (80.0%, 98.0%)	361.6/392 = 92.2% (79.7%, 97.3%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	68	224.4/323 = 69.5% (55.1%, 80.8%)	232.3/323 = 71.9% (57.8%, 82.7%)	205.9/323 = 63.7% (49.5%, 75.9%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	193	3374.5/3409 = 99.0% (95.2%, 99.8%)	3374.5/3409 = 99.0% (95.2%, 99.8%)	3322.1/3409 = 97.5% (93.0%, 99.1%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	61	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)	392/392 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)	0/3345 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	68	305.1/323 = 94.5% (82.1%, 98.5%)	305.1/323 = 94.5% (82.1%, 98.5%)	275.1/323 = 85.2% (71.6%, 92.9%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	191	5045.6/5486.2 = 92.0% (86.1%, 95.5%)	5045.6/5486.2 = 92.0% (86.1%, 95.5%)	4783.3/5486.2 = 87.2% (80.6%, 91.8%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	62	493.1/527.1 = 93.5% (80.8%, 98.0%)	493.1/527.1 = 93.5% (80.8%, 98.0%)	434.5/527.1 = 82.4% (67.4%, 91.4%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	59	423.4/524 = 80.8% (65.9%, 90.2%)	423.4/524 = 80.8% (65.9%, 90.2%)	363.3/524 = 69.3% (54.2%, 81.2%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	191	5414.6/5486.2 = 98.7% (94.9%, 99.7%)	5414.6/5486.2 = 98.7% (94.9%, 99.7%)	5342.9/5486.2 = 97.4% (93.2%, 99.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	62	513.2/527.1 = 97.4% (82.8%, 99.7%)	513.2/527.1 = 97.4% (82.8%, 99.7%)	513.2/527.1 = 97.4% (82.8%, 99.7%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)	0/5306.8 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	59	493.5/524 = 94.2% (81.5%, 98.3%)	493.5/524 = 94.2% (81.5%, 98.3%)	480.3/524 = 91.7% (78.3%, 97.1%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	200	904.5/923 = 98.0% (94.8%, 99.3%)	904.5/923 = 98.0% (94.8%, 99.3%)	853.8/923 = 92.5% (87.9%, 95.4%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	53	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	55.9/1006 = 5.6% (1.3%, 20.8%)	55.9/1006 = 5.6% (1.3%, 20.8%)	0/1006 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	48	62.6/77 = 81.2% (67.2%, 90.1%)	62.6/77 = 81.2% (67.2%, 90.1%)	54.5/77 = 70.8% (56.1%, 82.2%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	200	923/923 = 100.0% (100.0%, 100.0%)	923/923 = 100.0% (100.0%, 100.0%)	913.8/923 = 99.0% (96.0%, 99.8%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	53	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)	99/99 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	27.9/1006 = 2.8% (0.4%, 18.7%)	27.9/1006 = 2.8% (0.4%, 18.7%)	0/1006 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	48	75.4/77 = 97.9% (85.9%, 99.7%)	75.4/77 = 97.9% (85.9%, 99.7%)	73.8/77 = 95.8% (84.2%, 99.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	191	1301.5/1365.8 = 95.3% (91.2%, 97.5%)	1301.5/1365.8 = 95.3% (91.2%, 97.5%)	1237.1/1365.8 = 90.6% (85.5%, 94.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	67	152.9/155.2 = 98.5% (89.8%, 99.8%)	152.9/155.2 = 98.5% (89.8%, 99.8%)	143.6/155.2 = 92.5% (83.0%, 96.9%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	56	133.1/138 = 96.4% (86.4%, 99.1%)	133.1/138 = 96.4% (86.4%, 99.1%)	130.6/138 = 94.6% (84.3%, 98.3%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	191	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1365.8/1365.8 = 100.0% (100.0%, 100.0%)	1337.2/1365.8 = 97.9% (94.5%, 99.2%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	67	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)	155.2/155.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)	0/1605.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	56	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)	138/138 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>All participants</b>						
	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	898	10 (10, 10)
	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	898	10 (10, 10)
	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	898	10 (10, 10)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	898	5 (5, 5)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	898	5 (5, 5)
	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	282	10 (10, 10)
	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	282	10 (10, 10)
	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	282	10 (10, 10)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	282	5 (5, 5)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	282	5 (5, 5)
	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	159	10 (10, 10)
	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	159	10 (10, 10)
	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	159	10 (10, 10)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	159	5 (5, 5)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	159	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	265	10 (10, 10)
	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	265	10 (10, 10)
	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	265	10 (10, 10)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	265	5 (5, 5)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	265	5 (5, 5)
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	898	26107 (22373, 30465)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	898	24448 (21197, 28198)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	898	43768 (38849, 49310)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	898	114 (99, 132)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	898	202 (174, 235)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	282	34038 (26144, 44315)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	282	33791 (26156, 43654)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	282	68490 (55297, 84829)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	282	144 (111, 187)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	282	239 (186, 308)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	159	10 (10, 10)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	159	10 (10, 10)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	159	10 (10, 10)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	159	5 (5, 5)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	159	5 (5, 5)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	265	13376 (10324, 17330)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	265	13810 (10985, 17362)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	265	19842 (16261, 24211)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	265	53 (40, 70)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	265	115 (90, 147)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	898	406732 (334856, 494036)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	898	1175125 (1006818, 1371568)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	898	2327458 (2030732, 2667541)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	898	1149 (997, 1324)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	898	788 (721, 863)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	282	780035 (564199, 1078440)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	282	2375650 (1816163, 3107493)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	282	5020291 (4174972, 6036763)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	282	1779 (1424, 2224)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	282	968 (838, 1118)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	159	10 (10, 10)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	159	10 (10, 10)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	159	10 (10, 10)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	159	5 (5, 5)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	159	5 (5, 5)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	265	142567 (103139, 197068)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	265	395570 (298709, 523841)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	265	718182 (566932, 909785)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	265	501 (363, 691)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	265	606 (517, 712)

Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Age</b>						
Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	433	10 (10, 10)
Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	433	10 (10, 10)
Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	433	10 (10, 10)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	433	5 (5, 5)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	433	5 (5, 5)
Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	150	10 (10, 10)
Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	150	10 (10, 10)
Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	150	10 (10, 10)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	150	5 (5, 5)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	150	5 (5, 5)
Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	75	5 (5, 5)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	75	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	146	10 (10, 10)
Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	146	10 (10, 10)
Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	146	10 (10, 10)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	146	5 (5, 5)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	146	5 (5, 5)
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	433	20606 (17030, 24933)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	433	18690 (15666, 22298)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	433	32936 (28433, 38151)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	433	93 (77, 111)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	433	176 (146, 212)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	150	27208 (19791, 37404)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	150	25636 (18798, 34962)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	150	51114 (39492, 66155)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	150	119 (87, 163)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	150	212 (156, 289)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	75	5 (5, 5)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	75	5 (5, 5)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	146	10827 (7922, 14798)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	146	10904 (8271, 14375)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	146	15468 (12160, 19677)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	146	44 (31, 61)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	146	100 (74, 134)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	433	305133 (239829, 388219)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	433	895755 (739423, 1085138)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	433	1844841 (1557704, 2184906)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	433	993 (832, 1185)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	433	749 (669, 838)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	150	616032 (415812, 912661)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	150	1859839 (1339478, 2582350)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	150	4090288 (3266706, 5121508)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	150	1623 (1235, 2134)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	150	929 (778, 1111)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	75	10 (10, 10)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	75	5 (5, 5)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	75	5 (5, 5)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	146	112952 (76274, 167269)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	146	283611 (202119, 397958)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	146	527061 (396174, 701191)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	146	418 (282, 621)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	146	572 (471, 696)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	465	10 (10, 10)
Age $\geq$ 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	465	10 (10, 10)
Age $\geq$ 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	465	10 (10, 10)
Age $\geq$ 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	465	5 (5, 5)
Age $\geq$ 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	465	5 (5, 5)
Age $\geq$ 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	132	10 (10, 10)
Age $\geq$ 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	10 (10, 10)
Age $\geq$ 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	10 (10, 10)
Age $\geq$ 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	132	5 (5, 5)
Age $\geq$ 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	132	5 (5, 5)
Age $\geq$ 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)
Age $\geq$ 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)
Age $\geq$ 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 10)
Age $\geq$ 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)
Age $\geq$ 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	119	10 (10, 10)
Age $\geq$ 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	119	10 (10, 10)
Age $\geq$ 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	119	10 (10, 10)
Age $\geq$ 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	119	5 (5, 5)
Age $\geq$ 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	119	5 (5, 5)
Age $\geq$ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	465	62734 (53175, 74012)
Age $\geq$ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	465	66120 (57107, 76557)
Age $\geq$ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	465	125502 (110521, 142514)
Age $\geq$ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	465	247 (211, 290)
Age $\geq$ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	465	337 (297, 383)
Age $\geq$ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	132	85113 (62586, 115747)
Age $\geq$ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	104632 (80743, 135588)
Age $\geq$ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	226823 (181984, 282709)
Age $\geq$ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	132	319 (240, 424)
Age $\geq$ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	132	390 (314, 484)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 10)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	119	31844 (23632, 42911)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	119	36414 (28478, 46563)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	119	55117 (45541, 66708)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	119	116 (87, 155)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	119	209 (160, 273)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	465	1179594 (968207, 1437132)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	465	3212597 (2767271, 3729588)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	465	5505250 (4821760, 6285625)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	465	1977 (1746, 2239)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	465	954 (886, 1027)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	132	2049317 (1453877, 2888619)
Age ≥ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	6468629 (5183114, 8072975)
Age ≥ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	11609994 (9972859, 13515879)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	132	2591 (2154, 3117)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	132	1142 (1047, 1246)
Age ≥ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)
Age ≥ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)
Age ≥ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 10)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)
Age ≥ 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	119	370633 (263433, 521457)
Age ≥ 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	119	1549307 (1153510, 2080910)
Age ≥ 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	119	2556189 (2026611, 3224153)
Age ≥ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	119	1047 (795, 1380)
Age ≥ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	119	768 (648, 912)

Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Risk for Severe Covid-19</b>						
At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	457	10 (10, 10)
At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	457	10 (10, 10)
At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	457	10 (10, 10)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	457	5 (5, 5)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	457	5 (5, 5)
At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	131	10 (10, 10)
At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	131	10 (10, 10)
At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	131	10 (10, 10)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	131	5 (5, 5)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	131	5 (5, 5)
At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	81	5 (5, 5)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	81	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)
At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)
At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	457	28670 (24229, 33926)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	457	28540 (24712, 32962)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	457	53828 (47269, 61297)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	457	122 (104, 143)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	457	235 (205, 268)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	131	45549 (33622, 61708)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	131	50605 (38673, 66219)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	131	103708 (82198, 130847)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	131	187 (142, 247)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	131	313 (245, 401)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	81	5 (5, 5)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	81	5 (5, 5)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	115	16693 (11811, 23592)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	115	16432 (12204, 22126)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	115	25583 (19533, 33507)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115	62 (45, 86)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	115	143 (109, 190)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	457	445834 (360275, 551712)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	457	1319692 (1118561, 1556987)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	457	2575227 (2221001, 2985949)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	457	1124 (960, 1316)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	457	837 (767, 914)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	131	1225726 (870946, 1725027)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	131	3156401 (2463712, 4043844)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	131	6851214 (5608006, 8370022)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	131	2007 (1611, 2502)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	131	1048 (938, 1169)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	81	10 (10, 10)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	81	5 (5, 5)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	81	5 (5, 5)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115	182813 (120848, 276551)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	115	856287 (610469, 1201088)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	115	1028885 (775052, 1365850)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	115	734 (539, 1000)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	115	767 (652, 902)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	441	10 (10, 10)
Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	441	10 (10, 10)
Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	441	10 (10, 10)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	441	5 (5, 5)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	441	5 (5, 5)
Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	151	10 (10, 10)
Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	10 (10, 10)
Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	10 (10, 10)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5 (5, 5)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5 (5, 5)
Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	78	5 (5, 5)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	78	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	150	10 (10, 10)
Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	10 (10, 10)
Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	10 (10, 10)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	150	5 (5, 5)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	150	5 (5, 5)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	441	25170 (20506, 30894)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	441	23014 (19012, 27859)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	441	40370 (34441, 47319)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	441	112 (92, 136)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	441	191 (156, 233)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	151	31228 (22446, 43447)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	29987 (21717, 41406)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	60581 (46279, 79302)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	151	133 (96, 185)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	151	221 (160, 304)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	78	5 (5, 5)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	78	5 (5, 5)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	150	12441 (8987, 17222)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	150	13047 (9775, 17413)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	150	18259 (14224, 23440)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	150	50 (35, 72)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	150	107 (79, 146)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	441	392406 (303187, 507878)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	441	1123054 (914183, 1379646)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	441	2237277 (1866421, 2681821)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	441	1159 (961, 1399)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	441	770 (683, 868)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	151	682444 (454031, 1025766)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	2184166 (1553688, 3070489)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	4579234 (3631837, 5773768)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	151	1717 (1295, 2275)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	151	945 (786, 1136)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	78	10 (10, 10)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	78	5 (5, 5)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	78	5 (5, 5)
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	150	131432 (87374, 197705)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	150	307277 (215247, 438657)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	150	638515 (472586, 862703)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	150	442 (292, 670)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	150	562 (457, 690)

Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Age, Risk for Severe Covid-19</b>						
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	215	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	215	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	215	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	215	5 (5, 5)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	215	5 (5, 5)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	75	5 (5, 6)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	215	19005 (15082, 23949)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	215	18442 (15299, 22230)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	215	34807 (29395, 41215)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	215	86 (69, 107)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	215	188 (156, 226)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	75	33554 (23078, 48787)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	33530 (24358, 46155)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	70775 (53800, 93105)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	75	151 (106, 214)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	75	306 (221, 422)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	72	12678 (8175, 19661)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	72	12250 (8318, 18041)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	72	18062 (12699, 25690)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	72	47 (32, 71)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	72	112 (79, 159)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	215	276574 (207146, 369274)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	215	849331 (677493, 1064753)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	215	1804238 (1480129, 2199318)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	215	867 (693, 1086)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	215	790 (697, 896)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	75	985427 (642793, 1510699)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	2355679 (1716870, 3232175)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	5425974 (4187815, 7030203)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	75	1821 (1349, 2457)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	75	1016 (882, 1170)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	72	133545 (78788, 226358)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	72	616604 (402585, 944396)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	72	714436 (501642, 1017496)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	72	599 (405, 884)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	72	716 (580, 884)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	218	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5 (5, 5)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5 (5, 5)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	38	5 (5, 5)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	38	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	74	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	74	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	74	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	74	5 (5, 5)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	74	5 (5, 5)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	218	21072 (16663, 26647)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	18760 (15066, 23359)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	32437 (27047, 38900)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218	95 (76, 119)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	218	173 (138, 218)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	75	25989 (17790, 37968)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	24175 (16674, 35050)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	47604 (34972, 64799)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	75	113 (77, 164)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	75	196 (135, 284)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	38	5 (5, 5)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	38	5 (5, 5)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	74	10367 (7093, 15154)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	74	10560 (7547, 14775)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	74	14823 (11079, 19831)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	74	43 (28, 65)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	74	96 (67, 138)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	218	313531 (233014, 421869)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	909023 (717438, 1151769)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	1856219 (1506314, 2287404)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	218	1030 (829, 1280)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	218	738 (642, 848)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	75	555914 (347608, 889047)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	1766199 (1191219, 2618712)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	3845283 (2941570, 5026636)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	75	1583 (1142, 2195)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	75	912 (735, 1130)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	38	10 (10, 10)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	38	5 (5, 5)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	38	5 (5, 5)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	74	107869 (66810, 174161)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	74	229076 (151348, 346722)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	74	484772 (341439, 688275)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	74	379 (232, 619)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	74	538 (423, 685)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	242	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	242	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	242	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	242	5 (5, 5)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	242	5 (5, 5)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	56	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5 (5, 5)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5 (5, 5)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	43	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	43	10 (10, 10)
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	43	10 (10, 11)
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	43	5 (5, 5)
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	43	5 (5, 5)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	242	54078 (43102, 67850)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	242	55999 (45176, 69415)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	242	105500 (87212, 127621)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	242	208 (165, 261)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	242	331 (277, 396)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	56	76918 (46723, 126626)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	102480 (65733, 159772)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	199648 (136138, 292785)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	56	271 (174, 423)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	56	327 (224, 477)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 5)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	43	32071 (19673, 52283)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	43	33000 (23427, 46484)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	43	58456 (45049, 75852)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	43	119 (75, 189)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	43	257 (168, 394)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	242	931589 (691760, 1254563)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	242	2605444 (2083168, 3258661)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	242	4459763 (3608315, 5512125)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	242	1677 (1375, 2044)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	242	916 (820, 1023)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	56	1781777 (1017168, 3121147)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	5212369 (3582200, 7584388)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	10218944 (7605635, 13730191)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	56	2374 (1755, 3211)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	56	1105 (929, 1314)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 5)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	43	385267 (216300, 686226)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	43	1867122 (1162726, 2998251)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	43	2445717 (1675526, 3569942)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	43	1193 (762, 1868)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	43	901 (724, 1123)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	223	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	223	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	223	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	223	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	223	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	76	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	76	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	76	5 (5, 6)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	223	73663 (57986, 93579)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	223	79137 (65095, 96208)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	223	151428 (128696, 178176)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	223	299 (240, 371)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	223	344 (286, 413)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76	91816 (62470, 134950)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	106273 (78124, 144563)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	249569 (193516, 321857)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	76	360 (249, 520)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	76	444 (346, 570)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	76	31710 (21750, 46230)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	76	38609 (27620, 53970)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	76	53225 (40976, 69134)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	76	114 (79, 165)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	76	185 (132, 260)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	223	1522680 (1184331, 1957692)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	223	4029556 (3333554, 4870873)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	223	6913673 (5962965, 8015958)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	223	2363 (2052, 2722)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	223	996 (905, 1097)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	76	2275652 (1483459, 3490888)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	7603908 (5849216, 9884986)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	12774313 (11071512, 14739004)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	76	2767 (2202, 3477)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	76	1171 (1082, 1268)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	76	362201 (237645, 552041)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	76	1386685 (951612, 2020673)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	76	2624193 (1957915, 3517205)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	76	969 (683, 1375)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	76	699 (551, 886)

Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Sex</b>						
Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	413	10 (10, 10)
Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	413	10 (10, 10)
Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	413	10 (10, 10)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	413	5 (5, 5)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	413	5 (5, 5)
Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)
Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)
Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)
Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 10)
Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 10)
Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)
Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)
Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	413	27918 (22184, 35135)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	413	25464 (20474, 31672)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	413	47856 (39690, 57703)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	413	127 (102, 159)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	413	226 (183, 279)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	121	31634 (20063, 49877)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	35411 (22182, 56530)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	71516 (48882, 104632)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	121	132 (87, 201)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	121	220 (144, 335)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 10)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 10)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	123	13885 (9964, 19349)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	123	15684 (11249, 21868)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	123	19051 (14268, 25437)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	123	53 (38, 75)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	123	116 (85, 158)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	413	413245 (313550, 544639)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	413	1349730 (1058654, 1720836)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	413	2494356 (2024007, 3074009)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	413	1309 (1073, 1597)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	413	802 (702, 915)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	121	651471 (371844, 1141378)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	2214099 (1404894, 3489396)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	4657377 (3318602, 6536236)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	121	1845 (1334, 2553)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	121	911 (750, 1106)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 10)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 10)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	123	119308 (74464, 191160)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	123	406550 (258451, 639512)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	123	726888 (523093, 1010081)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	123	604 (387, 942)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	123	566 (446, 718)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	485	10 (10, 10)
Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	485	10 (10, 10)
Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	485	10 (10, 10)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	485	5 (5, 5)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	485	5 (5, 5)
Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	161	10 (10, 10)
Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	161	10 (10, 10)
Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	161	10 (10, 10)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	161	5 (5, 5)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	161	5 (5, 5)
Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 10)
Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 10)
Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	142	10 (10, 10)
Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	142	10 (10, 10)
Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	142	10 (10, 10)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	142	5 (5, 6)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	142	5 (5, 5)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	485	24780 (20095, 30555)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	485	23686 (19548, 28699)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	485	40829 (34866, 47811)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	485	105 (86, 128)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	485	186 (151, 228)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	161	36285 (26900, 48946)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	161	32437 (24984, 42114)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	161	65952 (51863, 83868)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	161	155 (112, 215)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	161	257 (191, 347)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 10)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 10)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	142	13010 (8886, 19048)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	142	12565 (9151, 17253)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	142	20450 (15506, 26971)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	142	53 (35, 80)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	142	115 (81, 163)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	485	401733 (305536, 528218)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	485	1055004 (863808, 1288519)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	485	2205314 (1838733, 2644980)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	485	1039 (851, 1267)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	485	778 (688, 880)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	161	912839 (634733, 1312797)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	161	2526281 (1844631, 3459821)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	161	5360132 (4442120, 6467860)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	161	1723 (1269, 2339)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	161	1021 (828, 1258)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 10)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 10)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	142	162718 (105337, 251358)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	142	387612 (266416, 563942)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	142	711788 (506763, 999761)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	142	436 (277, 686)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	142	639 (515, 792)

Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Age, sex</b>						
Age < 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	241	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	241	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	241	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	241	5 (5, 5)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	241	5 (5, 5)
Age < 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	81	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	81	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	81	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	81	5 (5, 5)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	81	5 (5, 5)
Age < 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	82	10 (10, 11)
Age < 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	82	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	82	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	82	5 (5, 6)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	82	5 (5, 5)
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	241	19834 (15401, 25543)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	241	18407 (14604, 23199)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	241	31037 (25718, 37457)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	241	85 (67, 108)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	241	161 (126, 206)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	81	27333 (19128, 39059)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	81	22259 (16475, 30072)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	81	46690 (35359, 61651)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	81	121 (81, 181)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	81	222 (153, 322)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	82	11120 (7096, 17425)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	82	10726 (7393, 15562)
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	82	17474 (12620, 24195)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	82	47 (29, 76)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	82	107 (71, 162)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	241	305770 (219380, 426179)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	241	796114 (625781, 1012809)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	241	1771866 (1422780, 2206602)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	241	906 (710, 1156)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	241	745 (641, 866)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	81	667054 (429471, 1036066)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	81	1871163 (1270557, 2755680)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	81	4261855 (3403042, 5337402)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	81	1556 (1059, 2286)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	81	973 (744, 1272)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	82	142811 (85604, 238248)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	82	305266 (197484, 471873)
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	82	556437 (374252, 827308)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	82	374 (219, 639)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	82	631 (490, 813)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	192	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	10 (10, 11)
Age < 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	192	5 (5, 5)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	192	5 (5, 5)
Age < 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	69	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	69	5 (5, 5)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	69	5 (5, 5)
Age < 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	64	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	64	5 (5, 5)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	64	5 (5, 5)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	192	21688 (16243, 28956)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	19078 (14529, 25051)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	35663 (28265, 44999)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	192	104 (79, 137)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	192	199 (152, 261)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	69	27075 (15829, 46310)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	29814 (17154, 51819)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	56307 (36089, 87850)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	69	116 (71, 189)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	69	203 (123, 334)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	10413 (6996, 15497)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	11169 (7430, 16790)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	12940 (9174, 18253)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	40 (26, 61)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	64	90 (61, 131)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	192	304281 (215298, 430041)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	1049134 (771985, 1425783)
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	1947384 (1495326, 2536105)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	192	1122 (871, 1445)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	192	754 (637, 894)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	69	565805 (291605, 1097839)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	1847812 (1079096, 3164140)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	3914541 (2623647, 5840586)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	69	1698 (1155, 2497)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	69	885 (704, 1114)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	80130 (44941, 142872)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	254653 (147354, 440085)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	486838 (329835, 718574)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	493 (280, 868)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	64	496 (368, 670)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	221	10 (10, 10)
Age ≥ 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	10 (10, 10)
Age ≥ 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	10 (10, 10)
Age ≥ 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	221	5 (5, 5)
Age ≥ 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	221	5 (5, 5)
Age ≥ 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)
Age ≥ 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)
Age ≥ 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)
Age ≥ 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 5)
Age ≥ 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)
Age ≥ 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	43	5 (5, 5)
Age ≥ 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	43	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)
Age $\geq$ 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)
Age $\geq$ 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)
Age $\geq$ 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)
Age $\geq$ 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)
Age $\geq$ 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	221	64637 (51094, 81771)
Age $\geq$ 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	66495 (54144, 81664)
Age $\geq$ 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	127197 (105499, 153358)
Age $\geq$ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	221	250 (200, 313)
Age $\geq$ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	221	345 (289, 413)
Age $\geq$ 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52	68915 (44735, 106166)
Age $\geq$ 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	83753 (56539, 124066)
Age $\geq$ 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	236583 (175079, 319694)
Age $\geq$ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	52	255 (165, 393)
Age $\geq$ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	52	331 (233, 472)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	43	5 (5, 5)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	43	5 (5, 5)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	59	35615 (22588, 56154)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	59	47657 (33321, 68161)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	59	67572 (51300, 89006)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	59	135 (91, 200)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	59	267 (185, 384)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	221	1143138 (866738, 1507680)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	3118628 (2488678, 3908036)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	5679764 (4750568, 6790707)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	221	2182 (1845, 2581)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	221	983 (895, 1079)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	52	1318988 (777995, 2236169)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	5472151 (3897399, 7683185)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	11109618 (8990099, 13728838)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	52	2798 (2160, 3624)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	52	1049 (861, 1278)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	43	10 (10, 10)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	43	5 (5, 5)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	43	5 (5, 5)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	59	439116 (273334, 705448)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	59	1880068 (1236170, 2859362)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	59	2699776 (1942829, 3751637)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	59	1168 (815, 1675)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	59	867 (695, 1080)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	244	10 (10, 10)
Age ≥ 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	244	10 (10, 10)
Age ≥ 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	244	10 (10, 10)
Age ≥ 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	244	5 (5, 5)
Age ≥ 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	244	5 (5, 5)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	80	10 (10, 10)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	80	10 (10, 10)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	80	10 (10, 10)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	80	5 (5, 5)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	80	5 (5, 5)
Age ≥ 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	41	5 (5, 5)
Age ≥ 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	41	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)
Age $\geq$ 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)
Age $\geq$ 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)
Age $\geq$ 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 6)
Age $\geq$ 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)
Age $\geq$ 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	244	61053 (48405, 77006)
Age $\geq$ 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	244	65781 (53405, 81026)
Age $\geq$ 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	244	123981 (104275, 147411)
Age $\geq$ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	244	245 (196, 307)
Age $\geq$ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	244	330 (275, 396)
Age $\geq$ 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	80	97709 (64219, 148663)
Age $\geq$ 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	80	121022 (86222, 169868)
Age $\geq$ 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	80	220660 (162489, 299656)
Age $\geq$ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	80	369 (254, 537)
Age $\geq$ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	80	433 (330, 569)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	41	5 (5, 5)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	41	5 (5, 5)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	28359 (19328, 41611)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	27558 (19975, 38019)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	44632 (34775, 57284)
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	100 (66, 152)
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	60	162 (111, 238)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	244	1213747 (916908, 1606684)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	244	3300488 (2708865, 4021322)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	244	5351243 (4407656, 6496833)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	244	1808 (1509, 2166)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	244	928 (829, 1038)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	80	2733558 (1760658, 4244061)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	80	7216299 (5400352, 9642884)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	80	11949268 (9684950, 14742979)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	80	2465 (1913, 3176)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	80	1208 (1135, 1285)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	41	10 (10, 10)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	41	5 (5, 5)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	41	5 (5, 5)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	310943 (190680, 507056)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	1267945 (838600, 1917106)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	2415521 (1741353, 3350694)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	935 (615, 1423)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	60	678 (524, 878)

Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Hispanic or Latino ethnicity</b>						
Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	127	10 (10, 11)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	127	5 (5, 5)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	127	5 (5, 6)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	26	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	26	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	26	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	26	5 (5, 5)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	26	5 (5, 5)
Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	23	5 (5, 5)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	23	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	28	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	28	5 (5, 5)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	28	5 (5, 5)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	127	24842 (17659, 34948)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	26916 (19291, 37557)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	47660 (36353, 62485)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	127	122 (84, 177)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	127	218 (154, 310)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	26	38184 (28133, 51824)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	26	43441 (16695, 113035)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	26	96930 (42595, 220574)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	26	114 (76, 169)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	26	241 (116, 497)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	23	5 (5, 5)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	23	5 (5, 5)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	28	9262 (3384, 25347)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	28	11518 (5977, 22195)
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	28	23768 (13230, 42701)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	28	51 (21, 123)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	28	170 (81, 354)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	127	426086 (277325, 654644)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	1437790 (1007780, 2051282)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	2142978 (1595637, 2878069)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	127	1228 (918, 1642)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	127	814 (674, 982)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	26	513694 (174929, 1508508)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	26	2840421 (1452662, 5553936)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	26	3551466 (1744682, 7229345)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	26	2889 (2174, 3839)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	26	1146 (1010, 1300)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	23	10 (10, 10)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	23	5 (5, 5)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	23	5 (5, 5)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	28	96806 (22163, 422848)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	28	423379 (153088, 1170893)
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	28	1028368 (385239, 2745154)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	28	435 (162, 1169)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	28	882 (700, 1110)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	704	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	704	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	704	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	704	5 (5, 5)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	704	5 (5, 5)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	236	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	236	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	236	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	236	5 (5, 5)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	236	5 (5, 5)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	125	5 (5, 5)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	125	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	216	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	216	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	216	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	216	5 (5, 5)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	216	5 (5, 5)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	704	25133 (21020, 30051)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	704	23223 (19715, 27356)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	704	42894 (37567, 48975)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	704	109 (93, 129)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	704	197 (167, 233)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	236	32689 (24048, 44436)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	236	32493 (24434, 43211)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	236	65428 (51624, 82923)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	236	148 (110, 198)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	236	248 (189, 325)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	125	5 (5, 5)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	125	5 (5, 5)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	216	13538 (10248, 17884)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	216	13974 (10813, 18059)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	216	19368 (15646, 23976)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	216	53 (39, 72)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	216	113 (87, 147)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	704	402096 (321228, 503320)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	704	1106904 (926650, 1322221)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	704	2352728 (2014696, 2747477)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	704	1087 (923, 1281)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	704	784 (708, 869)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	236	796506 (555972, 1141105)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	236	2326321 (1720759, 3144990)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	236	5141985 (4186895, 6314945)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	236	1699 (1322, 2183)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	236	981 (846, 1138)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	125	10 (10, 10)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	125	5 (5, 5)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	125	5 (5, 5)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	216	154261 (109458, 217402)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	216	403108 (300454, 540835)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	216	694970 (544427, 887140)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	216	477 (334, 683)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	216	595 (503, 703)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	20	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	20	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	20	5 (5, 6)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	11	5 (5, 5)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	11	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	21	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	21	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	21	10 (10, 11)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	21	5 (5, 6)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	21	5 (5, 5)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	67	42975 (26488, 69724)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	37243 (22676, 61168)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	47974 (26288, 87547)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	67	169 (96, 296)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	67	241 (131, 441)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	20	47881 (22603, 101431)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	39110 (22154, 69044)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	75669 (48184, 118833)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	20	146 (53, 402)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	20	152 (43, 537)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	11	5 (5, 5)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	11	5 (5, 5)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	21	16686 (6170, 45127)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	21	14429 (7374, 28235)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	21	21831 (8311, 57345)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	21	55 (23, 134)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	21	94 (33, 272)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	67	429775 (218216, 846438)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	1668633 (983415, 2831294)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	2346512 (1317804, 4178254)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	67	1922 (1233, 2996)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	67	799 (561, 1138)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	20	1048443 (367799, 2988680)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	2424361 (881948, 6664257)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	5915923 (4260178, 8215184)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	20	1651 (726, 3752)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	20	653 (244, 1745)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	11	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	11	5 (5, 5)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	11	5 (5, 5)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	21	85718 (29151, 252050)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	21	299657 (69957, 1283571)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	21	732832 (220527, 2435272)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	21	983 (401, 2408)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	21	526 (206, 1346)

Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Race</b>						
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	382	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	382	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	382	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	129	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	129	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	129	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	382	26779 (21016, 34123)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	24073 (19243, 30116)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	44837 (37733, 53280)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	382	116 (93, 145)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	382	204 (165, 253)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	129	32140 (21350, 48383)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	29603 (19188, 45670)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	64812 (45432, 92458)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	129	142 (96, 209)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	129	236 (164, 340)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	115	16332 (11301, 23603)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	115	14167 (10126, 19819)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	115	21729 (16518, 28584)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115	69 (46, 102)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	115	121 (85, 172)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	382	375305 (279792, 503424)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	1145512 (909652, 1442528)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	2459185 (2019406, 2994737)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	382	1125 (908, 1394)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	382	804 (714, 904)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	129	758610 (476254, 1208367)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	2229169 (1492057, 3330433)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	5100285 (3772135, 6896069)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	129	1594 (1095, 2320)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	129	932 (742, 1172)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115	169965 (105036, 275030)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	115	470592 (326087, 679136)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	115	837482 (614121, 1142080)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	115	437 (268, 713)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	115	739 (608, 898)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	171	10 (10, 10)
Black or African American	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	10 (10, 10)
Black or African American	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	10 (10, 10)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5 (5, 5)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5 (5, 5)
Black or African American	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	53	10 (10, 10)
Black or African American	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	10 (10, 10)
Black or African American	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	10 (10, 10)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	53	5 (5, 5)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	53	5 (5, 5)
Black or African American	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	57	10 (10, 10)
Black or African American	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	10 (10, 10)
Black or African American	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	10 (10, 10)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	57	5 (5, 6)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	57	5 (5, 5)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	171	29887 (22491, 39714)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	30003 (23297, 38639)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	47425 (37241, 60394)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	171	125 (95, 165)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	171	212 (154, 292)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	53	28851 (14520, 57328)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	36205 (21532, 60877)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	73221 (43288, 123852)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	53	129 (73, 228)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	53	215 (116, 399)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	57	11556 (7261, 18392)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	57	12089 (7715, 18943)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	57	19929 (13075, 30376)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	57	47 (27, 80)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	57	91 (54, 154)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	171	605088 (404884, 904288)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	1327188 (981725, 1794217)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	2410575 (1854720, 3133019)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	171	1247 (951, 1636)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	171	813 (689, 959)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	53	545488 (232954, 1277322)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	2182049 (1172039, 4062441)
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	4430744 (2966452, 6617834)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	53	1259 (717, 2209)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	53	891 (629, 1262)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	57	149099 (76074, 292224)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	57	372359 (185291, 748289)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	57	582225 (358855, 944635)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	57	511 (258, 1013)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	57	512 (340, 769)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	66	10 (10, 10)
Asian	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	66	10 (10, 10)
Asian	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	66	10 (10, 10)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	66	5 (5, 5)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	66	5 (5, 5)
Asian	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	29	10 (10, 10)
Asian	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	10 (10, 10)
Asian	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	10 (10, 10)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5 (5, 6)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5 (5, 5)
Asian	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)
Asian	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)
Asian	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	24	10 (10, 10)
Asian	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)
Asian	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	24	5 (5, 5)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	24	5 (5, 5)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	66	19609 (11547, 33299)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	66	25939 (16489, 40804)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	66	35919 (23896, 53992)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	66	96 (64, 146)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	66	202 (120, 340)
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	29	51114 (24326, 107397)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	40914 (21831, 76676)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	71143 (36178, 139901)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	29	251 (114, 555)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	29	237 (104, 536)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 6)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 6)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	24	6825 (3397, 13714)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	24	8181 (5043, 13272)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	24	15922 (8805, 28791)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	24	22 (11, 43)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	24	88 (39, 202)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	66	348306 (189672, 639615)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	66	906098 (490331, 1674406)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	66	1904953 (1082862, 3351163)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	66	983 (558, 1731)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	66	703 (521, 949)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	29	949883 (328789, 2744248)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	2924658 (1201092, 7121543)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	4636716 (2431319, 8842582)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	29	1913 (1251, 2927)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	29	1057 (885, 1263)
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 5)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	24	74137 (26567, 206880)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	24	197988 (98969, 396074)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	24	562342 (266894, 1184845)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	24	509 (158, 1647)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	24	277 (105, 730)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	18	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	18	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	18	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	18	5 (5, 5)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	18	5 (5, 5)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	6	12 (9, 15)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	6	6 (4, 7)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5 (5, 5)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	3	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	3	5 (5, 5)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	3	5 (5, 5)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	18	15017 (6900, 32685)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	18	11461 (4194, 31321)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	18	35638 (16000, 79381)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	18	55 (26, 113)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	18	149 (59, 380)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	234912 (74447, 741250)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	59199 (23886, 146717)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	142598 (50067, 406140)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	879 (253, 3055)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	6	874 (560, 1363)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	3	19985 (10696, 37340)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	3	10498 (5244, 21016)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	3	10397 (4869, 22198)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	3	108 (45, 256)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	3	300 (91, 997)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	18	167822 (51580, 546035)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	18	725992 (238768, 2207433)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	18	1930089 (855159, 4356201)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	18	435 (99, 1909)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	18	1218 (1127, 1315)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	3024823 (954940, 9581286)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	5105303 (2288167, 11390827)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	11621610 (6182061, 21847379)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	4404 (4404, 4404)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	6	1295 (1295, 1295)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	6 (4, 9)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	3	453454 (76267, 2696067)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	3	1243423 (96936, 15949666)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	3	1110197 (235572, 5232112)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3	281 (112, 704)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	3	1295 (1295, 1295)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	14	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	14	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	14	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	14	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	14	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	2	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	3	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	3	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	5	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	14	16151 (3597, 72529)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	14	39447 (17797, 87434)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	14	31462 (15511, 63816)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	14	89 (27, 289)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	14	322 (94, 1101)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	2	41841 (38644, 45303)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	22851 (2930, 178210)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	67369 (47260, 96035)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	2	214 (113, 407)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	2	1291 (1286, 1297)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	3	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	3	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	5	3103 (361, 26675)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	5	4638 (1418, 15175)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	5	14696 (6832, 31614)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	5	15 (3, 73)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	5	199 (114, 348)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	14	537536 (139491, 2071422)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	14	1848200 (433763, 7874901)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	14	2455977 (1127424, 5350092)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	14	1822 (931, 3566)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	14	1196 (1019, 1404)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2	414088 (162591, 1054602)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	5063269 (4385220, 5846160)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	11487555 (9576687, 13779706)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2	4404 (4404, 4404)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	2	1295 (1295, 1295)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	3	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	3	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	3	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	5	17543 (578, 532206)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	5	324963 (66924, 1577928)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	5	286089 (71349, 1147130)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	5	131 (43, 401)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	5	578 (316, 1057)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	59	10 (10, 10)
Multiracial	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	10 (10, 10)
Multiracial	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	10 (10, 10)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5 (5, 5)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5 (5, 6)
Multiracial	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	12	5 (5, 5)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	12	5 (5, 5)
Multiracial	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	13	10 (10, 10)
Multiracial	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	13	10 (10, 10)
Multiracial	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	13	10 (10, 10)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	13	5 (5, 5)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	13	5 (5, 5)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	59	15198 (8260, 27960)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	16641 (9544, 29015)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	43425 (26153, 72103)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	59	68 (39, 117)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	59	149 (81, 275)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	12	50664 (30305, 84701)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	28036 (4957, 158572)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	122110 (36471, 408837)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	12	145 (39, 540)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	12	192 (47, 780)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	13	5623 (1979, 15976)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	13	9440 (5319, 16754)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	13	15766 (6864, 36212)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	13	38 (14, 102)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	13	79 (43, 143)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	59	249009 (120236, 515698)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	1103628 (728193, 1672627)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	1620804 (995033, 2640118)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	59	967 (539, 1733)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	59	733 (519, 1034)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	12	866223 (92469, 8114517)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	2920073 (656502, 12988282)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	3281996 (831214, 12958755)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	12	2353 (1492, 3710)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	12	1240 (1172, 1312)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	13	74259 (13319, 414020)
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	13	397735 (151284, 1045671)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	13	341262 (111838, 1041330)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	13	208 (82, 528)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	13	274 (101, 741)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	26	10 (10, 10)
Other	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	26	10 (10, 10)
Other	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	26	10 (10, 10)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	26	5 (5, 5)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	26	6 (5, 8)
Other	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	6	10 (10, 10)
Other	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)
Other	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5 (5, 5)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5 (5, 5)
Other	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	4	5 (5, 5)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	4	5 (5, 5)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	26	21227 (12992, 34682)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	26	26084 (14192, 47941)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	26	43385 (25561, 73636)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	26	102 (49, 212)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	26	224 (95, 525)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	18265 (11735, 28429)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	76411 (30604, 190779)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	94179 (19948, 444638)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	121 (70, 207)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	6	267 (164, 434)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	4	27046 (16817, 43496)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	4	38412 (15313, 96357)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	4	85151 (41858, 173219)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	4	92 (33, 256)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	4	373 (162, 859)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	26	437326 (219049, 873111)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	26	1787226 (794365, 4021042)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	26	1649029 (961272, 2828854)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	26	1346 (762, 2377)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	26	957 (753, 1217)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	450093 (71561, 2830942)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	4732568 (2892045, 7744417)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	3835573 (2151501, 6837838)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	3294 (2436, 4456)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	6	1283 (1259, 1308)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	4	291515 (127370, 667200)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4	1355588 (417733, 4399029)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4	2753608 (989549, 7662441)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4	1318 (558, 3115)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	4	1039 (727, 1487)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	99	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	99	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	99	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	99	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	99	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	25	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5 (5, 5)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	19	5 (5, 5)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	19	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	21	11 (9, 12)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	21	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	21	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	21	6 (5, 7)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	21	5 (5, 6)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	99	25782 (15886, 41843)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	99	20590 (13148, 32244)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	99	39264 (26120, 59023)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	99	109 (67, 179)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	99	190 (117, 308)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	25	28552 (12054, 67631)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	33128 (16908, 64908)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	55809 (35428, 87915)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	25	105 (44, 251)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	25	369 (203, 672)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	19	5 (5, 5)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	19	5 (5, 5)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	21	8693 (3509, 21535)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	21	16964 (6980, 41227)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	21	14447 (7065, 29545)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	21	26 (9, 73)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	21	99 (48, 204)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	99	499821 (257189, 971351)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	99	1040782 (613558, 1765484)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	99	2590506 (1518126, 4420399)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	99	1144 (732, 1788)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	99	660 (428, 1017)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	25	1115210 (426106, 2918747)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	2328826 (1007293, 5384162)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	6182149 (4479678, 8531632)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	25	3035 (2203, 4181)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	25	1257 (1193, 1326)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	19	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	19	5 (5, 5)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	19	5 (5, 5)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	21	90079 (42759, 189764)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	21	207303 (76442, 562184)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	21	389421 (174424, 869424)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	21	689 (292, 1626)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	21	449 (302, 669)

Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Underrepresented minority status</b>						
Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	393	10 (10, 10)
Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	393	10 (10, 10)
Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	393	10 (10, 10)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	393	5 (5, 5)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	393	5 (5, 5)
Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	114	10 (10, 10)
Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	114	10 (10, 10)
Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	114	10 (10, 10)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	114	5 (5, 5)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	114	5 (5, 5)
Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	69	5 (5, 5)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	69	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	116	10 (10, 10)
Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	10 (10, 10)
Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	10 (10, 10)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	116	5 (5, 5)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	116	5 (5, 5)
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	393	23741 (19430, 29008)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	393	25576 (21309, 30698)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	393	43313 (36931, 50799)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	393	109 (89, 132)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	393	205 (165, 254)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	114	38342 (25744, 57105)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	114	40819 (28224, 59034)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	114	80359 (56437, 114420)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	114	170 (115, 252)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	114	236 (158, 353)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	69	5 (5, 5)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	69	5 (5, 5)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	116	10301 (7085, 14976)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	116	11593 (8642, 15552)
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	116	19791 (14900, 26287)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	116	42 (28, 62)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	116	110 (76, 159)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	393	440291 (337736, 573987)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	393	1235548 (995643, 1533259)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	393	2151402 (1801329, 2569508)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	393	1127 (922, 1377)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	393	814 (730, 908)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	114	707066 (402854, 1241003)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	114	2687527 (1765786, 4090419)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	114	4469619 (3275038, 6099925)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	114	1780 (1303, 2432)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	114	1012 (853, 1201)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	69	10 (10, 10)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	69	5 (5, 5)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	69	5 (5, 5)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	116	130463 (75585, 225185)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	116	388216 (247326, 609362)
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	116	656306 (447692, 962131)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	116	462 (282, 759)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	116	469 (335, 655)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	382	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	382	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	382	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	129	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	129	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	129	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	382	26779 (21016, 34123)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	24073 (19243, 30116)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	44837 (37733, 53280)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	382	116 (93, 145)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	382	204 (165, 253)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	129	32140 (21350, 48383)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	29603 (19188, 45670)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	64812 (45432, 92458)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	129	142 (96, 209)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	129	236 (164, 340)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	115	16332 (11301, 23603)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	115	14167 (10126, 19819)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	115	21729 (16518, 28584)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115	69 (46, 102)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	115	121 (85, 172)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	382	375305 (279792, 503424)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	1145512 (909652, 1442528)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	2459185 (2019406, 2994737)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	382	1125 (908, 1394)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	382	804 (714, 904)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	129	758610 (476254, 1208367)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	2229169 (1492057, 3330433)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	5100285 (3772135, 6896069)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	129	1594 (1095, 2320)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	129	932 (742, 1172)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115	169965 (105036, 275030)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	115	470592 (326087, 679136)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	115	837482 (614121, 1142080)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	115	437 (268, 713)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	115	739 (608, 898)

Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Age, Underrepresented minority status</b>						
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	193	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	193	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	193	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	193	5 (5, 5)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	193	5 (5, 5)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5 (5, 5)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	33	5 (5, 5)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	33	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	68	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	68	5 (5, 6)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	68	5 (5, 5)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	193	18617 (14581, 23771)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	193	19144 (15306, 23945)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	193	32027 (26367, 38903)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	193	86 (68, 110)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	193	179 (137, 234)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	61	30511 (18786, 49554)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	32209 (20542, 50504)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	61990 (40202, 95587)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	61	138 (86, 223)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	61	191 (116, 314)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	5 (5, 5)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	33	5 (5, 5)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	68	8750 (5610, 13649)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	68	9662 (6824, 13679)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	68	15502 (11053, 21741)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	68	39 (24, 62)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	68	101 (65, 158)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	193	338558 (243991, 469779)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	193	975160 (746375, 1274073)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	193	1676896 (1346960, 2087650)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	193	967 (754, 1242)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	193	776 (677, 889)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	61	512544 (256668, 1023507)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	2022149 (1205369, 3392395)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	3386971 (2310611, 4964736)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	61	1594 (1089, 2335)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	61	971 (785, 1201)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	10 (10, 10)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	5 (5, 5)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	33	5 (5, 5)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	68	112207 (57984, 217134)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	68	315796 (183352, 543909)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	68	495020 (312350, 784519)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	68	411 (225, 752)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	68	421 (280, 632)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	191	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	191	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	191	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	62	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	191	22210 (16522, 29856)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	19788 (15053, 26012)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	35886 (29131, 44208)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	191	100 (77, 132)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	191	185 (142, 241)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	62	25250 (15195, 41961)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	21183 (12320, 36424)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	45051 (29098, 69752)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	62	120 (74, 194)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	62	225 (142, 357)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	59	13087 (8369, 20465)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	59	10524 (7017, 15784)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	59	17209 (12342, 23995)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	59	55 (34, 89)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	59	102 (66, 158)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	191	296623 (207363, 424307)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	896327 (677101, 1186533)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	2068381 (1627522, 2628658)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	191	989 (760, 1287)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	191	775 (671, 895)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	62	606489 (339687, 1082845)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	1718791 (1036442, 2850370)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	4182125 (2860869, 6113586)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	62	1411 (874, 2278)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	62	891 (665, 1193)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	59	133554 (73958, 241173)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	59	325144 (210030, 503351)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	59	624130 (429465, 907033)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	59	351 (191, 643)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	59	739 (582, 937)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	200	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	200	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	200	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	200	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	200	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	53	10 (10, 11)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	53	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	53	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	48	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	48	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	48	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	200	58267 (45099, 75279)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	200	74553 (60301, 92174)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	200	132080 (108900, 160195)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	200	251 (199, 318)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	200	337 (283, 402)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	53	94738 (62290, 144087)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	104287 (72325, 150372)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	224552 (169253, 297919)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	53	388 (264, 573)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	53	551 (433, 701)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 6)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	48	20422 (12113, 34429)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	48	24899 (16577, 37400)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	48	55140 (40420, 75222)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	48	60 (36, 98)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	48	154 (99, 238)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	200	1161925 (875280, 1542444)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	200	2961289 (2382047, 3681384)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	200	5400113 (4473076, 6519276)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	200	1981 (1657, 2368)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	200	974 (882, 1074)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	53	2527735 (1605310, 3980191)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	8289342 (6234637, 11021202)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	13404146 (11368351, 15804504)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	53	2753 (1996, 3797)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	53	1194 (1084, 1315)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	48	245538 (136315, 442276)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	48	923015 (566896, 1502845)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	48	2142419 (1491534, 3077342)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	48	756 (483, 1183)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	48	737 (545, 995)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	191	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	191	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	191	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	67	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	67	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	67	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	56	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	56	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	56	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	191	56778 (44514, 72421)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	52907 (42543, 65796)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	109676 (90572, 132809)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	191	212 (166, 270)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	191	303 (248, 371)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	67	72925 (46287, 114895)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	92241 (63197, 134634)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	222873 (158277, 313832)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	67	253 (168, 383)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	67	281 (201, 392)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	56	37858 (24699, 58028)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	56	43776 (31011, 61795)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	56	52667 (39799, 69696)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	56	161 (111, 233)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	56	227 (160, 322)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	191	965639 (711968, 1309692)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	3068441 (2422082, 3887287)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	4928264 (3996777, 6076842)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	191	1888 (1555, 2293)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	191	931 (828, 1047)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	67	1622232 (969809, 2713563)
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	5390612 (3895457, 7459637)
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	10007727 (7816870, 12812623)
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	67	2410 (1869, 3108)
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	67	1089 (942, 1259)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	56	424439 (260765, 690846)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	56	1915041 (1278118, 2869362)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	56	2557032 (1861144, 3513115)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	56	1007 (691, 1468)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	56	739 (577, 946)

Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>All participants</b>								
	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	898	10 (10, 10)	26107 (22373, 30465)	2604.61 (2232.12, 3039.25)
	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	898	10 (10, 10)	24448 (21197, 28198)	2425.62 (2102.70, 2798.13)
	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	898	10 (10, 10)	43768 (38849, 49310)	4371.57 (3880.37, 4924.94)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	898	5 (5, 5)	114 (99, 132)	22.69 (19.58, 26.29)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	898	5 (5, 5)	202 (174, 235)	39.84 (34.38, 46.17)
	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	282	10 (10, 10)	34038 (26144, 44315)	3394.14 (2607.33, 4418.39)
	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	282	10 (10, 10)	33791 (26156, 43654)	3379.09 (2615.61, 4365.42)
	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	282	10 (10, 10)	68490 (55297, 84829)	6848.96 (5529.73, 8482.93)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	282	5 (5, 5)	144 (111, 187)	28.39 (21.91, 36.78)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	282	5 (5, 5)	239 (186, 308)	47.49 (36.89, 61.14)
	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	159	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	159	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	159	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	159	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.01)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	159	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	265	10 (10, 10)	13376 (10324, 17330)	1326.82 (1023.51, 1720.02)
	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	265	10 (10, 10)	13810 (10985, 17362)	1381.00 (1098.48, 1736.19)
	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	265	10 (10, 10)	19842 (16261, 24211)	1981.10 (1623.72, 2417.13)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	265	5 (5, 5)	53 (40, 70)	10.30 (7.80, 13.61)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	265	5 (5, 5)	115 (90, 147)	22.68 (17.77, 28.94)
	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	898	10 (10, 10)	406732 (334856, 494036)	40577.51 (33409.67, 49283.16)
	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	898	10 (10, 10)	1175125 (1006818, 1371568)	116588.61 (9918.58, 136039.80)
	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	898	10 (10, 10)	2327458 (2030732, 2667541)	232468.69 (202838.93, 266426.62)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	898	5 (5, 5)	1149 (997, 1324)	228.13 (197.96, 262.89)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	898	5 (5, 5)	788 (721, 863)	155.32 (141.92, 169.99)
	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	282	10 (10, 10)	780035 (564199, 1078440)	77782.72 (56256.85, 107545.14)
	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	282	10 (10, 10)	2375650 (1816163, 3107493)	237565.03 (181616.34, 310749.27)
	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	282	10 (10, 10)	5020291 (4174972, 6036763)	502029.06 (417497.18, 603676.34)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	282	5 (5, 5)	1779 (1424, 2224)	350.57 (280.67, 437.88)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	282	5 (5, 5)	968 (838, 1118)	192.23 (166.37, 222.10)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	159	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	159	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	159	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	159	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.01)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	159	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)
	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	265	10 (10, 10)	142567 (103139, 197068)	14142.02 (10217.26, 19574.41)
	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	265	10 (10, 10)	395570 (298709, 523841)	39557.03 (29870.89, 52384.06)
	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	265	10 (10, 10)	718182 (566932, 909785)	71707.12 (56611.20, 90828.50)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	265	5 (5, 5)	501 (363, 691)	97.09 (70.67, 133.38)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	265	5 (5, 5)	606 (517, 712)	119.41 (101.42, 140.61)

Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Age</b>								
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	433	10 (10, 10)	20606 (17030, 24933)	2054.45 (1697.95, 2485.79)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	433	10 (10, 10)	18690 (15666, 22298)	1850.41 (1550.69, 2208.05)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	433	10 (10, 10)	32936 (28433, 38151)	3288.58 (2839.17, 3809.13)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	433	5 (5, 5)	93 (77, 111)	18.45 (15.39, 22.13)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	433	5 (5, 5)	176 (146, 212)	34.68 (28.85, 41.68)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	150	10 (10, 10)	27208 (19791, 37404)	2715.24 (1975.21, 3732.51)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	150	10 (10, 10)	25636 (18798, 34962)	2563.59 (1879.77, 3496.17)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	150	10 (10, 10)	51114 (39492, 66155)	5111.38 (3949.24, 6615.52)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	150	5 (5, 5)	119 (87, 163)	23.38 (17.08, 31.99)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	150	5 (5, 5)	212 (156, 289)	42.08 (30.88, 57.34)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	75	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	75	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	75	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	75	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	75	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	146	10 (10, 10)	10827 (7922, 14798)	1071.88 (783.71, 1466.02)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	146	10 (10, 10)	10904 (8271, 14375)	1090.36 (827.07, 1437.48)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	146	10 (10, 10)	15468 (12160, 19677)	1546.82 (1215.97, 1967.70)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	146	5 (5, 5)	44 (31, 61)	8.50 (6.07, 11.92)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	146	5 (5, 5)	100 (74, 134)	19.58 (14.57, 26.31)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	433	10 (10, 10)	305133 (239829, 388219)	30422.17 (23913.93, 38701.65)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	433	10 (10, 10)	895755 (739423, 1085138)	88682.07 (73232.27, 107391.30)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	433	10 (10, 10)	1844841 (1557704, 2184906)	184205.14 (155542.51, 218149.59)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	433	5 (5, 5)	993 (832, 1185)	197.39 (165.40, 235.58)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	433	5 (5, 5)	749 (669, 838)	147.42 (131.69, 165.03)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	150	10 (10, 10)	616032 (415812, 912661)	61477.47 (41491.19, 91091.12)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	150	10 (10, 10)	1859839 (1339478, 2582350)	185983.94 (133947.85, 258235.01)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	150	10 (10, 10)	4090288 (3266706, 5121508)	409028.82 (326670.57, 512150.75)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	150	5 (5, 5)	1623 (1235, 2134)	319.73 (243.40, 419.99)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	150	5 (5, 5)	929 (778, 1111)	184.29 (154.18, 220.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	75	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	75	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	75	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	75	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	75	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.01)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	146	10 (10, 10)	112952 (76274, 167269)	11182.36 (7538.47, 16587.62)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	146	10 (10, 10)	283611 (202119, 397958)	28361.06 (20211.91, 39795.83)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	146	10 (10, 10)	527061 (396174, 701191)	52706.14 (39617.39, 70119.14)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	146	5 (5, 5)	418 (282, 621)	81.00 (54.92, 119.45)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	146	5 (5, 5)	572 (471, 696)	112.53 (92.26, 137.27)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	465	10 (10, 10)	62734 (53175, 74012)	6273.44 (5317.53, 7401.20)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	465	10 (10, 10)	66120 (57107, 76557)	6612.02 (5710.66, 7655.65)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	465	10 (10, 10)	125502 (110521, 142514)	12550.22 (11052.11, 14251.41)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	465	5 (5, 5)	247 (211, 290)	48.78 (41.62, 57.16)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	465	5 (5, 5)	337 (297, 383)	66.64 (58.65, 75.73)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	132	10 (10, 10)	85113 (62586, 115747)	8459.74 (6228.57, 11490.17)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	10 (10, 10)	104632 (80743, 135588)	10463.20 (8074.33, 13558.84)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	10 (10, 10)	226823 (181984, 282709)	22682.28 (18198.44, 28270.87)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	132	5 (5, 5)	319 (240, 424)	62.85 (47.30, 83.50)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	132	5 (5, 5)	390 (314, 484)	77.91 (62.76, 96.72)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.04)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)	5 (5, 5)	0.97 (0.92, 1.03)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	119	10 (10, 10)	31844 (23632, 42911)	3184.42 (2363.16, 4291.11)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	119	10 (10, 10)	36414 (28478, 46563)	3641.45 (2847.79, 4656.28)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	119	10 (10, 10)	55117 (45541, 66708)	5468.36 (4524.21, 6609.54)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	119	5 (5, 5)	116 (87, 155)	22.67 (17.14, 30.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	119	5 (5, 5)	209 (160, 273)	41.46 (31.77, 54.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	465	10 (10, 10)	1179594 (968207, 1437132)	117959.37 (96820.68, 143713.23)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	465	10 (10, 10)	3212597 (2767271, 3729588)	321259.71 (276727.11, 372958.78)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	465	10 (10, 10)	5505250 (4821760, 6285625)	550525.02 (482176.04, 628562.55)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	465	5 (5, 5)	1977 (1746, 2239)	389.94 (344.37, 441.54)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	465	5 (5, 5)	954 (886, 1027)	188.47 (174.94, 203.04)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	132	10 (10, 10)	2049317 (1453877, 2888619)	203690.81 (144618.06, 286893.27)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	10 (10, 10)	6468629 (5183114, 8072975)	646862.85 (518311.45, 807297.53)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	10 (10, 10)	11609994 (9972859, 13515879)	1160999.37 (997285.90, 1351587.88)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	132	5 (5, 5)	2591 (2154, 3117)	511.03 (424.86, 614.67)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	132	5 (5, 5)	1142 (1047, 1246)	228.45 (209.35, 249.29)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)	5 (5, 5)	0.96 (0.91, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	119	10 (10, 10)	370633 (263433, 521457)	37063.34 (26343.34, 52145.69)
Age $\geq$ 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	119	10 (10, 10)	1549307 (1153510, 2080910)	154930.66 (115350.99, 208091.05)
Age $\geq$ 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	119	10 (10, 10)	2556189 (2026611, 3224153)	253606.80 (201474.57, 319228.42)
Age $\geq$ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	119	5 (5, 5)	1047 (795, 1380)	204.24 (155.36, 268.51)
Age $\geq$ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	119	5 (5, 5)	768 (648, 912)	152.33 (128.42, 180.70)

Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Risk for Severe Covid-19</b>								
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	457	10 (10, 10)	28670 (24229, 33926)	2867.03 (2422.87, 3392.61)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	457	10 (10, 10)	28540 (24712, 32962)	2854.02 (2471.19, 3296.16)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	457	10 (10, 10)	53828 (47269, 61297)	5360.01 (4708.67, 6101.46)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	457	5 (5, 5)	122 (104, 143)	23.96 (20.38, 28.18)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	457	5 (5, 5)	235 (205, 268)	46.36 (40.56, 52.99)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	131	10 (10, 10)	45549 (33622, 61708)	4498.73 (3326.90, 6083.31)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	131	10 (10, 10)	50605 (38673, 66219)	5060.50 (3867.29, 6621.86)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	131	10 (10, 10)	103708 (82198, 130847)	10370.78 (8219.78, 13084.68)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	131	5 (5, 5)	187 (142, 247)	36.37 (27.60, 47.91)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	131	5 (5, 5)	313 (245, 401)	60.80 (47.55, 77.74)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	81	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	81	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	81	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)	16693 (11811, 23592)	1669.25 (1181.06, 2359.23)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)	16432 (12204, 22126)	1643.24 (1220.40, 2212.59)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)	25583 (19533, 33507)	2542.26 (1942.84, 3326.63)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)	62 (45, 86)	12.34 (9.03, 16.84)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)	143 (109, 190)	28.03 (21.18, 37.10)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	457	10 (10, 10)	445834 (360275, 551712)	44583.39 (36027.50, 55171.16)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	457	10 (10, 10)	1319692 (1118561, 1556987)	131969.16 (111856.14, 155698.73)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	457	10 (10, 10)	2575227 (2221001, 2985949)	256432.73 (221251.49, 297208.15)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	457	5 (5, 5)	1124 (960, 1316)	221.48 (188.97, 259.59)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	457	5 (5, 5)	837 (767, 914)	165.52 (151.51, 180.82)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	131	10 (10, 10)	1225726 (870946, 1725027)	121059.72 (85913.12, 170584.59)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	131	10 (10, 10)	3156401 (2463712, 4043844)	315640.09 (246371.17, 404384.44)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	131	10 (10, 10)	6851214 (5608006, 8370022)	685121.43 (560800.62, 837002.24)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	131	5 (5, 5)	2007 (1611, 2502)	390.27 (313.58, 485.72)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	131	5 (5, 5)	1048 (938, 1169)	203.26 (181.08, 228.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	81	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	81	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	81	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.03)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)	182813 (120848, 276551)	18281.29 (12084.78, 27655.07)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)	856287 (610469, 1201088)	85628.69 (61046.91, 120108.80)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)	1028885 (775052, 1365850)	102244.05 (77135.99, 135524.88)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)	734 (539, 1000)	145.37 (107.03, 197.44)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)	767 (652, 902)	149.79 (126.59, 177.25)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	441	10 (10, 10)	25170 (20506, 30894)	2508.74 (2043.99, 3079.16)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	441	10 (10, 10)	23014 (19012, 27859)	2276.30 (1879.99, 2756.16)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	441	10 (10, 10)	40370 (34441, 47319)	4036.96 (3444.09, 4731.88)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	441	5 (5, 5)	112 (92, 136)	22.21 (18.27, 26.99)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	441	5 (5, 5)	191 (156, 233)	37.55 (30.80, 45.79)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	151	10 (10, 10)	31228 (22446, 43447)	3122.80 (2244.56, 4344.67)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	10 (10, 10)	29987 (21717, 41406)	2998.67 (2171.66, 4140.62)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	10 (10, 10)	60581 (46279, 79302)	6058.10 (4627.93, 7930.24)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5 (5, 5)	133 (96, 185)	26.38 (19.05, 36.54)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5 (5, 5)	221 (160, 304)	44.14 (32.08, 60.74)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	78	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	78	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	78	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	78	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.01)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	78	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	150	10 (10, 10)	12441 (8987, 17222)	1230.84 (888.46, 1705.17)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	10 (10, 10)	13047 (9775, 17413)	1304.67 (977.50, 1741.33)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	10 (10, 10)	18259 (14224, 23440)	1825.92 (1422.37, 2343.96)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	150	5 (5, 5)	50 (35, 72)	9.72 (6.81, 13.86)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	150	5 (5, 5)	107 (79, 146)	21.16 (15.51, 28.86)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	441	10 (10, 10)	392406 (303187, 507878)	39112.27 (30223.29, 50615.59)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	441	10 (10, 10)	1123054 (914183, 1379646)	111079.35 (90456.76, 136403.54)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	441	10 (10, 10)	2237277 (1866421, 2681821)	223727.68 (186642.13, 268182.09)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	441	5 (5, 5)	1159 (961, 1399)	230.78 (191.33, 278.35)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	441	5 (5, 5)	770 (683, 868)	151.51 (134.28, 170.95)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	151	10 (10, 10)	682444 (454031, 1025766)	68244.41 (45403.15, 102576.57)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	10 (10, 10)	2184166 (1553688, 3070489)	218416.60 (155368.79, 307048.88)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	10 (10, 10)	4579234 (3631837, 5773768)	457923.40 (363183.70, 577376.79)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5 (5, 5)	1717 (1295, 2275)	339.62 (256.46, 449.75)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5 (5, 5)	945 (786, 1136)	189.08 (157.30, 227.29)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	78	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	78	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	78	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	78	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.01)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	78	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	150	10 (10, 10)	131432 (87374, 197705)	13003.09 (8628.18, 19596.27)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	10 (10, 10)	307277 (215247, 438657)	30727.75 (21524.67, 43865.69)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	10 (10, 10)	638515 (472586, 862703)	63851.47 (47258.55, 86270.33)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	150	5 (5, 5)	442 (292, 670)	85.08 (56.50, 128.13)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	150	5 (5, 5)	562 (457, 690)	110.88 (89.92, 136.73)

Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Age, Risk for Severe Covid-19</b>								
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	215	10 (10, 10)	19005 (15082, 23949)	1900.54 (1508.24, 2394.87)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	215	10 (10, 10)	18442 (15299, 22230)	1844.17 (1529.91, 2222.99)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	215	10 (10, 10)	34807 (29395, 41215)	3456.43 (2921.57, 4089.22)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	215	5 (5, 5)	86 (69, 107)	17.01 (13.66, 21.19)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	215	5 (5, 5)	188 (156, 226)	37.17 (30.85, 44.78)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)	33554 (23078, 48787)	3317.43 (2285.65, 4814.96)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)	33530 (24358, 46155)	3352.98 (2435.79, 4615.53)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)	70775 (53800, 93105)	7077.50 (5380.04, 9310.52)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)	151 (106, 214)	29.36 (20.72, 41.61)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	75	5 (5, 6)	306 (221, 422)	58.26 (42.28, 80.27)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 10)	12678 (8175, 19661)	1267.82 (817.54, 1966.11)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)	12250 (8318, 18041)	1225.03 (831.82, 1804.12)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)	18062 (12699, 25690)	1806.24 (1269.94, 2569.01)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)	47 (32, 71)	9.34 (6.33, 13.78)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)	112 (79, 159)	21.71 (15.35, 30.71)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	215	10 (10, 10)	276574 (207146, 369274)	27657.44 (20714.55, 36927.37)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	215	10 (10, 10)	849331 (677493, 1064753)	84933.05 (67749.27, 106475.30)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	215	10 (10, 10)	1804238 (1480129, 2199318)	179167.10 (147113.62, 218204.46)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	215	5 (5, 5)	867 (693, 1086)	171.62 (136.82, 215.27)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	215	5 (5, 5)	790 (697, 896)	156.60 (138.01, 177.69)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)	985427 (642793, 1510699)	97426.60 (63313.04, 149920.80)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)	2355679 (1716870, 3232175)	235567.91 (171686.97, 323217.53)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)	5425974 (4187815, 7030203)	542597.38 (418781.55, 703020.27)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)	1821 (1349, 2457)	354.84 (263.48, 477.88)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	75	5 (5, 6)	1016 (882, 1170)	193.62 (166.33, 225.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.05)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 10)	133545 (78788, 226358)	13354.48 (7878.77, 22635.80)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)	616604 (402585, 944396)	61660.36 (40258.53, 94439.60)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)	714436 (501642, 1017496)	71443.56 (50164.17, 101749.55)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)	599 (405, 884)	117.99 (80.17, 173.63)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)	716 (580, 884)	138.55 (111.24, 172.56)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	218	10 (10, 10)	21072 (16663, 26647)	2099.13 (1660.00, 2654.41)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	10 (10, 10)	18760 (15066, 23359)	1852.13 (1487.06, 2306.84)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	10 (10, 10)	32437 (27047, 38900)	3243.66 (2704.73, 3889.97)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5 (5, 5)	95 (76, 119)	18.87 (15.09, 23.61)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5 (5, 5)	173 (138, 218)	34.02 (27.06, 42.77)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)	25989 (17790, 37968)	2598.91 (1778.98, 3796.76)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)	24175 (16674, 35050)	2417.49 (1667.40, 3505.01)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)	47604 (34972, 64799)	4760.40 (3497.17, 6479.93)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)	113 (77, 164)	22.24 (15.29, 32.34)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)	196 (135, 284)	39.19 (27.06, 56.76)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	38	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	38	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	38	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	74	10 (10, 10)	10367 (7093, 15154)	1023.53 (699.59, 1497.46)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	74	10 (10, 10)	10560 (7547, 14775)	1056.00 (754.73, 1477.54)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	74	10 (10, 10)	14823 (11079, 19831)	1482.26 (1107.93, 1983.07)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	74	5 (5, 5)	43 (28, 65)	8.29 (5.46, 12.57)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	74	5 (5, 5)	96 (67, 138)	19.03 (13.22, 27.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	218	10 (10, 10)	313531 (233014, 421869)	31233.62 (23216.06, 42020.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	10 (10, 10)	909023 (717438, 1151769)	89746.73 (70866.77, 113656.58)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	10 (10, 10)	1856219 (1506314, 2287404)	185621.88 (150631.38, 228740.41)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5 (5, 5)	1030 (829, 1280)	205.17 (165.17, 254.86)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5 (5, 5)	738 (642, 848)	144.98 (126.08, 166.71)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)	555914 (347608, 889047)	55591.37 (34760.81, 88904.73)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)	1766199 (1191219, 2618712)	176619.93 (119121.92, 261871.22)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)	3845283 (2941570, 5026636)	384528.32 (294157.00, 502663.65)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)	1583 (1142, 2195)	312.53 (225.60, 432.95)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)	912 (735, 1130)	182.31 (147.06, 226.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	38	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	38	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	38	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	74	10 (10, 10)	107869 (66810, 174161)	10649.65 (6581.29, 17232.96)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	74	10 (10, 10)	229076 (151348, 346722)	22907.61 (15134.84, 34672.24)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	74	10 (10, 10)	484772 (341439, 688275)	48477.17 (34143.86, 68827.51)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	74	5 (5, 5)	379 (232, 619)	73.04 (45.03, 118.46)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	74	5 (5, 5)	538 (423, 685)	106.28 (83.11, 135.91)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	242	10 (10, 10)	54078 (43102, 67850)	5407.85 (4310.19, 6785.03)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	242	10 (10, 10)	55999 (45176, 69415)	5599.90 (4517.58, 6941.52)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	242	10 (10, 10)	105500 (87212, 127621)	10549.96 (8721.25, 12762.12)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	242	5 (5, 5)	208 (165, 261)	40.66 (32.37, 51.07)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	242	5 (5, 5)	331 (277, 396)	65.21 (54.58, 77.89)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	56	10 (10, 10)	76918 (46723, 126626)	7583.46 (4626.83, 12429.44)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	10 (10, 10)	102480 (65733, 159772)	10248.04 (6573.26, 15977.21)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	10 (10, 10)	199648 (136138, 292785)	19964.76 (13613.80, 29278.50)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5 (5, 5)	271 (174, 423)	52.48 (33.81, 81.48)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5 (5, 5)	327 (224, 477)	65.42 (44.85, 95.44)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.05)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 6)	5 (5, 5)	0.97 (0.89, 1.07)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	43	10 (10, 10)	32071 (19673, 52283)	3207.13 (1967.31, 5228.32)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	43	10 (10, 10)	33000 (23427, 46484)	3299.96 (2342.70, 4648.38)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	43	10 (10, 11)	58456 (45049, 75852)	5722.95 (4439.26, 7377.83)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	43	5 (5, 5)	119 (75, 189)	23.88 (15.07, 37.84)
Age $\geq$ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	43	5 (5, 5)	257 (168, 394)	51.42 (33.55, 78.83)
Age $\geq$ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	242	10 (10, 10)	931589 (691760, 1254563)	93158.86 (69176.05, 125456.33)
Age $\geq$ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	242	10 (10, 10)	2605444 (2083168, 3258661)	260544.40 (208316.81, 325866.10)
Age $\geq$ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	242	10 (10, 10)	4459763 (3608315, 5512125)	445976.26 (360831.49, 551212.50)
Age $\geq$ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	242	5 (5, 5)	1677 (1375, 2044)	328.33 (269.46, 400.07)
Age $\geq$ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	242	5 (5, 5)	916 (820, 1023)	180.29 (161.23, 201.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	56	10 (10, 10)	1781777 (1017168, 3121147)	175668.34 (100569.31, 306846.76)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	10 (10, 10)	5212369 (3582200, 7584388)	521236.92 (358219.97, 758438.83)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	10 (10, 10)	10218944 (7605635, 13730191)	1021894.41 (760563.49, 1373019.10)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5 (5, 5)	2374 (1755, 3211)	459.44 (340.08, 620.69)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5 (5, 5)	1105 (929, 1314)	220.92 (185.72, 262.80)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 6)	5 (5, 5)	0.96 (0.88, 1.04)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	43	10 (10, 10)	385267 (216300, 686226)	38526.73 (21630.02, 68622.65)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	43	10 (10, 10)	1867122 (1162726, 2998251)	186712.15 (116272.55, 299825.09)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	43	10 (10, 11)	2445717 (1675526, 3569942)	239441.27 (165642.75, 346119.11)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	43	5 (5, 5)	1193 (762, 1868)	238.59 (152.35, 373.65)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	43	5 (5, 5)	901 (724, 1123)	180.27 (144.75, 224.52)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	223	10 (10, 10)	73663 (57986, 93579)	7366.34 (5798.60, 9357.93)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	223	10 (10, 10)	79137 (65095, 96208)	7913.67 (6509.45, 9620.81)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	223	10 (10, 10)	151428 (128696, 178176)	15142.84 (12869.60, 17817.60)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	223	5 (5, 5)	299 (240, 371)	59.39 (47.83, 73.75)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	223	5 (5, 5)	344 (286, 413)	68.24 (56.78, 82.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	76	10 (10, 10)	91816 (62470, 134950)	9181.63 (6246.95, 13494.95)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)	106273 (78124, 144563)	10627.28 (7812.45, 14456.30)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)	249569 (193516, 321857)	24956.85 (19351.57, 32185.73)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5 (5, 5)	360 (249, 520)	71.93 (49.73, 104.04)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)	444 (346, 570)	88.80 (69.23, 113.91)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.04)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)	5 (5, 5)	0.97 (0.91, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	76	10 (10, 10)	31710 (21750, 46230)	3171.00 (2175.04, 4623.03)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)	38609 (27620, 53970)	3860.90 (2762.01, 5397.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)	53225 (40976, 69134)	5322.45 (4097.65, 6913.35)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	76	5 (5, 6)	114 (79, 165)	21.98 (15.41, 31.36)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)	185 (132, 260)	36.48 (26.02, 51.15)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	223	10 (10, 10)	1522680 (1184331, 1957692)	152268.00 (118433.07, 195769.17)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	223	10 (10, 10)	4029556 (3333554, 4870873)	402955.60 (333355.43, 487087.35)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	223	10 (10, 10)	6913673 (5962965, 8015958)	691367.33 (596296.55, 801595.76)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	223	5 (5, 5)	2363 (2052, 2722)	469.66 (407.83, 540.86)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	223	5 (5, 5)	996 (905, 1097)	197.73 (179.50, 217.81)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	76	10 (10, 10)	2275652 (1483459, 3490888)	227565.17 (148345.93, 349088.82)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)	7603908 (5849216, 9884986)	760390.81 (584921.58, 988498.63)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)	12774313 (11071512, 14739004)	1277431.27 (1107151.19, 1473900.45)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5 (5, 5)	2767 (2202, 3477)	553.42 (440.38, 695.48)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)	1171 (1082, 1268)	234.26 (216.39, 253.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.05)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)	5 (5, 5)	0.97 (0.91, 1.03)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	76	10 (10, 10)	362201 (237645, 552041)	36220.12 (23764.47, 55204.14)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)	1386685 (951612, 2020673)	138668.52 (95161.18, 202067.27)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)	2624193 (1957915, 3517205)	262419.33 (195791.54, 351720.52)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	76	5 (5, 6)	969 (683, 1375)	186.22 (132.03, 262.66)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)	699 (551, 886)	137.83 (108.80, 174.59)



Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Sex</b>								
Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	413	10 (10, 10)	27918 (22184, 35135)	2791.84 (2218.42, 3513.47)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	413	10 (10, 10)	25464 (20474, 31672)	2508.92 (2015.93, 3122.47)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	413	10 (10, 10)	47856 (39690, 57703)	4785.60 (3968.97, 5770.26)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	413	5 (5, 5)	127 (102, 159)	25.34 (20.34, 31.56)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	413	5 (5, 5)	226 (183, 279)	44.45 (35.99, 54.89)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)	31634 (20063, 49877)	3152.24 (1999.57, 4969.38)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)	35411 (22182, 56530)	3541.13 (2218.23, 5652.98)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)	71516 (48882, 104632)	7151.65 (4888.20, 10463.17)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)	132 (87, 201)	26.23 (17.28, 39.79)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)	220 (144, 335)	43.98 (28.87, 66.99)
Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)	13885 (9964, 19349)	1388.46 (996.35, 1934.87)
Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)	15684 (11249, 21868)	1568.44 (1124.92, 2186.84)
Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)	19051 (14268, 25437)	1898.18 (1422.28, 2533.31)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)	53 (38, 75)	10.62 (7.57, 14.90)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)	116 (85, 158)	22.79 (16.67, 31.17)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	413	10 (10, 10)	413245 (313550, 544639)	41324.49 (31354.99, 54463.86)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	413	10 (10, 10)	1349730 (1058654, 1720836)	132983.90 (104362.62, 169454.52)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	413	10 (10, 10)	2494356 (2024007, 3074009)	249435.65 (202400.67, 307400.88)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	413	5 (5, 5)	1309 (1073, 1597)	260.12 (213.12, 317.47)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	413	5 (5, 5)	802 (702, 915)	157.80 (138.22, 180.16)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)	651471 (371844, 1141378)	64917.97 (37045.32, 113761.80)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)	2214099 (1404894, 3489396)	221409.86 (140489.41, 348939.64)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)	4657377 (3318602, 6536236)	465737.72 (331860.16, 653623.57)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)	1845 (1334, 2553)	366.15 (264.70, 506.50)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)	911 (750, 1106)	182.14 (149.95, 221.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.02)
Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)	119308 (74464, 191160)	11930.81 (7446.36, 19115.95)
Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)	406550 (258451, 639512)	40655.00 (25845.14, 63951.24)
Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)	726888 (523093, 1010081)	72425.06 (52151.92, 100579.02)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)	604 (387, 942)	120.71 (77.36, 188.34)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)	566 (446, 718)	111.45 (87.74, 141.57)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	485	10 (10, 10)	24780 (20095, 30555)	2467.60 (2001.23, 3042.66)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	485	10 (10, 10)	23686 (19548, 28699)	2362.70 (1949.87, 2862.93)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	485	10 (10, 10)	40829 (34866, 47811)	4074.24 (3479.58, 4770.53)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	485	5 (5, 5)	105 (86, 128)	20.82 (17.07, 25.39)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	485	5 (5, 5)	186 (151, 228)	36.59 (29.85, 44.85)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	161	10 (10, 10)	36285 (26900, 48946)	3620.44 (2684.66, 4882.39)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	161	10 (10, 10)	32437 (24984, 42114)	3243.71 (2498.36, 4211.41)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	161	10 (10, 10)	65952 (51863, 83868)	6595.23 (5186.35, 8386.84)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	161	5 (5, 5)	155 (112, 215)	30.42 (22.03, 42.02)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	161	5 (5, 5)	257 (191, 347)	50.79 (37.68, 68.46)
Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)	5 (5, 5)	1.01 (1.00, 1.02)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.02)
Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	142	10 (10, 10)	13010 (8886, 19048)	1282.84 (874.99, 1880.80)
Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	142	10 (10, 10)	12565 (9151, 17253)	1256.50 (915.06, 1725.35)
Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	142	10 (10, 10)	20450 (15506, 26971)	2044.98 (1550.57, 2697.05)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	142	5 (5, 6)	53 (35, 80)	10.07 (6.64, 15.28)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	142	5 (5, 5)	115 (81, 163)	22.60 (15.83, 32.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	485	10 (10, 10)	401733 (305536, 528218)	40005.42 (30432.22, 52590.10)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	485	10 (10, 10)	1055004 (863808, 1288519)	105238.95 (86150.15, 128557.36)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	485	10 (10, 10)	2205314 (1838733, 2644980)	220064.65 (183501.60, 263912.96)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	485	5 (5, 5)	1039 (851, 1267)	205.98 (168.87, 251.23)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	485	5 (5, 5)	778 (688, 880)	153.42 (135.60, 173.58)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	161	10 (10, 10)	912839 (634733, 1312797)	91080.23 (63342.51, 130964.29)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	161	10 (10, 10)	2526281 (1844631, 3459821)	252628.07 (184463.11, 345982.14)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	161	10 (10, 10)	5360132 (4442120, 6467860)	536013.15 (444212.00, 646785.99)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	161	5 (5, 5)	1723 (1269, 2339)	337.51 (248.96, 457.55)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	161	5 (5, 5)	1021 (828, 1258)	201.49 (163.34, 248.54)
Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.01)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	142	10 (10, 10)	162718 (105337, 251358)	16044.49 (10346.44, 24880.60)
Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	142	10 (10, 10)	387612 (266416, 563942)	38761.20 (26641.57, 56394.20)
Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	142	10 (10, 10)	711788 (506763, 999761)	71178.77 (50676.28, 99976.12)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	142	5 (5, 6)	436 (277, 686)	82.60 (53.10, 128.50)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	142	5 (5, 5)	639 (515, 792)	125.69 (100.72, 156.85)

Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Age, sex</b>								
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	241	10 (10, 10)	19834 (15401, 25543)	1973.10 (1532.21, 2540.86)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	241	10 (10, 10)	18407 (14604, 23199)	1834.97 (1455.81, 2312.86)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	241	10 (10, 10)	31037 (25718, 37457)	3095.53 (2565.30, 3735.35)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	241	5 (5, 5)	85 (67, 108)	16.93 (13.33, 21.51)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	241	5 (5, 5)	161 (126, 206)	31.71 (24.72, 40.66)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	81	10 (10, 10)	27333 (19128, 39059)	2733.32 (1912.76, 3905.91)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	81	10 (10, 10)	22259 (16475, 30072)	2225.86 (1647.51, 3007.22)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	81	10 (10, 10)	46690 (35359, 61651)	4668.99 (3535.93, 6165.12)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	81	5 (5, 5)	121 (81, 181)	23.77 (16.01, 35.29)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	81	5 (5, 5)	222 (153, 322)	43.59 (30.02, 63.32)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	82	10 (10, 11) 10 (10, 10) 10 (10, 10) 5 (5, 6) 5 (5, 5) 10 (10, 10) 10 (10, 10) 10 (10, 10) 5 (5, 5) 5 (5, 5) 10 (10, 10) 10 (10, 10) 10 (10, 10) 5 (5, 5) 5 (5, 5) 10 (10, 10) 10 (10, 10) 10 (10, 10) 5 (5, 5) 5 (5, 5)	11120 (7096, 17425) 10726 (7393, 15562) 17474 (12620, 24195) 47 (29, 76) 107 (71, 162) 305770 (219380, 426179) 796114 (625781, 1012809) 1771866 (1422780, 2206602) 906 (710, 1156) 745 (641, 866) 667054 (429471, 1036066) 1871163 (1270557, 2755680) 4261855 (3403042, 5337402) 1556 (1059, 2286) 973 (744, 1272)	1093.32 (696.58, 1716.04) 1072.58 (739.26, 1556.19) 1747.37 (1261.97, 2419.48) 8.87 (5.42, 14.51) 21.00 (13.80, 31.96) 30417.74 (21829.71, 42384.40) 79365.49 (62369.74, 100992.57) 176719.12 (141918.85, 220052.84) 180.09 (141.24, 229.63) 146.73 (126.14, 170.68) 66705.37 (42947.12, 103606.62) 187116.29 (127055.75, 275568.05) 426185.45 (340304.23, 533740.18) 304.87 (207.85, 447.20) 191.30 (146.19, 250.35)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	82			
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	82			
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	82			
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	82			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	241			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	241			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	241			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	241			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	241			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	81			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	81			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	81			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	81			
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	81			

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	82	10 (10, 11)	142811 (85604, 238248)	14041.72 (8377.83, 23534.75)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	82	10 (10, 10)	305266 (197484, 471873)	30526.58 (19748.35, 47187.33)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	82	10 (10, 10)	556437 (374252, 827308)	55643.69 (37425.23, 82730.84)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	82	5 (5, 6)	374 (219, 639)	70.78 (41.99, 119.31)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	82	5 (5, 5)	631 (490, 813)	123.77 (95.35, 160.67)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	192	10 (10, 10)	21688 (16243, 28956)	2168.76 (1624.34, 2895.65)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	10 (10, 11)	19078 (14529, 25051)	1871.31 (1424.33, 2458.55)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	10 (10, 10)	35663 (28265, 44999)	3566.34 (2826.48, 4499.88)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	192	5 (5, 5)	104 (79, 137)	20.70 (15.70, 27.31)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	192	5 (5, 5)	199 (152, 261)	39.10 (29.89, 51.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	69	10 (10, 10)	27075 (15829, 46310)	2696.03 (1576.51, 4610.58)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	10 (10, 10)	29814 (17154, 51819)	2981.41 (1715.35, 5181.90)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	10 (10, 10)	56307 (36089, 87850)	5630.68 (3608.92, 8785.03)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	69	5 (5, 5)	116 (71, 189)	22.97 (14.06, 37.51)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	69	5 (5, 5)	203 (123, 334)	40.52 (24.59, 66.76)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	10 (10, 10)	10413 (6996, 15497)	1041.26 (699.62, 1549.73)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	10 (10, 10)	11169 (7430, 16790)	1116.92 (743.02, 1678.99)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	10 (10, 10)	12940 (9174, 18253)	1294.03 (917.39, 1825.31)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5 (5, 5)	40 (26, 61)	7.99 (5.28, 12.10)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5 (5, 5)	90 (61, 131)	17.67 (12.06, 25.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	192	10 (10, 10)	304281 (215298, 430041)	30428.10 (21529.80, 43004.07)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	10 (10, 11)	1049134 (771985, 1425783)	102906.70 (75793.21, 139719.49)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	10 (10, 10)	1947384 (1495326, 2536105)	194738.37 (149532.57, 253610.51)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	192	5 (5, 5)	1122 (871, 1445)	223.22 (173.24, 287.63)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	192	5 (5, 5)	754 (637, 894)	148.35 (125.21, 175.76)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	69	10 (10, 10)	565805 (291605, 1097839)	56341.88 (29029.39, 109351.53)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	10 (10, 10)	1847812 (1079096, 3164140)	184781.22 (107909.55, 316414.05)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	10 (10, 10)	3914541 (2623647, 5840586)	391454.14 (262364.69, 584058.55)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	69	5 (5, 5)	1698 (1155, 2497)	336.40 (228.84, 494.53)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	69	5 (5, 5)	885 (704, 1114)	177.07 (140.72, 222.81)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	10 (10, 10)	80130 (44941, 142872)	8012.98 (4494.09, 14287.16)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	10 (10, 10)	254653 (147354, 440085)	25465.32 (14735.40, 44008.48)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	10 (10, 10)	486838 (329835, 718574)	48683.79 (32983.53, 71857.44)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5 (5, 5)	493 (280, 868)	98.66 (56.07, 173.61)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5 (5, 5)	496 (368, 670)	97.90 (72.40, 132.37)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	221	10 (10, 10)	64637 (51094, 81771)	6463.72 (5109.36, 8177.10)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	10 (10, 10)	66495 (54144, 81664)	6649.48 (5414.36, 8166.37)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	10 (10, 10)	127197 (105499, 153358)	12719.71 (10549.88, 15335.82)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	221	5 (5, 5)	250 (200, 313)	49.57 (39.70, 61.89)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	221	5 (5, 5)	345 (289, 413)	68.05 (56.92, 81.35)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)	68915 (44735, 106166)	6891.55 (4473.52, 10616.58)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)	83753 (56539, 124066)	8375.28 (5653.86, 12406.61)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)	236583 (175079, 319694)	23658.34 (17507.88, 31969.44)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 5)	255 (165, 393)	50.95 (33.01, 78.63)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)	331 (233, 472)	66.24 (46.51, 94.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	43	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	43	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	43	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	43	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	43	5 (5, 5)	5 (5, 5)	0.97 (0.92, 1.03)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)	35615 (22588, 56154)	3561.49 (2258.83, 5615.38)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)	47657 (33321, 68161)	4765.72 (3332.12, 6816.10)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)	67572 (51300, 89006)	6653.07 (5064.15, 8740.51)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)	135 (91, 200)	26.94 (18.16, 39.98)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)	267 (185, 384)	52.49 (36.58, 75.32)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	221	10 (10, 10)	1143138 (866738, 1507680)	114313.80 (86673.83, 150768.05)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	10 (10, 10)	3118628 (2488678, 3908036)	311862.83 (248867.78, 390803.58)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	10 (10, 10)	5679764 (4750568, 6790707)	567976.37 (475056.80, 679070.70)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	221	5 (5, 5)	2182 (1845, 2581)	432.52 (365.59, 511.71)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	221	5 (5, 5)	983 (895, 1079)	193.75 (176.35, 212.87)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)	1318988 (777995, 2236169)	131898.80 (77799.53, 223616.94)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)	5472151 (3897399, 7683185)	547215.13 (389739.94, 768318.48)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)	11109618 (8990099, 13728838)	1110961.79 (899009.90, 1372883.76)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 5)	2798 (2160, 3624)	559.51 (431.94, 724.74)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)	1049 (861, 1278)	209.77 (172.20, 255.54)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	43	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	43	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	43	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	43	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	43	5 (5, 5)	5 (5, 5)	0.97 (0.92, 1.03)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)	439116 (273334, 705448)	43911.63 (27333.43, 70544.79)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)	1880068 (1236170, 2859362)	188006.84 (123616.98, 285936.21)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)	2699776 (1942829, 3751637)	265816.43 (192326.63, 367387.37)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)	1168 (815, 1675)	233.58 (162.91, 334.91)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)	867 (695, 1080)	170.39 (136.67, 212.44)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	244	10 (10, 10)	61053 (48405, 77006)	6105.31 (4840.53, 7700.56)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	244	10 (10, 10)	65781 (53405, 81026)	6578.14 (5340.52, 8102.58)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	244	10 (10, 10)	123981 (104275, 147411)	12398.09 (10427.49, 14741.10)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	244	5 (5, 5)	245 (196, 307)	48.07 (38.36, 60.24)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	244	5 (5, 5)	330 (275, 396)	65.39 (54.51, 78.45)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	80	10 (10, 10)	97709 (64219, 148663)	9673.27 (6373.24, 14682.01)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	80	10 (10, 10)	121022 (86222, 169868)	12102.25 (8622.24, 16986.81)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	80	10 (10, 10)	220660 (162489, 299656)	22065.99 (16248.92, 29965.56)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	80	5 (5, 5)	369 (254, 537)	72.10 (49.70, 104.59)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	80	5 (5, 5)	433 (330, 569)	86.63 (65.96, 113.77)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	41	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	41	5 (5, 5)	5 (5, 5)	1.03 (0.99, 1.08)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	41	5 (5, 6)	5 (5, 5)	0.97 (0.88, 1.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)	28359 (19328, 41611)	2835.92 (1932.77, 4161.10)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)	27558 (19975, 38019)	2755.79 (1997.51, 3801.92)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)	44632 (34775, 57284)	4463.25 (3477.49, 5728.43)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 6)	100 (66, 152)	18.96 (12.72, 28.27)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)	162 (111, 238)	32.48 (22.15, 47.62)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	244	10 (10, 10)	1213747 (916908, 1606684)	121374.69 (91690.83, 160668.36)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	244	10 (10, 10)	3300488 (2708865, 4021322)	330048.77 (270886.53, 402132.19)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	244	10 (10, 10)	5351243 (4407656, 6496833)	535124.28 (440765.55, 649683.25)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	244	5 (5, 5)	1808 (1509, 2166)	354.88 (296.31, 425.02)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	244	5 (5, 5)	928 (829, 1038)	183.79 (164.09, 205.87)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	80	10 (10, 10)	2733558 (1760658, 4244061)	270623.92 (174549.19, 419579.75)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	80	10 (10, 10)	7216299 (5400352, 9642884)	721629.87 (540035.21, 964288.37)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	80	10 (10, 10)	11949268 (9684950, 14742979)	1194926.85 (968494.99, 1474297.93)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	80	5 (5, 5)	2465 (1913, 3176)	481.63 (373.96, 620.29)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	80	5 (5, 5)	1208 (1135, 1285)	241.55 (227.04, 256.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	41	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	41	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.05)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	41	5 (5, 6)	5 (5, 5)	0.95 (0.87, 1.05)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)	310943 (190680, 507056)	31094.27 (19067.99, 50705.59)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)	1267945 (838600, 1917106)	126794.50 (83859.98, 191710.57)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)	2415521 (1741353, 3350694)	241552.08 (174135.31, 335069.37)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 6)	935 (615, 1423)	177.73 (117.77, 268.24)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)	678 (524, 878)	135.64 (104.73, 175.68)

Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Hispanic or Latino ethnicity</b>								
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	127	10 (10, 11) (17659, 34948)	24842 (1730.33, 3421.69)	2433.24 (1730.33, 3421.69)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	10 (10, 10) (19291, 37557)	26916 (1903.43, 3713.87)	2658.77 (1903.43, 3713.87)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	10 (10, 10) (36353, 62485)	47660 (3613.91, 6204.42)	4735.21 (3613.91, 6204.42)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	127	5 (5, 5) (84, 177)	122 (16.41, 34.54)	23.81 (16.41, 34.54)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	127	5 (5, 6) (154, 310)	218 (28.85, 58.43)	41.06 (28.85, 58.43)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	26	10 (10, 10) (28133, 51824)	38184 (2813.34, 5182.43)	3818.37 (2813.34, 5182.43)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	26	10 (10, 10) (16695, 113035)	43441 (1669.52, 11303.54)	4344.14 (1669.52, 11303.54)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	26	10 (10, 10) (42595, 220574)	96930 (4259.54, 22057.36)	9693.00 (4259.54, 22057.36)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	26	5 (5, 5) (76, 169)	114 (15.24, 33.87)	22.72 (15.24, 33.87)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	26	5 (5, 5) (116, 497)	241 (23.30, 99.49)	48.15 (23.30, 99.49)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	23	10 (10, 10) (10, 10)	10 (1.00, 1.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	23	10 (10, 10) (10, 10)	10 (1.00, 1.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	23	10 (10, 10) (10, 10)	10 (1.00, 1.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	23	5 (5, 5) (5, 5)	5 (0.99, 1.04)	1.01 (0.99, 1.04)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	23	5 (5, 5) (5, 5)	5 (1.00, 1.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	28	10 (10, 10)	9262 (3384, 25347)	926.21 (338.44, 2534.74)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	10 (10, 10)	11518 (5977, 22195)	1151.79 (597.70, 2219.55)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	10 (10, 10)	23768 (13230, 42701)	2376.81 (1322.98, 4270.10)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	28	5 (5, 5)	51 (21, 123)	10.13 (4.18, 24.54)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	28	5 (5, 5)	170 (81, 354)	33.91 (16.24, 70.79)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	127	10 (10, 11)	426086 (277325, 654644)	41734.10 (27231.97, 63959.19)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	10 (10, 10)	1437790 (1007780, 2051282)	142023.62 (99209.31, 203314.66)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	10 (10, 10)	2142978 (1595637, 2878069)	212912.25 (158673.61, 285691.01)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	127	5 (5, 5)	1228 (918, 1642)	238.91 (179.38, 318.20)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	127	5 (5, 6)	814 (674, 982)	152.96 (125.10, 187.02)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	26	10 (10, 10)	513694 (174929, 1508508)	51369.41 (17492.89, 150850.78)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	26	10 (10, 10)	2840421 (1452662, 5553936)	284042.12 (145266.20, 555393.64)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	26	10 (10, 10)	3551466 (1744682, 7229345)	355146.56 (174468.21, 722934.47)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	26	5 (5, 5)	2889 (2174, 3839)	577.82 (434.87, 767.76)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	26	5 (5, 5)	1146 (1010, 1300)	229.14 (202.01, 259.90)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	23	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	23	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	23	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	23	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	23	5 (5, 5)	5 (5, 5)	1.03 (0.97, 1.08)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	28	10 (10, 10)	96806 (22163, 422848)	9680.65 (2216.28, 42284.78)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	10 (10, 10)	423379 (153088, 1170893)	42337.88 (15308.79, 117089.31)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	10 (10, 10)	1028368 (385239, 2745154)	102836.81 (38523.92, 274515.36)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	28	5 (5, 5)	435 (162, 1169)	86.99 (32.38, 233.75)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	28	5 (5, 5)	882 (700, 1110)	176.32 (140.01, 222.06)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	704	10 (10, 10)	25133 (21020, 30051)	2513.34 (2102.05, 3005.12)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	704	10 (10, 10)	23223 (19715, 27356)	2303.86 (1955.53, 2714.23)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	704	10 (10, 10)	42894 (37567, 48975)	4286.95 (3754.70, 4894.66)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	704	5 (5, 5)	109 (93, 129)	21.74 (18.42, 25.67)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	704	5 (5, 5)	197 (167, 233)	39.23 (33.20, 46.36)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	236	10 (10, 10)	32689 (24048, 44436)	3257.91 (2397.03, 4427.97)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	236	10 (10, 10)	32493 (24434, 43211)	3249.33 (2443.37, 4321.15)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	236	10 (10, 10)	65428 (51624, 82923)	6542.83 (5162.45, 8292.31)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	236	5 (5, 5)	148 (110, 198)	29.02 (21.61, 38.95)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	236	5 (5, 5)	248 (189, 325)	49.39 (37.73, 64.65)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	125	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	125	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	125	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	125	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.01)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	125	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	216	10 (10, 10)	13538 (10248, 17884)	1341.04 (1014.47, 1772.74)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	216	10 (10, 10)	13974 (10813, 18059)	1397.38 (1081.25, 1805.94)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	216	10 (10, 10)	19368 (15646, 23976)	1936.85 (1564.65, 2397.59)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	216	5 (5, 5)	53 (39, 72)	10.29 (7.56, 14.01)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	216	5 (5, 5)	113 (87, 147)	22.32 (17.17, 29.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	704	10 (10, 10)	402096 (321228, 503320)	40209.55 (32122.84, 50332.04)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	704	10 (10, 10)	1106904 (926650, 1322221)	109809.28 (91973.52, 131103.79)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	704	10 (10, 10)	2352728 (2014696, 2747477)	235141.25 (201360.00, 274589.83)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	704	5 (5, 5)	1087 (923, 1281)	216.23 (183.49, 254.82)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	704	5 (5, 5)	784 (708, 869)	156.16 (140.93, 173.03)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	236	10 (10, 10)	796506 (555972, 1141105)	79382.34 (55406.70, 113732.74)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	236	10 (10, 10)	2326321 (1720759, 3144990)	232632.13 (172075.91, 314499.03)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	236	10 (10, 10)	5141985 (4186895, 6314945)	514198.50 (418689.49, 631494.48)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	236	5 (5, 5)	1699 (1322, 2183)	333.77 (260.03, 428.42)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	236	5 (5, 5)	981 (846, 1138)	195.50 (168.58, 226.73)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	125	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	125	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	125	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	125	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.01)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	125	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	216	10 (10, 10)	154261 (109458, 217402)	15280.35 (10822.20, 21575.01)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	216	10 (10, 10)	403108 (300454, 540835)	40310.79 (30045.41, 54083.45)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	216	10 (10, 10)	694970 (544427, 887140)	69496.96 (54442.67, 88714.01)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	216	5 (5, 5)	477 (334, 683)	92.40 (64.92, 131.51)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	216	5 (5, 5)	595 (503, 703)	117.00 (98.59, 138.84)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)	42975 (26488, 69724)	4297.50 (2648.79, 6972.44)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	37243 (22676, 61168)	3724.31 (2267.59, 6116.84)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	47974 (26288, 87547)	4797.36 (2628.85, 8754.65)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	169 (96, 296)	33.77 (19.25, 59.22)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)	241 (131, 441)	45.14 (25.26, 80.66)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	20	10 (10, 10)	47881 (22603, 101431)	4788.14 (2260.29, 10143.09)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	10 (10, 10)	39110 (22154, 69044)	3911.05 (2215.43, 6904.44)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	10 (10, 10)	75669 (48184, 118833)	7566.93 (4818.38, 11883.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	20	5 (5, 5)	146 (53, 402)	29.17 (10.59, 80.32)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	20	5 (5, 6)	152 (43, 537)	28.93 (8.31, 100.73)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	11	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	11	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	11	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	21	10 (10, 10)	16686 (6170, 45127)	1668.62 (616.99, 4512.74)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	21	10 (10, 10)	14429 (7374, 28235)	1442.93 (737.40, 2823.49)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	21	10 (10, 11)	21831 (8311, 57345)	2138.98 (818.71, 5588.38)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	21	5 (5, 6)	55 (23, 134)	10.62 (4.45, 25.31)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	21	5 (5, 5)	94 (33, 272)	18.38 (6.40, 52.79)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)	429775 (218216, 846438)	42977.49 (21821.62, 84643.79)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	1668633 (983415, 2831294)	166863.34 (98341.52, 283129.38)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	2346512 (1317804, 4178254)	234651.23 (131780.40, 417825.43)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	1922 (1233, 2996)	384.48 (246.68, 599.26)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)	799 (561, 1138)	149.87 (105.15, 213.61)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	20	10 (10, 10)	1048443 (367799, 2988680)	104844.29 (36779.87, 298867.97)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	10 (10, 10)	2424361 (881948, 6664257)	242436.08 (88194.76, 666425.73)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	10 (10, 10)	5915923 (4260178, 8215184)	591592.30 (426017.78, 821518.42)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	20	5 (5, 5)	1651 (726, 3752)	330.17 (145.27, 750.42)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	20	5 (5, 6)	653 (244, 1745)	124.13 (46.60, 330.63)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	11	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	11	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	11	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	21	10 (10, 10)	85718 (29151, 252050)	8571.76 (2915.10, 25204.98)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	21	10 (10, 10)	299657 (69957, 1283571)	29965.71 (6995.67, 128357.06)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	21	10 (10, 11)	732832 (220527, 2435272)	71801.65 (21748.41, 237050.73)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	21	5 (5, 6)	983 (401, 2408)	188.33 (77.19, 459.46)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	21	5 (5, 5)	526 (206, 1346)	102.92 (40.31, 262.73)

Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Race</b>								
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	382	10 (10, 10)	26779 (21016, 34123)	2677.93 (2101.59, 3412.34)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	10 (10, 10)	24073 (19243, 30116)	2377.24 (1899.30, 2975.46)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	10 (10, 10)	44837 (37733, 53280)	4483.75 (3773.28, 5328.00)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	382	5 (5, 5)	116 (93, 145)	23.26 (18.62, 29.04)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	382	5 (5, 5)	204 (165, 253)	40.66 (32.80, 50.39)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	129	10 (10, 10)	32140 (21350, 48383)	3202.89 (2128.04, 4820.65)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	10 (10, 10)	29603 (19188, 45670)	2960.25 (1918.78, 4567.01)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	10 (10, 10)	64812 (45432, 92458)	6481.16 (4543.19, 9245.79)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	129	5 (5, 5)	142 (96, 209)	28.22 (19.18, 41.54)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	129	5 (5, 5)	236 (164, 340)	47.27 (32.81, 68.09)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)	16332 (11301, 23603)	1633.19 (1130.10, 2360.25)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)	14167 (10126, 19819)	1416.65 (1012.60, 1981.93)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)	21729 (16518, 28584)	2172.89 (1651.80, 2858.37)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)	69 (46, 102)	13.62 (9.23, 20.11)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)	121 (85, 172)	24.05 (16.89, 34.25)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	382	10 (10, 10)	375305 (279792, 503424)	37530.54 (27979.22, 50342.40)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	10 (10, 10)	1145512 (909652, 1442528)	113119.92 (89898.96, 142338.86)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	10 (10, 10)	2459185 (2019406, 2994737)	245918.47 (201940.56, 299473.74)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	382	5 (5, 5)	1125 (908, 1394)	224.59 (181.22, 278.35)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	382	5 (5, 5)	804 (714, 904)	159.85 (142.07, 179.85)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	129	10 (10, 10)	758610 (476254, 1208367)	75599.31 (47448.93, 120450.68)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	10 (10, 10)	2229169 (1492057, 3330433)	222916.94 (149205.69, 333043.33)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	10 (10, 10)	5100285 (3772135, 6896069)	510028.49 (377213.53, 689606.91)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	129	5 (5, 5)	1594 (1095, 2320)	316.63 (217.53, 460.88)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	129	5 (5, 5)	932 (742, 1172)	186.47 (148.38, 234.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.01)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)	169965 (105036, 275030)	16996.51 (10503.63, 27503.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)	470592 (326087, 679136)	47059.23 (32608.68, 67913.55)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)	837482 (614121, 1142080)	83748.17 (61412.13, 114208.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)	437 (268, 713)	86.67 (53.17, 141.29)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)	739 (608, 898)	146.96 (120.78, 178.80)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	171	10 (10, 10)	29887 (22491, 39714)	2988.66 (2249.09, 3971.41)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	10 (10, 10)	30003 (23297, 38639)	3000.27 (2329.66, 3863.92)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	10 (10, 10)	47425 (37241, 60394)	4727.29 (3713.94, 6017.12)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5 (5, 5)	125 (95, 165)	24.88 (18.87, 32.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5 (5, 5)	212 (154, 292)	42.25 (30.68, 58.20)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	53	10 (10, 10)	28851 (14520, 57328)	2885.13 (1452.00, 5732.76)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	10 (10, 10)	36205 (21532, 60877)	3620.48 (2153.18, 6087.68)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	10 (10, 10)	73221 (43288, 123852)	7322.07 (4328.77, 12385.19)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	53	5 (5, 5)	129 (73, 228)	25.70 (14.51, 45.54)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	53	5 (5, 5)	215 (116, 399)	43.04 (23.21, 79.81)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	57	10 (10, 10)	11556 (7261, 18392)	1155.58 (726.06, 1839.20)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	10 (10, 10)	12089 (7715, 18943)	1208.94 (771.54, 1894.31)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	10 (10, 10)	19929 (13075, 30376)	1992.91 (1307.52, 3037.59)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	57	5 (5, 6)	47 (27, 80)	8.80 (5.14, 15.07)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	57	5 (5, 5)	91 (54, 154)	18.10 (10.72, 30.57)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	171	10 (10, 10)	605088 (404884, 904288)	60508.85 (40488.44, 90428.79)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	10 (10, 10)	1327188 (981725, 1794217)	132718.77 (98172.48, 179421.69)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	10 (10, 10)	2410575 (1854720, 3133019)	240285.11 (184935.23, 312200.85)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5 (5, 5)	1247 (951, 1636)	247.39 (188.49, 324.71)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5 (5, 5)	813 (689, 959)	161.95 (137.25, 191.08)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	53	10 (10, 10)	545488 (232954, 1277322)	54548.78 (23295.37, 127732.22)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	10 (10, 10)	2182049 (1172039, 4062441)	218204.93 (117203.90, 406244.09)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	10 (10, 10)	4430744 (2966452, 6617834)	443074.36 (296645.23, 661783.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	53	5 (5, 5)	1259 (717, 2209)	251.78 (143.47, 441.83)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	53	5 (5, 5)	891 (629, 1262)	178.15 (125.72, 252.46)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	57	10 (10, 10)	149099 (76074, 292224)	14909.91 (7607.36, 29222.39)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	10 (10, 10)	372359 (185291, 748289)	37235.91 (18529.11, 74828.88)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	10 (10, 10)	582225 (358855, 944635)	58222.54 (35885.46, 94463.45)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	57	5 (5, 6)	511 (258, 1013)	96.42 (49.55, 187.64)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	57	5 (5, 5)	512 (340, 769)	101.57 (67.60, 152.62)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	66	10 (10, 10)	19609 (11547, 33299)	1960.87 (1154.68, 3329.93)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	66	10 (10, 10)	25939 (16489, 40804)	2593.89 (1648.92, 4080.38)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	66	10 (10, 10)	35919 (23896, 53992)	3591.91 (2389.57, 5399.23)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	66	5 (5, 5)	96 (64, 146)	19.15 (12.66, 28.98)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	66	5 (5, 5)	202 (120, 340)	40.33 (23.95, 67.91)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	29	10 (10, 10)	51114 (24326, 107397)	5111.35 (2432.65, 10739.71)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	10 (10, 10)	40914 (21831, 76676)	4091.37 (2183.11, 7667.61)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	10 (10, 10)	71143 (36178, 139901)	7114.28 (3617.78, 13990.07)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5 (5, 6)	251 (114, 555)	46.28 (21.12, 101.40)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5 (5, 5)	237 (104, 536)	47.32 (20.87, 107.29)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)	5 (5, 6)	1.07 (0.93, 1.24)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 5)	5 (5, 6)	1.07 (0.93, 1.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	24	10 (10, 10)	6825 (3397, 13714)	682.52 (339.68, 1371.36)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)	8181 (5043, 13272)	818.07 (504.27, 1327.16)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)	15922 (8805, 28791)	1592.16 (880.47, 2879.10)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	24	5 (5, 5)	22 (11, 43)	4.33 (2.20, 8.55)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	24	5 (5, 5)	88 (39, 202)	17.20 (7.48, 39.55)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	66	10 (10, 10)	348306 (189672, 639615)	34830.58 (18967.19, 63961.49)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	66	10 (10, 10)	906098 (490331, 1674406)	90609.80 (49033.13, 167440.59)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	66	10 (10, 10)	1904953 (1082862, 3351163)	190495.28 (108286.16, 335116.27)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	66	5 (5, 5)	983 (558, 1731)	195.68 (111.15, 344.52)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	66	5 (5, 5)	703 (521, 949)	140.66 (104.20, 189.89)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	29	10 (10, 10)	949883 (328789, 2744248)	94988.35 (32878.90, 274424.81)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	10 (10, 10)	2924658 (1201092, 7121543)	292465.84 (120109.18, 712154.31)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	10 (10, 10)	4636716 (2431319, 8842582)	463671.64 (243131.93, 884258.16)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5 (5, 6)	1913 (1251, 2927)	352.21 (235.06, 527.74)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5 (5, 5)	1057 (885, 1263)	211.35 (176.91, 252.50)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	24	10 (10, 10)	74137 (26567, 206880)	7413.65 (2656.71, 20688.05)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)	197988 (98969, 396074)	19798.80 (9896.94, 39607.44)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)	562342 (266894, 1184845)	56234.21 (26689.45, 118484.53)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	24	5 (5, 5)	509 (158, 1647)	101.89 (31.51, 329.48)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	24	5 (5, 5)	277 (105, 730)	53.90 (20.47, 141.96)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	18	10 (10, 10)	15017 (6900, 32685)	1501.75 (689.99, 3268.51)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	18	10 (10, 10)	11461 (4194, 31321)	1146.08 (419.37, 3132.11)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	18	10 (10, 10)	35638 (16000, 79381)	3563.78 (1599.95, 7938.08)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	18	5 (5, 5)	55 (26, 113)	10.91 (5.25, 22.65)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	18	5 (5, 5)	149 (59, 380)	29.90 (11.75, 76.09)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	12 (9, 15)	234912 (74447, 741250)	20348.03 (7369.11, 56186.25)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)	59199 (23886, 146717)	5919.88 (2388.62, 14671.66)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)	142598 (50067, 406140)	14259.85 (5006.72, 40614.04)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	6 (4, 7)	879 (253, 3055)	153.37 (48.34, 486.56)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5 (5, 5)	874 (560, 1363)	174.80 (112.05, 272.68)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	3	10 (10, 10)	19985 (10696, 37340)	1998.48 (1069.62, 3733.97)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	10 (10, 10)	10498 (5244, 21016)	1049.78 (524.39, 2101.56)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	10 (10, 10)	10397 (4869, 22198)	1039.68 (486.95, 2219.81)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	3	5 (5, 5)	108 (45, 256)	21.55 (9.06, 51.25)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	3	5 (5, 5)	300 (91, 997)	60.10 (18.11, 199.38)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	18	10 (10, 10)	167822 (51580, 546035)	16782.22 (5157.96, 54603.54)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	18	10 (10, 10)	725992 (238768, 2207433)	72599.17 (23876.78, 220743.30)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	18	10 (10, 10)	1930089 (855159, 4356201)	193008.89 (85515.86, 435620.12)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	18	5 (5, 5)	435 (99, 1909)	86.91 (19.78, 381.89)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	18	5 (5, 5)	1218 (1127, 1315)	243.56 (225.50, 263.07)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	12 (9, 15)	3024823 (954940, 9581286)	262009.71 (93500.92, 734207.61)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)	5105303 (2288167, 11390827)	510530.31 (228816.74, 1139082.75)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)	11621610 (6182061, 21847379)	1162161.04 (618206.08, 2184737.95)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	6 (4, 7)	4404 (4404, 4404)	768.69 (600.26, 984.38)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5 (5, 5)	1295 (1295, 1295)	259.00 (259.00, 259.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)	6 (4, 9)	1.23 (0.86, 1.75)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	3	10 (10, 10)	453454 (76267, 2696067)	45345.41 (7626.69, 269606.73)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	10 (10, 10)	1243423 (96936, 15949666)	124342.31 (9693.63, 1594966.60)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	10 (10, 10)	1110197 (235572, 5232112)	111019.69 (23557.16, 523211.22)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	3	5 (5, 5)	281 (112, 704)	56.26 (22.48, 140.82)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	3	5 (5, 5)	1295 (1295, 1295)	259.00 (259.00, 259.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	14	10 (10, 10)	16151 (3597, 72529)	1615.14 (359.67, 7252.91)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	14	10 (10, 10)	39447 (17797, 87434)	3944.67 (1779.68, 8743.40)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	14	10 (10, 10)	31462 (15511, 63816)	3146.22 (1551.14, 6381.56)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	14	5 (5, 5)	89 (27, 289)	17.74 (5.45, 57.78)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	14	5 (5, 5)	322 (94, 1101)	64.44 (18.85, 220.21)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	2	10 (10, 10)	41841 (38644, 45303)	4184.14 (3864.43, 4530.29)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	10 (10, 10)	22851 (2930, 178210)	2285.06 (293.00, 17821.03)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	10 (10, 10)	67369 (47260, 96035)	6736.95 (4726.02, 9603.52)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5 (5, 5)	214 (113, 407)	42.81 (22.51, 81.43)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5 (5, 5)	1291 (1286, 1297)	258.25 (257.12, 259.38)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	3	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	3	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	3	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)	3103 (361, 26675)	310.27 (36.09, 2667.52)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)	4638 (1418, 15175)	463.82 (141.77, 1517.45)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	5	10 (10, 10)	14696 (6832, 31614)	1469.61 (683.16, 3161.38)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	5	5 (5, 5)	15 (3, 73)	3.00 (0.62, 14.55)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)	199 (114, 348)	39.82 (22.77, 69.64)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	14	10 (10, 10)	537536 (139491, 2071422)	53753.58 (13949.10, 207142.19)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	14	10 (10, 10)	1848200 (433763, 7874901)	184820.00 (43376.33, 787490.08)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	14	10 (10, 10)	2455977 (1127424, 5350092)	245597.72 (112742.43, 535009.19)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	14	5 (5, 5)	1822 (931, 3566)	364.44 (186.21, 713.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	14	5 (5, 5)	1196 (1019, 1404)	239.20 (203.71, 280.86)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	2	10 (10, 10)	414088 (162591, 1054602)	41408.84 (16259.14, 105460.18)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	10 (10, 10)	5063269 (4385220, 5846160)	506326.95 (438521.97, 584616.04)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	10 (10, 10)	11487555 (9576687, 13779706)	1148755.51 (957668.66, 1377970.57)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5 (5, 5)	4404 (4404, 4404)	880.80 (880.80, 880.80)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5 (5, 5)	1295 (1295, 1295)	259.00 (259.00, 259.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	3	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	3	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	3	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)	17543 (578, 532206)	1754.28 (57.83, 53220.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)	324963 (66924, 1577928)	32496.26 (6692.36, 157792.79)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	5	10 (10, 10)	286089 (71349, 1147130)	28608.88 (7134.92, 114712.96)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	5	5 (5, 5)	131 (43, 401)	26.15 (8.53, 80.13)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)	578 (316, 1057)	115.65 (63.24, 211.47)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	59	10 (10, 10)	15198 (8260, 27960)	1519.75 (826.04, 2796.04)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	10 (10, 10)	16641 (9544, 29015)	1664.06 (954.37, 2901.49)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	10 (10, 10)	43425 (26153, 72103)	4342.46 (2615.28, 7210.31)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5 (5, 5)	68 (39, 117)	13.45 (7.78, 23.26)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5 (5, 6)	149 (81, 275)	28.68 (15.66, 52.54)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	12	10 (10, 10)	50664 (30305, 84701)	5066.40 (3030.47, 8470.11)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	10 (10, 10)	28036 (4957, 158572)	2803.55 (495.67, 15857.18)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	10 (10, 10)	122110 (36471, 408837)	12210.97 (3647.12, 40883.73)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	12	5 (5, 5)	145 (39, 540)	28.97 (7.77, 108.03)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	12	5 (5, 5)	192 (47, 780)	38.41 (9.46, 155.98)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	13	10 (10, 10)	5623 (1979, 15976)	562.28 (197.90, 1597.58)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	13	10 (10, 10)	9440 (5319, 16754)	944.00 (531.88, 1675.45)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	13	10 (10, 10)	15766 (6864, 36212)	1576.62 (686.44, 3621.16)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	13	5 (5, 5)	38 (14, 102)	7.66 (2.87, 20.42)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	13	5 (5, 5)	79 (43, 143)	15.75 (8.69, 28.55)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	59	10 (10, 10)	249009 (120236, 515698)	24900.87 (12023.57, 51569.80)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	10 (10, 10)	1103628 (728193, 1672627)	110362.80 (72819.25, 167262.74)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	10 (10, 10)	1620804 (995033, 2640118)	162080.36 (99503.27, 264011.84)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5 (5, 5)	967 (539, 1733)	191.84 (107.09, 343.63)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5 (5, 6)	733 (519, 1034)	141.25 (98.85, 201.84)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	12	10 (10, 10)	866223 (92469, 8114517)	86622.25 (9246.90, 811451.74)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	10 (10, 10)	2920073 (656502, 12988282)	292007.32 (65650.16, 1298828.20)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	10 (10, 10)	3281996 (831214, 12958755)	328199.62 (83121.40, 1295875.46)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	12	5 (5, 5)	2353 (1492, 3710)	470.54 (298.43, 741.92)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	12	5 (5, 5)	1240 (1172, 1312)	248.01 (234.33, 262.49)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	13	10 (10, 10)	74259 (13319, 414020)	7425.90 (1331.92, 41401.98)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	13	10 (10, 10)	397735 (151284, 1045671)	39773.45 (15128.35, 104567.08)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	13	10 (10, 10)	341262 (111838, 1041330)	34126.21 (11183.76, 104132.96)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	13	5 (5, 5)	208 (82, 528)	41.60 (16.41, 105.51)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	13	5 (5, 5)	274 (101, 741)	54.82 (20.28, 148.22)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	26	10 (10, 10)	21227 (12992, 34682)	2122.74 (1299.22, 3468.25)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	26	10 (10, 10)	26084 (14192, 47941)	2608.38 (1419.17, 4794.08)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	26	10 (10, 10)	43385 (25561, 73636)	4338.49 (2556.14, 7363.64)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	26	5 (5, 5)	102 (49, 212)	20.41 (9.82, 42.44)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	26	6 (5, 8)	224 (95, 525)	35.96 (15.05, 85.90)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	10 (10, 10)	18265 (11735, 28429)	1826.51 (1173.48, 2842.94)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)	76411 (30604, 190779)	7641.07 (3060.41, 19077.85)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)	94179 (19948, 444638)	9417.89 (1994.81, 44463.78)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5 (5, 5)	121 (70, 207)	24.12 (14.04, 41.42)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5 (5, 5)	267 (164, 434)	53.33 (32.80, 86.73)
Other	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	4	10 (10, 10)	27046 (16817, 43496)	2704.61 (1681.74, 4349.61)
Other	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	10 (10, 10)	38412 (15313, 96357)	3841.20 (1531.26, 9635.69)
Other	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	10 (10, 10)	85151 (41858, 173219)	8515.08 (4185.82, 17321.95)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	4	5 (5, 5)	92 (33, 256)	18.31 (6.53, 51.29)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	4	5 (5, 5)	373 (162, 859)	74.63 (32.43, 171.75)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	26	10 (10, 10)	437326 (219049, 873111)	43732.62 (21904.91, 87311.13)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	26	10 (10, 10)	1787226 (794365, 4021042)	178722.55 (79436.49, 402104.23)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	26	10 (10, 10)	1649029 (961272, 2828854)	164902.91 (96127.17, 282885.39)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	26	5 (5, 5)	1346 (762, 2377)	269.20 (152.47, 475.31)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	26	6 (5, 8)	957 (753, 1217)	153.78 (106.72, 221.60)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	10 (10, 10)	450093 (71561, 2830942)	45009.31 (7156.06, 283094.19)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)	4732568 (2892045, 7744417)	473256.83 (289204.50, 774441.69)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)	3835573 (2151501, 6837838)	383557.27 (215150.12, 683783.85)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5 (5, 5)	3294 (2436, 4456)	658.88 (487.12, 891.21)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5 (5, 5)	1283 (1259, 1308)	256.67 (251.83, 261.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	4	10 (10, 10)	291515 (127370, 667200)	29151.54 (12736.99, 66720.01)
Other	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	10 (10, 10)	1355588 (417733, 4399029)	135558.83 (41773.30, 439902.90)
Other	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	10 (10, 10)	2753608 (989549, 7662441)	275360.81 (98954.86, 766244.07)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	4	5 (5, 5)	1318 (558, 3115)	263.58 (111.51, 623.06)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	4	5 (5, 5)	1039 (727, 1487)	207.88 (145.35, 297.30)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	99	10 (10, 10)	25782 (15886, 41843)	2578.22 (1588.61, 4184.28)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	99	10 (10, 10)	20590 (13148, 32244)	2059.00 (1314.83, 3224.35)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	99	10 (10, 10)	39264 (26120, 59023)	3926.39 (2611.95, 5902.30)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	99	5 (5, 5)	109 (67, 179)	21.45 (13.08, 35.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	99	5 (5, 5)	190 (117, 308)	38.04 (23.47, 61.66)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	25	10 (10, 10)	28552 (12054, 67631)	2855.21 (1205.39, 6763.11)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	10 (10, 10)	33128 (16908, 64908)	3312.81 (1690.79, 6490.85)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	10 (10, 10)	55809 (35428, 87915)	5580.87 (3542.76, 8791.49)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5 (5, 5)	105 (44, 251)	20.54 (8.57, 49.24)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5 (5, 5)	369 (203, 672)	71.78 (39.37, 130.87)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	19	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	19	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	19	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	21	11 (9, 12)	8693 (3509, 21535)	812.96 (328.08, 2014.44)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	21	10 (10, 10)	16964 (6980, 41227)	1696.41 (698.04, 4122.73)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	21	10 (10, 10)	14447 (7065, 29545)	1444.71 (706.45, 2954.45)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	21	6 (5, 7)	26 (9, 73)	4.60 (1.59, 13.27)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	21	5 (5, 6)	99 (48, 204)	18.51 (8.66, 39.56)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	99	10 (10, 10)	499821 (257189, 971351)	49982.06 (25718.87, 97135.14)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	99	10 (10, 10)	1040782 (613558, 1765484)	104078.18 (61355.78, 176548.45)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	99	10 (10, 10)	2590506 (1518126, 4420399)	259050.64 (151812.61, 442039.93)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	99	5 (5, 5)	1144 (732, 1788)	224.72 (143.95, 350.82)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	99	5 (5, 5)	660 (428, 1017)	131.95 (85.59, 203.42)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	25	10 (10, 10)	1115210 (426106, 2918747)	111521.04 (42610.56, 291874.68)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	10 (10, 10)	2328826 (1007293, 5384162)	232882.61 (100729.33, 538416.23)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	10 (10, 10)	6182149 (4479678, 8531632)	618214.86 (447967.76, 853163.21)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5 (5, 5)	3035 (2203, 4181)	596.42 (432.73, 822.04)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5 (5, 5)	1257 (1193, 1326)	244.70 (226.83, 263.97)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	19	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	19	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	19	5 (5, 5)	5 (5, 5)	1.03 (0.97, 1.08)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	21	11 (9, 12)	90079 (42759, 189764)	8423.65 (3880.11, 18287.61)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	21	10 (10, 10)	207303 (76442, 562184)	20730.33 (7644.23, 56218.43)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	21	10 (10, 10)	389421 (174424, 869424)	38942.08 (17442.41, 86942.44)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	21	6 (5, 7)	689 (292, 1626)	122.43 (55.08, 272.11)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	21	5 (5, 6)	449 (302, 669)	84.05 (53.82, 131.26)

Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Underrepresented minority status</b>								
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	393	10 (10, 10)	23741 (19430, 29008)	2357.02 (1929.39, 2879.43)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	393	10 (10, 10)	25576 (21309, 30698)	2546.75 (2121.49, 3057.26)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	393	10 (10, 10)	43313 (36931, 50799)	4315.57 (3680.56, 5060.13)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	393	5 (5, 5)	109 (89, 132)	21.40 (17.61, 26.01)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	393	5 (5, 5)	205 (165, 254)	39.98 (32.22, 49.61)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	114	10 (10, 10)	38342 (25744, 57105)	3820.85 (2566.39, 5688.49)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	114	10 (10, 10)	40819 (28224, 59034)	4081.88 (2822.39, 5903.42)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	114	10 (10, 10)	80359 (56437, 114420)	8035.88 (5643.74, 11441.95)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	114	5 (5, 5)	170 (115, 252)	33.13 (22.53, 48.72)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	114	5 (5, 5)	236 (158, 353)	47.24 (31.57, 70.69)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	69	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	69	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	69	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	69	5 (5, 5)	5 (5, 5)	1.01 (1.00, 1.03)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	69	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	116	10 (10, 10)	10301 (7085, 14976)	1030.08 (708.49, 1497.63)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	10 (10, 10)	11593 (8642, 15552)	1159.29 (864.18, 1555.17)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	10 (10, 10)	19791 (14900, 26287)	1979.10 (1490.01, 2628.73)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	116	5 (5, 5)	42 (28, 62)	8.14 (5.52, 12.02)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	116	5 (5, 5)	110 (76, 159)	21.76 (15.06, 31.45)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	393	10 (10, 10)	440291 (337736, 573987)	43712.88 (33550.60, 56953.26)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	393	10 (10, 10)	1235548 (995643, 1533259)	123028.38 (99083.54, 152759.81)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	393	10 (10, 10)	2151402 (1801329, 2569508)	214357.07 (179525.32, 255946.92)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	393	5 (5, 5)	1127 (922, 1377)	222.29 (182.05, 271.43)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	393	5 (5, 5)	814 (730, 908)	159.02 (142.19, 177.84)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	114	10 (10, 10)	707066 (402854, 1241003)	70460.43 (40153.35, 123642.79)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	114	10 (10, 10)	2687527 (1765786, 4090419)	268752.73 (176578.56, 409041.90)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	114	10 (10, 10)	4469619 (3275038, 6099925)	446961.85 (327503.83, 609992.54)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	114	5 (5, 5)	1780 (1303, 2432)	346.17 (254.25, 471.31)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	114	5 (5, 5)	1012 (853, 1201)	202.43 (170.62, 240.19)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	69	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	69	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	69	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	69	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	69	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.03)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	116	10 (10, 10)	130463 (75585, 225185)	13046.34 (7558.53, 22518.52)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	10 (10, 10)	388216 (247326, 609362)	38821.57 (24732.65, 60936.22)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	10 (10, 10)	656306 (447692, 962131)	65630.64 (44769.18, 96213.08)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	116	5 (5, 5)	462 (282, 759)	89.62 (55.04, 145.95)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	116	5 (5, 5)	469 (335, 655)	92.81 (66.38, 129.75)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	382	10 (10, 10)	26779 (21016, 34123)	2677.93 (2101.59, 3412.34)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	10 (10, 10)	24073 (19243, 30116)	2377.24 (1899.30, 2975.46)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	10 (10, 10)	44837 (37733, 53280)	4483.75 (3773.28, 5328.00)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	382	5 (5, 5)	116 (93, 145)	23.26 (18.62, 29.04)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	382	5 (5, 5)	204 (165, 253)	40.66 (32.80, 50.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	129	10 (10, 10)	32140 (21350, 48383)	3202.89 (2128.04, 4820.65)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	10 (10, 10)	29603 (19188, 45670)	2960.25 (1918.78, 4567.01)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	10 (10, 10)	64812 (45432, 92458)	6481.16 (4543.19, 9245.79)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	129	5 (5, 5)	142 (96, 209)	28.22 (19.18, 41.54)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	129	5 (5, 5)	236 (164, 340)	47.27 (32.81, 68.09)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.01)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)	16332 (11301, 23603)	1633.19 (1130.10, 2360.25)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)	14167 (10126, 19819)	1416.65 (1012.60, 1981.93)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)	21729 (16518, 28584)	2172.89 (1651.80, 2858.37)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)	69 (46, 102)	13.62 (9.23, 20.11)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)	121 (85, 172)	24.05 (16.89, 34.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	382	10 (10, 10)	375305 (279792, 503424)	37530.54 (27979.22, 50342.40)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	382	10 (10, 10)	1145512 (909652, 1442528)	113119.92 (89898.96, 142338.86)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	382	10 (10, 10)	2459185 (2019406, 2994737)	245918.47 (201940.56, 299473.74)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	382	5 (5, 5)	1125 (908, 1394)	224.59 (181.22, 278.35)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	382	5 (5, 5)	804 (714, 904)	159.85 (142.07, 179.85)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	129	10 (10, 10)	758610 (476254, 1208367)	75599.31 (47448.93, 120450.68)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	129	10 (10, 10)	2229169 (1492057, 3330433)	222916.94 (149205.69, 333043.33)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	129	10 (10, 10)	5100285 (3772135, 6896069)	510028.49 (377213.53, 689606.91)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	129	5 (5, 5)	1594 (1095, 2320)	316.63 (217.53, 460.88)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	129	5 (5, 5)	932 (742, 1172)	186.47 (148.38, 234.34)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)	169965 (105036, 275030)	16996.51 (10503.63, 27503.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)	470592 (326087, 679136)	47059.23 (32608.68, 67913.55)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)	837482 (614121, 1142080)	83748.17 (61412.13, 114208.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)	437 (268, 713)	86.67 (53.17, 141.29)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)	739 (608, 898)	146.96 (120.78, 178.80)

Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Age, Underrepresented minority status</b>								
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	193	10 (10, 10)	18617 (14581, 23771)	1844.76 (1445.19, 2354.81)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	193	10 (10, 10)	19144 (15306, 23945)	1904.08 (1522.04, 2382.02)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	193	10 (10, 10)	32027 (26367, 38903)	3187.91 (2625.36, 3870.99)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	193	5 (5, 5)	86 (68, 110)	17.05 (13.43, 21.65)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	193	5 (5, 5)	179 (137, 234)	34.81 (26.58, 45.61)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)	30511 (18786, 49554)	3051.13 (1878.62, 4955.44)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)	32209 (20542, 50504)	3220.92 (2054.16, 5050.39)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)	61990 (40202, 95587)	6199.04 (4020.23, 9558.66)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5 (5, 5)	138 (86, 223)	26.83 (16.75, 42.96)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)	191 (116, 314)	38.14 (23.16, 62.82)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	68	10 (10, 10)	8750 (5610, 13649)	875.01 (560.96, 1364.88)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	10 (10, 10)	9662 (6824, 13679)	966.15 (682.40, 1367.90)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	10 (10, 10)	15502 (11053, 21741)	1550.18 (1105.32, 2174.09)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	68	5 (5, 6)	39 (24, 62)	7.43 (4.66, 11.86)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	68	5 (5, 5)	101 (65, 158)	20.05 (12.87, 31.23)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	193	10 (10, 10)	338558 (243991, 469779)	33547.16 (24195.30, 46513.68)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	193	10 (10, 10)	975160 (746375, 1274073)	96988.30 (74178.81, 126811.57)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	193	10 (10, 10)	1676896 (1346960, 2087650)	166914.37 (134121.13, 207725.72)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	193	5 (5, 5)	967 (754, 1242)	190.79 (148.75, 244.70)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	193	5 (5, 5)	776 (677, 889)	151.02 (131.35, 173.64)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)	512544 (256668, 1023507)	51254.38 (25666.76, 102350.70)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)	2022149 (1205369, 3392395)	202214.93 (120536.90, 339239.48)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)	3386971 (2310611, 4964736)	338697.14 (231061.12, 496473.61)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5 (5, 5)	1594 (1089, 2335)	309.15 (212.03, 450.76)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)	971 (785, 1201)	194.18 (156.99, 240.18)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	68	10 (10, 10)	112207 (57984, 217134)	11220.70 (5798.44, 21713.42)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	10 (10, 10)	315796 (183352, 543909)	31579.56 (18335.22, 54390.88)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	10 (10, 10)	495020 (312350, 784519)	49501.95 (31234.97, 78451.93)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	68	5 (5, 6)	411 (225, 752)	79.12 (43.70, 143.24)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	68	5 (5, 5)	421 (280, 632)	83.12 (55.28, 124.98)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	191	10 (10, 10)	22210 (16522, 29856)	2220.98 (1652.21, 2985.56)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	10 (10, 10)	19788 (15053, 26012)	1947.94 (1480.95, 2562.18)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	10 (10, 10)	35886 (29131, 44208)	3588.64 (2913.13, 4420.78)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	191	5 (5, 5)	100 (77, 132)	20.03 (15.29, 26.25)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	191	5 (5, 5)	185 (142, 241)	36.91 (28.37, 48.02)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	62	10 (10, 10)	25250 (15195, 41961)	2513.77 (1513.07, 4176.30)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	10 (10, 10)	21183 (12320, 36424)	2118.31 (1231.95, 3642.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	10 (10, 10)	45051 (29098, 69752)	4505.14 (2909.77, 6975.22)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5 (5, 5)	120 (74, 194)	23.86 (14.72, 38.68)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5 (5, 5)	225 (142, 357)	44.94 (28.32, 71.31)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)	13087 (8369, 20465)	1308.74 (836.93, 2046.53)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)	10524 (7017, 15784)	1052.42 (701.72, 1578.39)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)	17209 (12342, 23995)	1720.87 (1234.18, 2399.49)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)	55 (34, 89)	10.91 (6.76, 17.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)	102 (66, 158)	20.35 (13.18, 31.43)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	191	10 (10, 10)	296623 (207363, 424307)	29662.35 (20736.26, 42430.74)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	10 (10, 10)	896327 (677101, 1186533)	88236.16 (66725.93, 116680.58)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	10 (10, 10)	2068381 (1627522, 2628658)	206838.07 (162752.17, 262865.84)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	191	5 (5, 5)	989 (760, 1287)	197.34 (151.67, 256.77)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	191	5 (5, 5)	775 (671, 895)	154.39 (133.65, 178.34)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	62	10 (10, 10)	606489 (339687, 1082845)	60378.15 (33805.20, 107839.09)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	10 (10, 10)	1718791 (1036442, 2850370)	171879.14 (103644.24, 285036.95)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	10 (10, 10)	4182125 (2860869, 6113586)	418212.49 (286086.90, 611358.58)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5 (5, 5)	1411 (874, 2278)	281.01 (174.06, 453.68)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5 (5, 5)	891 (665, 1193)	178.14 (132.99, 238.62)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)	133554 (73958, 241173)	13355.45 (7395.84, 24117.34)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)	325144 (210030, 503351)	32514.43 (21003.02, 50335.05)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)	624130 (429465, 907033)	62413.04 (42946.48, 90703.29)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)	351 (191, 643)	69.70 (38.03, 127.75)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)	739 (582, 937)	146.75 (115.55, 186.38)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	200	10 (10, 10)	58267 (45099, 75279)	5826.69 (4509.94, 7527.89)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	200	10 (10, 10)	74553 (60301, 92174)	7455.32 (6030.09, 9217.40)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	200	10 (10, 10)	132080 (108900, 160195)	13208.01 (10889.96, 16019.48)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	200	5 (5, 5)	251 (199, 318)	49.57 (39.16, 62.73)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	200	5 (5, 5)	337 (283, 402)	66.65 (55.94, 79.42)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	53	10 (10, 11)	94738 (62290, 144087)	9311.28 (6167.46, 14057.64)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	10 (10, 10)	104287 (72325, 150372)	10428.66 (7232.52, 15037.20)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	10 (10, 10)	224552 (169253, 297919)	22455.20 (16925.29, 29791.87)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	53	5 (5, 5)	388 (264, 573)	76.43 (52.18, 111.95)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	53	5 (5, 5)	551 (433, 701)	110.22 (86.66, 140.17)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 6)	1.05 (0.98, 1.12)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)	5 (5, 5)	1.03 (0.97, 1.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	48	10 (10, 10)	20422 (12113, 34429)	2042.17 (1211.32, 3442.91)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	10 (10, 10)	24899 (16577, 37400)	2489.92 (1657.70, 3739.95)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	10 (10, 10)	55140 (40420, 75222)	5514.03 (4041.97, 7522.20)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	48	5 (5, 5)	60 (36, 98)	11.93 (7.25, 19.63)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	48	5 (5, 5)	154 (99, 238)	30.73 (19.83, 47.63)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	200	10 (10, 10)	1161925 (875280, 1542444)	116192.50 (87527.95, 154244.42)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	200	10 (10, 10)	2961289 (2382047, 3681384)	296128.86 (238204.73, 368138.36)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	200	10 (10, 10)	5400113 (4473076, 6519276)	540011.30 (447307.64, 651927.62)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	200	5 (5, 5)	1981 (1657, 2368)	390.89 (326.93, 467.37)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	200	5 (5, 5)	974 (882, 1074)	192.41 (174.30, 212.41)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	53	10 (10, 11)	2527735 (1605310, 3980191)	248438.14 (158474.90, 389471.83)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	53	10 (10, 10)	8289342 (6234637, 11021202)	828934.24 (623463.75, 1102120.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	53	10 (10, 10)	13404146 (11368351, 15804504)	1340414.64 (1136835.05, 1580450.39)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	53	5 (5, 5)	2753 (1996, 3797)	541.71 (392.83, 747.01)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	53	5 (5, 5)	1194 (1084, 1315)	238.72 (216.75, 262.90)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.07)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	48	10 (10, 10)	245538 (136315, 442276)	24553.75 (13631.47, 44227.57)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	10 (10, 10)	923015 (566896, 1502845)	92301.47 (56689.56, 150284.49)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	10 (10, 10)	2142419 (1491534, 3077342)	214241.92 (149153.39, 307734.21)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	48	5 (5, 5)	756 (483, 1183)	151.19 (96.60, 236.65)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	48	5 (5, 5)	737 (545, 995)	147.36 (109.10, 199.05)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	191	10 (10, 10)	56778 (44514, 72421)	5677.79 (4451.35, 7242.13)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	10 (10, 10)	52907 (42543, 65796)	5290.74 (4254.33, 6579.64)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	10 (10, 10)	109676 (90572, 132809)	10967.58 (9057.23, 13280.87)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	191	5 (5, 5)	212 (166, 270)	42.35 (33.28, 53.90)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	191	5 (5, 5)	303 (248, 371)	59.93 (48.97, 73.35)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	67	10 (10, 10)	72925 (46287, 114895)	7292.52 (4628.66, 11489.48)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	10 (10, 10)	92241 (63197, 134634)	9224.10 (6319.66, 13463.37)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	10 (10, 10)	222873 (158277, 313832)	22287.34 (15827.75, 31383.21)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	67	5 (5, 5)	253 (168, 383)	49.94 (33.12, 75.30)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	67	5 (5, 5)	281 (201, 392)	56.12 (40.12, 78.49)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 6)	5 (5, 5)	0.93 (0.84, 1.03)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	56	10 (10, 10)	37858 (24699, 58028)	3785.80 (2469.89, 5802.79)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	10 (10, 10)	43776 (31011, 61795)	4377.61 (3101.15, 6179.49)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	10 (10, 10)	52667 (39799, 69696)	5266.69 (3979.86, 6969.59)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	56	5 (5, 5)	161 (111, 233)	31.66 (22.00, 45.56)
Age $\geq$ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	56	5 (5, 5)	227 (160, 322)	45.33 (31.90, 64.41)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	191	10 (10, 10)	965639 (711968, 1309692)	96563.88 (71196.76, 130969.21)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	191	10 (10, 10)	3068441 (2422082, 3887287)	306844.08 (242208.22, 388728.71)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	191	10 (10, 10)	4928264 (3996777, 6076842)	492826.36 (399677.67, 607684.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	191	5 (5, 5)	1888 (1555, 2293)	377.61 (310.94, 458.59)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	191	5 (5, 5)	931 (828, 1047)	183.82 (163.42, 206.76)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	67	10 (10, 10)	1622232 (969809, 2713563)	162223.20 (96980.86, 271356.28)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	10 (10, 10)	5390612 (3895457, 7459637)	539061.19 (389545.70, 745963.73)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10007727 (7816870, 12812623)	1000772.72 (781686.98, 1281262.26)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	67	5 (5, 5)	2410 (1869, 3108)	474.86 (368.42, 612.07)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	67	5 (5, 5)	1089 (942, 1259)	217.78 (188.35, 251.81)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 6)	5 (5, 5)	0.93 (0.84, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	56	10 (10, 10)	424439 (260765, 690846)	42443.90 (26076.50, 69084.62)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	10 (10, 10)	1915041 (1278118, 2869362)	191504.09 (127811.75, 286936.18)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	10 (10, 10)	2557032 (1861144, 3513115)	255703.22 (186114.43, 351311.49)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	56	5 (5, 5)	1007 (691, 1468)	198.26 (136.42, 288.13)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	56	5 (5, 5)	739 (577, 946)	147.72 (115.34, 189.18)

Table 7a. The ratios of GMTs/GMCs between groups by Age

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Age</b>							
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.97, 1.03)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.04 (0.98, 1.10)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.94, 1.05)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.02)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	62734 (53175, 74012)	20606 (17030, 24933)	3.04 (2.37, 3.92)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	66120 (57107, 76557)	18690 (15666, 22298)	3.54 (2.81, 4.45)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	125502 (110521, 142514)	32936 (28433, 38151)	3.81 (3.14, 4.63)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	247 (211, 290)	93 (77, 111)	2.67 (2.09, 3.39)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	337 (297, 383)	176 (146, 212)	1.91 (1.53, 2.40)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	85113 (62586, 115747)	27208 (19791, 37404)	3.13 (2.01, 4.87)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	104632 (80743, 135588)	25636 (18798, 34962)	4.08 (2.72, 6.11)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	226823 (181984, 282709)	51114 (39492, 66155)	4.44 (3.16, 6.23)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	319 (240, 424)	119 (87, 163)	2.69 (1.76, 4.11)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	390 (314, 484)	212 (156, 289)	1.84 (1.26, 2.68)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.04)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.03)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	31844 (23632, 42911)	10827 (7922, 14798)	2.94 (1.91, 4.53)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	36414 (28478, 46563)	10904 (8271, 14375)	3.34 (2.31, 4.83)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	55117 (45541, 66708)	15468 (12160, 19677)	3.56 (2.62, 4.84)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	116 (87, 155)	44 (31, 61)	2.65 (1.70, 4.11)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	209 (160, 273)	100 (74, 134)	2.10 (1.41, 3.12)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	1179594 (968207, 1437132)	305133 (239829, 388219)	3.87 (2.83, 5.28)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	3212597 (2767271, 3729588)	895755 (739423, 1085138)	3.59 (2.81, 4.57)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	5505250 (4821760, 6285625)	1844841 (1557704, 2184906)	2.98 (2.41, 3.70)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1977 (1746, 2239)	993 (832, 1185)	1.99 (1.60, 2.47)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	954 (886, 1027)	749 (669, 838)	1.27 (1.11, 1.46)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2049317 (1453877, 2888619)	616032 (415812, 912661)	3.33 (1.97, 5.61)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6468629 (5183114, 8072975)	1859839 (1339478, 2582350)	3.48 (2.34, 5.17)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	11609994 (9972859, 13515879)	4090288 (3266706, 5121508)	2.84 (2.16, 3.72)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2591 (2154, 3117)	1623 (1235, 2134)	1.60 (1.15, 2.22)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1142 (1047, 1246)	929 (778, 1111)	1.23 (1.01, 1.50)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	370633 (263433, 521457)	112952 (76274, 167269)	3.28 (1.95, 5.52)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	1549307 (1153510, 2080910)	283611 (202119, 397958)	5.46 (3.49, 8.56)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	2556189 (2026611, 3224153)	527061 (396174, 701191)	4.85 (3.36, 7.01)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	1047 (795, 1380)	418 (282, 621)	2.50 (1.55, 4.05)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	768 (648, 912)	572 (471, 696)	1.34 (1.04, 1.74)

Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Risk for Severe Covid-19</b>							
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (1.00, 1.02)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.02)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (1.00, 1.03)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.05)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.03 (0.99, 1.07)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.98, 1.05)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.97 (0.93, 1.02)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.98, 1.05)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	28670 (24229, 33926)	25170 (20506, 30894)	1.14 (0.87, 1.49)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	28540 (24712, 32962)	23014 (19012, 27859)	1.24 (0.97, 1.58)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	53828 (47269, 61297)	40370 (34441, 47319)	1.33 (1.08, 1.64)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	122 (104, 143)	112 (92, 136)	1.09 (0.85, 1.40)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	235 (205, 268)	191 (156, 233)	1.23 (0.97, 1.56)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	45549 (33622, 61708)	31228 (22446, 43447)	1.46 (0.93, 2.29)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50605 (38673, 66219)	29987 (21717, 41406)	1.69 (1.11, 2.57)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	103708 (82198, 130847)	60581 (46279, 79302)	1.71 (1.20, 2.45)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	187 (142, 247)	133 (96, 185)	1.40 (0.91, 2.16)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	313 (245, 401)	221 (160, 304)	1.42 (0.95, 2.13)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.02)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	16693 (11811, 23592)	12441 (8987, 17222)	1.34 (0.83, 2.16)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	16432 (12204, 22126)	13047 (9775, 17413)	1.26 (0.83, 1.91)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	25583 (19533, 33507)	18259 (14224, 23440)	1.40 (0.97, 2.03)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	62 (45, 86)	50 (35, 72)	1.23 (0.77, 1.99)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	143 (109, 190)	107 (79, 146)	1.34 (0.88, 2.03)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	445834 (360275, 551712)	392406 (303187, 507878)	1.14 (0.81, 1.59)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	1319692 (1118561, 1556987)	1123054 (914183, 1379646)	1.18 (0.90, 1.53)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	2575227 (2221001, 2985949)	2237277 (1866421, 2681821)	1.15 (0.91, 1.46)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1124 (960, 1316)	1159 (961, 1399)	0.97 (0.76, 1.24)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	837 (767, 914)	770 (683, 868)	1.09 (0.94, 1.26)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1225726 (870946, 1725027)	682444 (454031, 1025766)	1.80 (1.05, 3.06)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	3156401 (2463712, 4043844)	2184166 (1553688, 3070489)	1.45 (0.95, 2.20)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6851214 (5608006, 8370022)	4579234 (3631837, 5773768)	1.50 (1.10, 2.03)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2007 (1611, 2502)	1717 (1295, 2275)	1.17 (0.82, 1.67)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1048 (938, 1169)	945 (786, 1136)	1.11 (0.89, 1.37)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.03)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	182813 (120848, 276551)	131432 (87374, 197705)	1.39 (0.78, 2.49)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	856287 (610469, 1201088)	307277 (215247, 438657)	2.79 (1.70, 4.57)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	1028885 (775052, 1365850)	638515 (472586, 862703)	1.61 (1.06, 2.44)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	734 (539, 1000)	442 (292, 670)	1.66 (0.99, 2.79)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	767 (652, 902)	562 (457, 690)	1.37 (1.05, 1.77)

Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Age &lt; 65, Risk for Severe Covid-19</b>							
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (1.00, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.97, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 6)	5 (5, 5)	1.05 (0.98, 1.12)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.96, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.98 (0.92, 1.04)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.02 (0.97, 1.07)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	19005 (15082, 23949)	21072 (16663, 26647)	0.90 (0.65, 1.25)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	18442 (15299, 22230)	18760 (15066, 23359)	0.98 (0.74, 1.31)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	34807 (29395, 41215)	32437 (27047, 38900)	1.07 (0.84, 1.38)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	86 (69, 107)	95 (76, 119)	0.91 (0.66, 1.24)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	188 (156, 226)	173 (138, 218)	1.08 (0.81, 1.46)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	33554 (23078, 48787)	25989 (17790, 37968)	1.29 (0.76, 2.20)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	33530 (24358, 46155)	24175 (16674, 35050)	1.39 (0.85, 2.26)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	70775 (53800, 93105)	47604 (34972, 64799)	1.49 (0.98, 2.25)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	151 (106, 214)	113 (77, 164)	1.34 (0.80, 2.24)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	306 (221, 422)	196 (135, 284)	1.56 (0.95, 2.55)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	12678 (8175, 19661)	10367 (7093, 15154)	1.22 (0.68, 2.18)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	12250 (8318, 18041)	10560 (7547, 14775)	1.16 (0.69, 1.94)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	18062 (12699, 25690)	14823 (11079, 19831)	1.22 (0.77, 1.92)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	47 (32, 71)	43 (28, 65)	1.10 (0.62, 1.96)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	112 (79, 159)	96 (67, 138)	1.16 (0.71, 1.92)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	276574 (207146, 369274)	313531 (233014, 421869)	0.88 (0.58, 1.33)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	849331 (677493, 1064753)	909023 (717438, 1151769)	0.93 (0.67, 1.30)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	1804238 (1480129, 2199318)	1856219 (1506314, 2287404)	0.97 (0.73, 1.30)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	867 (693, 1086)	1030 (829, 1280)	0.84 (0.62, 1.15)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	790 (697, 896)	738 (642, 848)	1.07 (0.89, 1.29)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	985427 (642793, 1510699)	555914 (347608, 889047)	1.77 (0.94, 3.34)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2355679 (1716870, 3232175)	1766199 (1191219, 2618712)	1.33 (0.80, 2.21)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5425974 (4187815, 7030203)	3845283 (2941570, 5026636)	1.41 (0.97, 2.05)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	1821 (1349, 2457)	1583 (1142, 2195)	1.15 (0.74, 1.79)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1016 (882, 1170)	912 (735, 1130)	1.11 (0.86, 1.44)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.05)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	133545 (78788, 226358)	107869 (66810, 174161)	1.24 (0.61, 2.52)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	616604 (402585, 944396)	229076 (151348, 346722)	2.69 (1.49, 4.88)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	714436 (501642, 1017496)	484772 (341439, 688275)	1.47 (0.90, 2.42)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	599 (405, 884)	379 (232, 619)	1.58 (0.84, 2.96)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	716 (580, 884)	538 (423, 685)	1.33 (0.97, 1.83)

MOCK

Table 7d. The ratios of GMTs/GMCs between groups by Age  $\geq 65$ , Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Age <math>\geq 65</math>, Risk for Severe Covid-19</b>							
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.04)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.03)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.04)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.03 (0.99, 1.08)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 6)	5 (5, 5)	1.01 (0.91, 1.13)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 11)	10 (10, 10)	1.02 (0.98, 1.06)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 6)	0.96 (0.91, 1.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	54078 (43102, 67850)	73663 (57986, 93579)	0.73 (0.53, 1.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	55999 (45176, 69415)	79137 (65095, 96208)	0.71 (0.53, 0.95)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	105500 (87212, 127621)	151428 (128696, 178176)	0.70 (0.54, 0.89)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	208 (165, 261)	299 (240, 371)	0.69 (0.51, 0.95)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	331 (277, 396)	344 (286, 413)	0.96 (0.75, 1.24)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76918 (46723, 126626)	91816 (62470, 134950)	0.84 (0.45, 1.57)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	102480 (65733, 159772)	106273 (78124, 144563)	0.96 (0.56, 1.65)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	199648 (136138, 292785)	249569 (193516, 321857)	0.80 (0.51, 1.27)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	271 (174, 423)	360 (249, 520)	0.75 (0.42, 1.35)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	327 (224, 477)	444 (346, 570)	0.74 (0.47, 1.16)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.96, 1.05)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.05)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	32071 (19673, 52283)	31710 (21750, 46230)	1.01 (0.55, 1.88)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	33000 (23427, 46484)	38609 (27620, 53970)	0.85 (0.53, 1.38)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	58456 (45049, 75852)	53225 (40976, 69134)	1.10 (0.76, 1.59)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	119 (75, 189)	114 (79, 165)	1.04 (0.58, 1.88)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	257 (168, 394)	185 (132, 260)	1.39 (0.81, 2.40)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	931589 (691760, 1254563)	1522680 (1184331, 1957692)	0.61 (0.41, 0.90)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	2605444 (2083168, 3258661)	4029556 (3333554, 4870873)	0.65 (0.48, 0.87)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	4459763 (3608315, 5512125)	6913673 (5962965, 8015958)	0.65 (0.50, 0.84)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1677 (1375, 2044)	2363 (2052, 2722)	0.71 (0.56, 0.90)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	916 (820, 1023)	996 (905, 1097)	0.92 (0.79, 1.06)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1781777 (1017168, 3121147)	2275652 (1483459, 3490888)	0.78 (0.39, 1.59)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5212369 (3582200, 7584388)	7603908 (5849216, 9884986)	0.69 (0.43, 1.08)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	10218944 (7605635, 13730191)	12774313 (11071512, 14739004)	0.80 (0.58, 1.11)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2374 (1755, 3211)	2767 (2202, 3477)	0.86 (0.59, 1.25)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1105 (929, 1314)	1171 (1082, 1268)	0.94 (0.78, 1.14)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.98 (0.95, 1.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	385267 (216300, 686226)	362201 (237645, 552041)	1.06 (0.52, 2.17)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	1867122 (1162726, 2998251)	1386685 (951612, 2020673)	1.35 (0.74, 2.47)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	2445717 (1675526, 3569942)	2624193 (1957915, 3517205)	0.93 (0.58, 1.50)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	1193 (762, 1868)	969 (683, 1375)	1.23 (0.70, 2.18)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	901 (724, 1123)	699 (551, 886)	1.29 (0.93, 1.78)

MOCK

Table 7e. The ratios of GMTs/GMCs between groups by Sex

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Sex</b>							
Male vs Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.98, 1.04)
Male vs Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.01)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.03)
Male vs Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.01)
Male vs Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.02)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.97, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.96, 1.01)
Male vs Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.01)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 6)	0.95 (0.89, 1.01)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.97, 1.03)
Male vs Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	27918 (22184, 35135)	24780 (20095, 30555)	1.13 (0.82, 1.54)
Male vs Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	25464 (20474, 31672)	23686 (19548, 28699)	1.08 (0.80, 1.44)
Male vs Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	47856 (39690, 57703)	40829 (34866, 47811)	1.17 (0.91, 1.50)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	127 (102, 159)	105 (86, 128)	1.21 (0.90, 1.63)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	226 (183, 279)	186 (151, 228)	1.22 (0.91, 1.63)
Male vs Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	31634 (20063, 49877)	36285 (26900, 48946)	0.87 (0.50, 1.51)
Male vs Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	35411 (22182, 56530)	32437 (24984, 42114)	1.09 (0.63, 1.88)
Male vs Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	71516 (48882, 104632)	65952 (51863, 83868)	1.08 (0.68, 1.72)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	132 (87, 201)	155 (112, 215)	0.85 (0.50, 1.45)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	220 (144, 335)	257 (191, 347)	0.85 (0.51, 1.43)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.00)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)
Male vs Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	13885 (9964, 19349)	13010 (8886, 19048)	1.07 (0.64, 1.77)
Male vs Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	15684 (11249, 21868)	12565 (9151, 17253)	1.25 (0.79, 1.98)
Male vs Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	19051 (14268, 25437)	20450 (15506, 26971)	0.93 (0.62, 1.40)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	53 (38, 75)	53 (35, 80)	1.00 (0.58, 1.71)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	116 (85, 158)	115 (81, 163)	1.01 (0.63, 1.61)
Male vs Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	413245 (313550, 544639)	401733 (305536, 528218)	1.03 (0.70, 1.52)
Male vs Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	1349730 (1058654, 1720836)	1055004 (863808, 1288519)	1.28 (0.93, 1.76)
Male vs Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	2494356 (2024007, 3074009)	2205314 (1838733, 2644980)	1.13 (0.86, 1.49)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1309 (1073, 1597)	1039 (851, 1267)	1.26 (0.95, 1.67)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	802 (702, 915)	778 (688, 880)	1.03 (0.86, 1.23)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	651471 (371844, 1141378)	912839 (634733, 1312797)	0.71 (0.36, 1.40)
Male vs Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2214099 (1404894, 3489396)	2526281 (1844631, 3459821)	0.88 (0.50, 1.53)
Male vs Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	4657377 (3318602, 6536236)	5360132 (4442120, 6467860)	0.87 (0.59, 1.29)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	1845 (1334, 2553)	1723 (1269, 2339)	1.07 (0.69, 1.67)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	911 (750, 1106)	1021 (828, 1258)	0.89 (0.67, 1.19)
Male vs Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Male vs Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	119308 (74464, 191160)	162718 (105337, 251358)	0.73 (0.39, 1.39)
Male vs Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	406550 (258451, 639512)	387612 (266416, 563942)	1.05 (0.57, 1.92)
Male vs Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	726888 (523093, 1010081)	711788 (506763, 999761)	1.02 (0.63, 1.65)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	604 (387, 942)	436 (277, 686)	1.38 (0.73, 2.61)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	566 (446, 718)	639 (515, 792)	0.89 (0.64, 1.22)

Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Hispanic or Latino ethnicity</b>							
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 11)	10 (10, 10)	1.02 (0.98, 1.06)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.98, 1.03)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.97, 1.07)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 6)	5 (5, 5)	1.06 (0.99, 1.14)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.97 (0.93, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	24842 (17659, 34948)	25133 (21020, 30051)	0.99 (0.67, 1.45)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	26916 (19291, 37557)	23223 (19715, 27356)	1.16 (0.80, 1.68)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	47660 (36353, 62485)	42894 (37567, 48975)	1.11 (0.82, 1.50)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	122 (84, 177)	109 (93, 129)	1.12 (0.75, 1.68)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	218 (154, 310)	197 (167, 233)	1.11 (0.75, 1.63)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	38184 (28133, 51824)	32689 (24048, 44436)	1.17 (0.76, 1.80)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	43441 (16695, 113035)	32493 (24434, 43211)	1.34 (0.49, 3.63)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	96930 (42595, 220574)	65428 (51624, 82923)	1.48 (0.63, 3.49)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	114 (76, 169)	148 (110, 198)	0.77 (0.47, 1.26)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	241 (116, 497)	248 (189, 325)	0.97 (0.45, 2.11)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.98, 1.04)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	9262 (3384, 25347)	13538 (10248, 17884)	0.68 (0.24, 1.95)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	11518 (5977, 22195)	13974 (10813, 18059)	0.82 (0.41, 1.67)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	23768 (13230, 42701)	19368 (15646, 23976)	1.23 (0.66, 2.30)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	51 (21, 123)	53 (39, 72)	0.95 (0.37, 2.43)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	170 (81, 354)	113 (87, 147)	1.49 (0.68, 3.26)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	426086 (277325, 654644)	402096 (321228, 503320)	1.06 (0.65, 1.72)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	1437790 (1007780, 2051282)	1106904 (926650, 1322221)	1.30 (0.87, 1.93)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	2142978 (1595637, 2878069)	2352728 (2014696, 2747477)	0.91 (0.65, 1.27)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1228 (918, 1642)	1087 (923, 1281)	1.13 (0.81, 1.58)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	814 (674, 982)	784 (708, 869)	1.04 (0.84, 1.29)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	513694 (174929, 1508508)	796506 (555972, 1141105)	0.64 (0.21, 2.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2840421 (1452662, 5553936)	2326321 (1720759, 3144990)	1.22 (0.58, 2.55)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	3551466 (1744682, 7229345)	5141985 (4186895, 6314945)	0.69 (0.33, 1.45)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2889 (2174, 3839)	1699 (1322, 2183)	1.70 (1.17, 2.47)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1146 (1010, 1300)	981 (846, 1138)	1.17 (0.96, 1.42)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.03 (0.97, 1.08)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	96806 (22163, 422848)	154261 (109458, 217402)	0.63 (0.14, 2.85)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	423379 (153088, 1170893)	403108 (300454, 540835)	1.05 (0.36, 3.03)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	1028368 (385239, 2745154)	694970 (544427, 887140)	1.48 (0.54, 4.07)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	435 (162, 1169)	477 (334, 683)	0.91 (0.32, 2.61)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	882 (700, 1110)	595 (503, 703)	1.48 (1.11, 1.97)

MOCK

Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Underrepresented minority status</b>							
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.02)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.03)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.05)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.97, 1.07)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.96, 1.09)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.02)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	23741 (19430, 29008)	26779 (21016, 34123)	0.89 (0.65, 1.21)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	25576 (21309, 30698)	24073 (19243, 30116)	1.06 (0.80, 1.42)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	43313 (36931, 50799)	44837 (37733, 53280)	0.97 (0.76, 1.22)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	109 (89, 132)	116 (93, 145)	0.93 (0.69, 1.25)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	205 (165, 254)	204 (165, 253)	1.00 (0.74, 1.36)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	38342 (25744, 57105)	32140 (21350, 48383)	1.19 (0.67, 2.11)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	40819 (28224, 59034)	29603 (19188, 45670)	1.38 (0.78, 2.44)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	80359 (56437, 114420)	64812 (45432, 92458)	1.24 (0.75, 2.05)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	170 (115, 252)	142 (96, 209)	1.20 (0.69, 2.08)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	236 (158, 353)	236 (164, 340)	1.00 (0.58, 1.72)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (1.00, 1.03)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	10301 (7085, 14976)	16332 (11301, 23603)	0.63 (0.37, 1.07)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	11593 (8642, 15552)	14167 (10126, 19819)	0.82 (0.52, 1.28)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	19791 (14900, 26287)	21729 (16518, 28584)	0.91 (0.61, 1.35)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	42 (28, 62)	69 (46, 102)	0.61 (0.35, 1.06)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	110 (76, 159)	121 (85, 172)	0.91 (0.55, 1.51)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	440291 (337736, 573987)	375305 (279792, 503424)	1.17 (0.79, 1.74)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	1235548 (995643, 1533259)	1145512 (909652, 1442528)	1.08 (0.79, 1.48)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	2151402 (1801329, 2569508)	2459185 (2019406, 2994737)	0.87 (0.67, 1.14)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1127 (922, 1377)	1125 (908, 1394)	1.00 (0.75, 1.34)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	814 (730, 908)	804 (714, 904)	1.01 (0.86, 1.19)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	707066 (402854, 1241003)	758610 (476254, 1208367)	0.93 (0.45, 1.93)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2687527 (1765786, 4090419)	2229169 (1492057, 3330433)	1.21 (0.67, 2.16)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	4469619 (3275038, 6099925)	5100285 (3772135, 6896069)	0.88 (0.57, 1.35)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	1780 (1303, 2432)	1594 (1095, 2320)	1.12 (0.69, 1.82)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1012 (853, 1201)	932 (742, 1172)	1.09 (0.82, 1.44)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.03)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	130463 (75585, 225185)	169965 (105036, 275030)	0.77 (0.37, 1.59)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	388216 (247326, 609362)	470592 (326087, 679136)	0.82 (0.46, 1.48)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	656306 (447692, 962131)	837482 (614121, 1142080)	0.78 (0.48, 1.28)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	462 (282, 759)	437 (268, 713)	1.06 (0.53, 2.12)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	469 (335, 655)	739 (608, 898)	0.63 (0.43, 0.93)

MOCK

Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Arm</b>							
Vaccine vs Placebo	Negative	-	Day 29	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID50	85.7% (82.1%, 88.7%)	91.3% (88%, 93.6%)	91.3% (88%, 93.6%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID80	90.5% (87.2%, 93%)	95.2% (92.2%, 96.9%)	95.2% (92.2%, 96.9%)
Vaccine vs Placebo	Positive	-	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID50	19.8% (9.8%, 29.3%)	17% (8.7%, 25.2%)	17.6% (9.3%, 25.9%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID80	4.2% (-3.5%, 11.6%)	3.5% (-2.9%, 9.9%)	4.6% (-2%, 11.3%)
Vaccine vs Placebo	Negative	-	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID50	97.8% (96.1%, 98.8%)	99% (97%, 99.5%)	99% (97%, 99.5%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID80	98.9% (97.2%, 99.6%)	99.1% (96.2%, 99.6%)	99.1% (96.2%, 99.6%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Vaccine vs Placebo	Positive	-	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID50	7.6% (0.8%, 13.8%)	2.9% (-3.2%, 8.2%)	2.9% (-3.2%, 8.2%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID80	-0.2% (-5.9%, 3%)	0.7% (0.1%, 3.8%)	0.7% (0.1%, 3.8%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Baseline SARS-CoV-2</b>							
Positive vs Negative	-	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID50	0.8% (-6.8%, 6.9%)	3% (-3%, 7.1%)	3% (-3%, 7.1%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID50	66.7% (58.6%, 73.9%)	77.2% (69.4%, 83.4%)	76.6% (68.8%, 82.9%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID80	1.4% (-5.4%, 6.3%)	0.3% (-5.4%, 3.9%)	0.3% (-5.4%, 3.9%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID80	87.7% (81.2%, 92.1%)	91.9% (85.9%, 95.4%)	90.9% (84.5%, 94.7%)
Positive vs Negative	-	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Positive vs Negative	-	Placebo	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID50	1.2% (-4.6%, 3.1%)	-0.2% (-5.9%, 1.5%)	-0.2% (-5.9%, 1.5%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID50	91.4% (85.3%, 95.1%)	95.9% (90.6%, 98.2%)	95.9% (90.6%, 98.2%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID80	0.1% (-5.6%, 2%)	0.5% (0.1%, 2.1%)	0.5% (0.1%, 2.1%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID80	99.3% (96.2%, 99.9%)	98.9% (95%, 99.6%)	98.9% (95%, 99.6%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.




Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Age</b>							
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	7.9% (3.2%, 13%)	6.2% (2.6%, 10.3%)	6.2% (2.6%, 10.3%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	1.8% (0.4%, 6.9%)	1.8% (0.4%, 6.9%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	7.3% (3.4%, 11.7%)	4.7% (2.1%, 8.1%)	4.7% (2.1%, 8.1%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0.9% (0.1%, 6.2%)	0.9% (0.1%, 6.2%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	11.6% (3.5%, 20.7%)	5.6% (-0.4%, 12.5%)	5.6% (-0.4%, 12.5%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	25.4% (14.2%, 36.3%)	17% (7.2%, 27.2%)	17.8% (7.9%, 28%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	8.1% (1.5%, 16%)	4.4% (-1.4%, 11.2%)	4.4% (-1.4%, 11.2%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	9.3% (1.4%, 17.7%)	3.8% (-3.4%, 11.7%)	5.1% (-2.3%, 13.3%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0.7% (-1.4%, 3.2%)	1% (0.4%, 2.9%)	1% (0.4%, 2.9%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0.9% (0.1%, 6.2%)	0.9% (0.1%, 6.2%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0.4% (-1.3%, 2.8%)	0.3% (-1.3%, 2.6%)	0.3% (-1.3%, 2.6%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.5% (-3.7%, -0.1%)	-0.5% (-3.7%, -0.1%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	1.2% (0.2%, 8.2%)	1.2% (0.2%, 8.2%)	1.2% (0.2%, 8.2%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	7.9% (1.3%, 15.6%)	4% (-0.7%, 10.5%)	4% (-0.7%, 10.5%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	1.2% (0.2%, 8.2%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0.1% (-3.8%, 4.7%)	0.1% (-3.8%, 4.7%)	0.1% (-3.8%, 4.7%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Risk for Severe Covid-19</b>							
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-0.7% (-6.1%, 5.2%)	0.4% (-4%, 5.2%)	0.4% (-4%, 5.2%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0.4% (-1.6%, 4.5%)	0.4% (-1.6%, 4.5%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	5.7% (1.4%, 10.6%)	2.7% (-0.3%, 6.6%)	2.7% (-0.3%, 6.6%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0.7% (0.1%, 4.8%)	0.7% (0.1%, 4.8%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	5.3% (-3.7%, 15.3%)	1.7% (-4.7%, 9.6%)	1.7% (-4.7%, 9.6%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	6.8% (-6.4%, 19.8%)	8.8% (-2.4%, 20.3%)	9.6% (-1.7%, 21.1%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	4.5% (-2.7%, 13.2%)	1.7% (-4.1%, 9.3%)	1.7% (-4.1%, 9.3%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	1.4% (-8.4%, 11.2%)	4.1% (-2.5%, 12.4%)	5.4% (-1.5%, 14.1%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-1.2% (-3.8%, 1.7%)	-0.1% (-2.1%, 2.4%)	-0.1% (-2.1%, 2.4%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.3% (-2.2%, 0%)	-0.3% (-2.2%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	-0.1% (-1.9%, 2.8%)	0.1% (-1.2%, 3.1%)	0.1% (-1.2%, 3.1%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	1.3% (0.2%, 8.8%)	1.3% (0.2%, 8.8%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	1.3% (0.2%, 8.6%)	1.3% (0.2%, 8.6%)	1.3% (0.2%, 8.6%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	6.1% (-1.3%, 14.5%)	2.5% (-4.3%, 9.7%)	2.5% (-4.3%, 9.7%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	1.3% (0.2%, 8.6%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	1% (0.2%, 5.1%)	1% (0.2%, 5.1%)	1% (0.2%, 5.1%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Age &lt; 65, Risk for Severe Covid-19</b>							
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-2% (-9.3%, 5.3%)	-0.4% (-6.4%, 5.6%)	-0.4% (-6.4%, 5.6%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	5.5% (-0.1%, 11.5%)	3% (-1.1%, 7.6%)	3% (-1.1%, 7.6%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	6.6% (-5.3%, 18.5%)	1.5% (-7.7%, 10.9%)	1.5% (-7.7%, 10.9%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	3.3% (-13.1%, 19.4%)	7.4% (-6.7%, 21.6%)	8.4% (-5.8%, 22.6%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	5.6% (-4.3%, 15.8%)	1.9% (-6.4%, 10.9%)	1.9% (-6.4%, 10.9%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-1% (-13.8%, 11.3%)	3.7% (-4.5%, 13.9%)	5.3% (-3.2%, 15.9%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-0.9% (-4.8%, 2.6%)	-0.5% (-3.7%, 2.5%)	-0.5% (-3.7%, 2.5%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	-0.1% (-3%, 3.4%)	0.2% (-2.1%, 3.7%)	0.2% (-2.1%, 3.7%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	2.1% (0.3%, 14.7%)	2.1% (0.3%, 14.7%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	1.5% (0.2%, 10.1%)	1.5% (0.2%, 10.1%)	1.5% (0.2%, 10.1%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	5.7% (-4.1%, 16%)	2.4% (-7%, 11.2%)	2.4% (-7%, 11.2%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	1.5% (0.2%, 10.1%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	1% (0.1%, 6.8%)	1% (0.1%, 6.8%)	1% (0.1%, 6.8%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age  $\geq 65$ , Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Age <math>\geq 65</math>, Risk for Severe Covid-19</b>							
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-5.1% (-10.3%, 0.2%)	-3.6% (-7.6%, 0.4%)	-3.6% (-7.6%, 0.4%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.2% (-11.6%, 9.8%)	-0.2% (-11.6%, 9.8%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	0.8% (-3.1%, 5%)	-1.8% (-4.7%, -0.7%)	-1.8% (-4.7%, -0.7%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	1.7% (0.2%, 11.6%)	1.7% (0.2%, 11.6%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	-6.2% (-17.7%, 3.4%)	-1.9% (-13%, -0.3%)	-1.9% (-13%, -0.3%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	3.9% (-10.6%, 14.9%)	4.2% (-8.9%, 13.8%)	4.2% (-8.9%, 13.8%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-3.8% (-14.5%, -0.9%)	-1.9% (-13%, -0.3%)	-1.9% (-13%, -0.3%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	3.5% (-11.6%, 12.2%)	3.5% (-11.6%, 12.2%)	3.5% (-11.6%, 12.2%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-3.1% (-6.4%, -1.4%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-1.9% (-13.2%, -0.2%)	-1.9% (-13.2%, -0.2%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	-0.4% (-3.4%, 2.8%)	-0.5% (-3.4%, -0.1%)	-0.5% (-3.4%, -0.1%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	3.6% (1.1%, 11%)	1% (0.1%, 7.1%)	1% (0.1%, 7.1%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	1% (0.1%, 7.1%)	1% (0.1%, 7.1%)	1% (0.1%, 7.1%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Sex</b>							
Male vs Female	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	5.1% (-1.5%, 11.5%)	2.6% (-2.8%, 8%)	2.6% (-2.8%, 8%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.8% (-3.2%, -0.2%)	-0.8% (-3.2%, -0.2%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	3% (-2.9%, 8.8%)	0.6% (-4.4%, 5%)	0.6% (-4.4%, 5%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.4% (-2.9%, -0.1%)	-0.4% (-2.9%, -0.1%)
Male vs Female	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0.3% (-12.8%, 12.5%)	-5.1% (-15.9%, 3.6%)	-5.1% (-15.9%, 3.6%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	8.4% (-7.2%, 23.1%)	11% (-2.6%, 24.2%)	12.1% (-1.7%, 25.2%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-3.7% (-15.6%, 6.7%)	-3.9% (-14.5%, 5%)	-3.9% (-14.5%, 5%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	7% (-4.2%, 17.8%)	3% (-7.1%, 12.9%)	4.8% (-5.6%, 15.3%)
Male vs Female	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	1.2% (-1.1%, 4.4%)	0.7% (-0.8%, 3.6%)	0.7% (-0.8%, 3.6%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.4% (-2.9%, -0.1%)	-0.4% (-2.9%, -0.1%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	-0.1% (-3.8%, 2.6%)	0.6% (-0.5%, 3.9%)	0.6% (-0.5%, 3.9%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0.8% (0.1%, 5.8%)	0.8% (0.1%, 5.8%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	1.8% (0.2%, 12%)	1.8% (0.2%, 12%)	1.8% (0.2%, 12%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	3.2% (-8.6%, 12.9%)	1.3% (-10%, 9.3%)	1.3% (-10%, 9.3%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	1.8% (0.2%, 12%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	1.3% (0.2%, 6.6%)	1.3% (0.2%, 6.6%)	1.3% (0.2%, 6.6%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Hispanic or Latino ethnicity</b>							
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-1.9% (-12.9%, 6.1%)	-1.6% (-12.1%, 4.7%)	-1.6% (-12.1%, 4.7%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	1.5% (-0.7%, 12.8%)	1.5% (-0.7%, 12.8%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	0.3% (-9.5%, 6.6%)	-0.3% (-8.8%, 4.1%)	-0.3% (-8.8%, 4.1%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.3% (-1.8%, 0%)	-0.3% (-1.8%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	14.9% (9.3%, 22.9%)	6.3% (3%, 12.8%)	6.3% (3%, 12.8%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	6.7% (-20.9%, 25.5%)	-2.5% (-30.4%, 15.7%)	-1.8% (-29.7%, 16.4%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-0.6% (-36.6%, 9.4%)	4% (1.6%, 9.8%)	4% (1.6%, 9.8%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-1.5% (-29.8%, 10.4%)	2.2% (-11.5%, 9.4%)	3.4% (-10.5%, 11.1%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	2.7% (1.5%, 4.8%)	1% (0.3%, 2.8%)	1% (0.3%, 2.8%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.3% (-1.8%, 0%)	-0.3% (-1.8%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0.7% (-2.7%, 2.9%)	0% (-3.4%, 2.3%)	0% (-3.4%, 2.3%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	3.2% (0.4%, 22.5%)	3.2% (0.4%, 22.5%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	1.1% (0.2%, 7.8%)	1.1% (0.2%, 7.8%)	1.1% (0.2%, 7.8%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	-1.6% (-32.4%, 9.5%)	4.6% (1.9%, 10.6%)	4.6% (1.9%, 10.6%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	1.1% (0.2%, 7.8%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0.1% (0%, 1%)	0.1% (0%, 1%)	0.1% (0%, 1%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Underrepresented minority status</b>							
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-2.4% (-8.9%, 4.3%)	-0.6% (-6.1%, 4.9%)	-0.6% (-6.1%, 4.9%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	1.3% (0.3%, 5.1%)	1.3% (0.3%, 5.1%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-1.6% (-7.8%, 4.8%)	-2.2% (-6.8%, 2.6%)	-2.2% (-6.8%, 2.6%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0.6% (0.1%, 4.6%)	0.6% (0.1%, 4.6%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	9.1% (-3.3%, 21.3%)	0% (-11.3%, 10.3%)	0% (-11.3%, 10.3%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	-9.5% (-24.5%, 6.4%)	-10.4% (-24.1%, 4.6%)	-12.3% (-26.3%, 2.9%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0.2% (-12.2%, 11.6%)	1.8% (-8.3%, 12%)	1.8% (-8.3%, 12%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-7.6% (-19.9%, 4.7%)	-3.6% (-14%, 8.2%)	-3.6% (-14%, 8.2%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0.3% (-3.4%, 3.7%)	0.2% (-2.8%, 3.4%)	0.2% (-2.8%, 3.4%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0.6% (0.1%, 4.6%)	0.6% (0.1%, 4.6%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0.1% (-1.1%, 1%)	-0.1% (-1.3%, 0.6%)	-0.1% (-1.3%, 0.6%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	1.2% (0.2%, 8.4%)	1.2% (0.2%, 8.4%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	2% (0.3%, 13.4%)	2% (0.3%, 13.4%)	2% (0.3%, 13.4%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	-6.2% (-18%, 6.3%)	-0.3% (-10.5%, 10.4%)	-0.3% (-10.5%, 10.4%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	2% (0.3%, 13.4%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	-2.4% (-11.9%, -0.4%)	-2.4% (-11.9%, -0.4%)	-2.4% (-11.9%, -0.4%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Negative							
		Vaccine				Placebo			
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	898 13258/13258 = 100.0% (100.0%, 100.0%)	26107 (22373, 30465)	159 0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	2610.75 (2237.32, 3046.50)		
Day 29	Anti RBD IgG (IU/ml)	898 13258/13258 = 100.0% (100.0%, 100.0%)	24448 (21197, 28198)	159 0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	2444.84 (2119.70, 2819.85)		
Day 29	Anti Spike IgG (IU/ml)	898 13258/13258 = 100.0% (100.0%, 100.0%)	43768 (38849, 49310)	159 0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	4376.78 (3884.86, 4930.98)		
Day 29	Pseudovirus-nAb ID50	898 12154/13258 = 91.7% (88.6%, 94.0%)	114 (99, 132)	159 55.9/13373 = 0.4% (0.1%, 1.6%)	5 (5, 5)	91.3% (88%, 93.6%)	22.78 (19.66, 26.39)		
Day 29	Pseudovirus-nAb ID80	898 12643.4/13258 = 95.4% (92.7%, 97.1%)	202 (174, 235)	159 27.9/13373 = 0.2% (0.0%, 1.5%)	5 (5, 5)	95.2% (92.2%, 96.9%)	40.37 (34.82, 46.81)		
Day 57	Anti N IgG (IU/ml)	898 13258/13258 = 100.0% (100.0%, 100.0%)	406732 (334856, 494036)	159 0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	40673.18 (33485.59, 49403.57)		
Day 57	Anti RBD IgG (IU/ml)	898 13258/13258 = 100.0% (100.0%, 100.0%)	1175125 (1006818, 1371568)	159 0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	117512.53 (100681.79, 137156.82)		
Day 57	Anti Spike IgG (IU/ml)	898 13258/13258 = 100.0% (100.0%, 100.0%)	2327458 (2030732, 2667541)	159 0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	232745.84 (203073.24, 266754.13)		
Day 57	Pseudovirus-nAb ID50	898 13151.9/13258 = 99.2% (97.7%, 99.7%)	1149 (997, 1324)	159 27.9/13373 = 0.2% (0.0%, 1.5%)	5 (5, 5)	99% (97%, 99.5%)	229.46 (199.10, 264.45)		
Day 57	Pseudovirus-nAb ID80	898 13195.3/13258 = 99.5% (97.9%, 99.9%)	788 (721, 863)	159 52.3/13373 = 0.4% (0.1%, 2.8%)	5 (5, 5)	99.1% (96.2%, 99.6%)	157.18 (143.64, 171.99)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Positive								
		Vaccine				Placebo				Comparison
		N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR	
Day 29	Anti N IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	34038 (26144, 44315)	265	1286/1286 = 100.0% (100.0%, 100.0%)	13376 (10324, 17330)	0% (0%, 0%)	2.54 (1.76, 3.68)	
Day 29	Anti RBD IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	33791 (26156, 43654)	265	1286/1286 = 100.0% (100.0%, 100.0%)	13810 (10985, 17362)	0% (0%, 0%)	2.45 (1.74, 3.45)	
Day 29	Anti Spike IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	68490 (55297, 84829)	265	1286/1286 = 100.0% (100.0%, 100.0%)	19842 (16261, 24211)	0% (0%, 0%)	3.45 (2.58, 4.62)	
Day 29	Pseudovirus-nAb ID50	282	1359.8/1436 = 94.7% (89.2%, 97.5%)	144 (111, 187)	265	990.9/1286 = 77.1% (69.3%, 83.3%)	53 (40, 70)	17.6% (9.3%, 25.9%)	2.71 (1.86, 3.96)	
Day 29	Pseudovirus-nAb ID80	282	1373.7/1436 = 95.7% (90.2%, 98.1%)	239 (186, 308)	265	1171.4/1286 = 91.1% (84.9%, 94.9%)	115 (90, 147)	4.6% (-2%, 11.3%)	2.08 (1.46, 2.95)	
Day 57	Anti N IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	780035 (564199, 1078440)	265	1286/1286 = 100.0% (100.0%, 100.0%)	142567 (103139, 197068)	0% (0%, 0%)	5.47 (3.46, 8.65)	
Day 57	Anti RBD IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	2375650 (1816163, 3107493)	265	1286/1286 = 100.0% (100.0%, 100.0%)	395570 (298709, 523841)	0% (0%, 0%)	6.01 (4.07, 8.86)	
Day 57	Anti Spike IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	5020291 (4174972, 6036763)	265	1286/1286 = 100.0% (100.0%, 100.0%)	718182 (566932, 909785)	0% (0%, 0%)	6.99 (5.18, 9.43)	
Day 57	Pseudovirus-nAb ID50	282	1422.1/1436 = 99.0% (93.4%, 99.9%)	1779 (1424, 2224)	265	1236/1286 = 96.1% (91.0%, 98.4%)	501 (363, 691)	2.9% (-3.2%, 8.2%)	3.55 (2.40, 5.26)	
Day 57	Pseudovirus-nAb ID80	282	1436/1436 = 100.0% (100.0%, 100.0%)	968 (838, 1118)	265	1276.5/1286 = 99.3% (96.2%, 99.9%)	606 (517, 712)	0.7% (0.1%, 3.8%)	1.60 (1.29, 1.98)	

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)

Visit	Marker	Vaccine Recipients						Comparison	
		Baseline SARS-CoV-2 Positive			Baseline SARS-CoV-2 Negative				
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/ GMCR		
Day 29	Anti N IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	34038 (26144, 44315)	898	13258/13258 = 100.0% (100.0%, 100.0%)	26107 (22373, 30465)	0% (0%, 0%)	1.30 (0.96, 1.77)
Day 29	Anti RBD IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	33791 (26156, 43654)	898	13258/13258 = 100.0% (100.0%, 100.0%)	24448 (21197, 28198)	0% (0%, 0%)	1.38 (1.03, 1.85)
Day 29	Anti Spike IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	68490 (55297, 84829)	898	13258/13258 = 100.0% (100.0%, 100.0%)	43768 (38849, 49310)	0% (0%, 0%)	1.56 (1.22, 2.00)
Day 29	Pseudovirus-nAb ID50	282	1359.8/1436 = 94.7% (89.2%, 97.5%)	144 (111, 187)	898	12154/13258 = 91.7% (88.6%, 94.0%)	114 (99, 132)	3% (-3%, 7.1%)	1.26 (0.94, 1.70)
Day 29	Pseudovirus-nAb ID80	282	1373.7/1436 = 95.7% (90.2%, 98.1%)	239 (186, 308)	898	12643.4/13258 = 95.4% (92.7%, 97.1%)	202 (174, 235)	0.3% (-5.4%, 3.9%)	1.18 (0.88, 1.58)
Day 57	Anti N IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	780035 (564199, 1078440)	898	13258/13258 = 100.0% (100.0%, 100.0%)	406732 (334856, 494036)	0% (0%, 0%)	1.92 (1.31, 2.80)
Day 57	Anti RBD IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	2375650 (1816163, 3107493)	898	13258/13258 = 100.0% (100.0%, 100.0%)	1175125 (1006818, 1371568)	0% (0%, 0%)	2.02 (1.48, 2.76)
Day 57	Anti Spike IgG (IU/ml)	282	1436/1436 = 100.0% (100.0%, 100.0%)	5020291 (4174972, 6036763)	898	13258/13258 = 100.0% (100.0%, 100.0%)	2327458 (2030732, 2667541)	0% (0%, 0%)	2.16 (1.71, 2.71)
Day 57	Pseudovirus-nAb ID50	282	1422.1/1436 = 99.0% (93.4%, 99.9%)	1779 (1424, 2224)	898	13151.9/13258 = 99.2% (97.7%, 99.7%)	1149 (997, 1324)	-0.2% (-5.9%, 1.5%)	1.55 (1.19, 2.02)
Day 57	Pseudovirus-nAb ID80	282	1436/1436 = 100.0% (100.0%, 100.0%)	968 (838, 1118)	898	13195.3/13258 = 99.5% (97.9%, 99.9%)	788 (721, 863)	0.5% (0.1%, 2.1%)	1.23 (1.04, 1.45)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 12. Antibody levels in the per-protocol cohort (placebo recipients)

Visit	Marker	Placebo Recipients							
		Baseline SARS-CoV-2 Positive				Baseline SARS-CoV-2 Negative		Comparison	
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	265 1286/1286 = 100.0% (100.0%, 100.0%)	13376 (10324, 17330)	159	0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	1337.58 (1032.38, 1732.99)	
Day 29	Anti RBD IgG (IU/ml)	265 1286/1286 = 100.0% (100.0%, 100.0%)	13810 (10985, 17362)	159	0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	1381.00 (1098.48, 1736.19)	
Day 29	Anti Spike IgG (IU/ml)	265 1286/1286 = 100.0% (100.0%, 100.0%)	19842 (16261, 24211)	159	0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	1984.17 (1626.12, 2421.05)	
Day 29	Pseudovirus-nAb ID50	265 990.9/1286 = 77.1% (69.3%, 83.3%)	53 (40, 70)	159	55.9/13373 = 0.4% (0.1%, 1.6%)	5 (5, 5)	76.6% (68.8%, 82.9%)	10.59 (8.04, 13.96)	
Day 29	Pseudovirus-nAb ID80	265 1171.4/1286 = 91.1% (84.9%, 94.9%)	115 (90, 147)	159	27.9/13373 = 0.2% (0.0%, 1.5%)	5 (5, 5)	90.9% (84.5%, 94.7%)	22.99 (18.05, 29.29)	
Day 57	Anti N IgG (IU/ml)	265 1286/1286 = 100.0% (100.0%, 100.0%)	142567 (103139, 197068)	159	0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	14256.67 (10313.86, 19706.76)	
Day 57	Anti RBD IgG (IU/ml)	265 1286/1286 = 100.0% (100.0%, 100.0%)	395570 (298709, 523841)	159	0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	39557.03 (29870.89, 52384.06)	
Day 57	Anti Spike IgG (IU/ml)	265 1286/1286 = 100.0% (100.0%, 100.0%)	718182 (566932, 909785)	159	0/13373 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	71818.25 (56693.21, 90978.46)	
Day 57	Pseudovirus-nAb ID50	265 1236/1286 = 96.1% (91.0%, 98.4%)	501 (363, 691)	159	27.9/13373 = 0.2% (0.0%, 1.5%)	5 (5, 5)	95.9% (90.6%, 98.2%)	100.00 (72.45, 138.01)	
Day 57	Pseudovirus-nAb ID80	265 1276.5/1286 = 99.3% (96.2%, 99.9%)	606 (517, 712)	159	52.3/13373 = 0.4% (0.1%, 2.8%)	5 (5, 5)	98.9% (95%, 99.6%)	120.89 (102.96, 141.95)	

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

## Chapter 2

# Graphical Description of Immunogenicity Data

### 2.1 Pairs plots of antibody markers for overall per-protocol cohort

### 2.1.1 Baseline SARS-CoV-2 Negative




Figure 2.1: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.2: Pair plots of D57 Ab markers: baseline negative vaccine arm

D29 Fold-rise over D1 Ab markers: baseline negative, vaccine arm




Figure 2.3: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.4: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.5: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm




Figure 2.6: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm

## PsV Neutralization 50% Titer: baseline negative vaccine arm




Figure 2.7: Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm




Figure 2.8: Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm

### 2.1.2 Baseline SARS-CoV-2 Positive




Figure 2.9: Pair plots of D29 Ab markers: baseline positive vaccine arm




Figure 2.10: Pair plots of D57 Ab markers: baseline positive vaccine arm

D29 Fold-rise over D1 Ab markers: baseline positive, vaccine arm




Figure 2.11: Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.12: Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.13: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm




Figure 2.14: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm

## PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.15: Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.16: Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline positive vaccine arm

## 2.2 RCDF plots of antibody markers for overall per-protocol cohort




Figure 2.17: RCDF plots for D29 Ab markers: by baseline status x randomization arm




Figure 2.18: RCDF plots for D57 Ab markers: by baseline status x randomization arm




Figure 2.19: RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.20: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.21: RCDF plots for D29 Ab markers: by baseline status for the vaccine arm




Figure 2.22: RCDF plots for D57 Ab markers: by baseline status for the vaccine arm




Figure 2.23: RCDF plots for D29 over D1 fold-rise Ab markers: by baseline status for the vaccine arm




Figure 2.24: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status for the vaccine arm




Figure 2.25: RCDF plots for D29 Ab markers: baseline negative vaccine arm




Figure 2.26: RCDF plots for D57 Ab markers: baseline negative vaccine arm




Figure 2.27: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.28: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.29: RCDF plots for D29 Ab markers: baseline positive vaccine arm




Figure 2.30: RCDF plots for D57 Ab markers: baseline positive vaccine arm




Figure 2.31: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.32: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm

## 2.3 Scatter plots of antibody markers versus age for overall per-protocol cohort

### 2.3.1 Baseline SARS-CoV-2 negative




Figure 2.33: Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT445




Figure 2.34: Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm

### 2.3.2 Baseline SARS-CoV-2 positive




Figure 2.35: Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT447




Figure 2.36: Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm

## 2.4 Box plots of antibody markers for overall per-protocol cohort

### 2.4.1 Baseline SARS-CoV-2 negative




Figure 2.37: Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms




Figure 2.38: Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms




Figure 2.39: Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms




Figure 2.40: Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms

### 2.4.2 Baseline SARS-CoV-2 positive




Figure 2.41: Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms




Figure 2.42: Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms




Figure 2.43: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms




Figure 2.44: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms

### 2.4.3 Baseline negative vs. positive vaccine recipients




Figure 2.45: Boxplots of D29 Ab markers: baseline positive + negative vaccine arm




Figure 2.46: Boxplots of D57 Ab markers: baseline positive + negative vaccine arm




Figure 2.47: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm




Figure 2.48: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm

#### 2.4.4 Baseline negative vs. positive placebo recipients




Figure 2.49: Boxplots of D29 Ab markers: baseline positive + negative placebo arm




Figure 2.50: Boxplots of D57 Ab markers: baseline positive + negative placebo arm




Figure 2.51: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm




Figure 2.52: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm

## 2.5 Spaghetti plots of antibody markers over time for the overall per-protocol cohort

### 2.5.1 Baseline SARS-CoV-2 negative




Figure 2.53: Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm

## 2.5. SPAGHETTI PLOTS OF ANTIBODY MARKERS OVER TIME FOR THE OVERALL PER-PROTOCOL COHORT40

### 2.5.2 Baseline SARS-CoV-2 positive




Figure 2.54: Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm

## 2.6 RCDF plots of antibody markers by demographics for per-protocol cohort

### 2.6.1 Baseline SARS-CoV-2 negative




Figure 2.55: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT467




Figure 2.56: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.57: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT469




Figure 2.58: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.59: RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT471




Figure 2.60: RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.61: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT473




Figure 2.62: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.63: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.64: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.65: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT477




Figure 2.66: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.67: RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.68: RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.69: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT481




Figure 2.70: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.71: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT483




Figure 2.72: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.73: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT485




Figure 2.74: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.




Figure 2.75: RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT487




Figure 2.76: RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.77: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT489




Figure 2.78: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.79: RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT491




Figure 2.80: RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.




Figure 2.81: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT493




Figure 2.82: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.




Figure 2.83: RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT495




Figure 2.84: RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.85: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT497




Figure 2.86: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.87: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT499




Figure 2.88: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.89: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT501




Figure 2.90: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

### 2.6.2 Baseline SARS-CoV-2 positive




Figure 2.91: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT503




Figure 2.92: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.93: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT505




Figure 2.94: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.95: RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT507




Figure 2.96: RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.97: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT509




Figure 2.98: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.99: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT511




Figure 2.100: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.101: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT513




Figure 2.102: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.103: RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT515




Figure 2.104: RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.105: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT517




Figure 2.106: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.107: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT519




Figure 2.108: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.109: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT521




Figure 2.110: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.111: RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT523




Figure 2.112: RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.113: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT525




Figure 2.114: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.115: RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT527




Figure 2.116: RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.




Figure 2.117: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT529




Figure 2.118: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.119: RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.120: RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.121: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT533




Figure 2.122: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.123: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT535




Figure 2.124: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.125: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT537




Figure 2.126: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

## 2.7 Boxplots of antibody markers by demographics for per-protocol cohort

### 2.7.1 Baseline SARS-CoV-2 negative




Figure 2.127: Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT539




Figure 2.128: Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.




Figure 2.129: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT541




Figure 2.130: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.131: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT543




Figure 2.132: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.




Figure 2.133: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT545




Figure 2.134: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.




Figure 2.135: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT547




Figure 2.136: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.137: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT549




Figure 2.138: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

**2.7.2 Baseline SARS-CoV-2 positive**

MOCK

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT551




Figure 2.139: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.




Figure 2.140: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT553




Figure 2.141: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.142: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT555




Figure 2.143: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.144: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT557




Figure 2.145: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.146: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT559




Figure 2.147: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.148: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT561




Figure 2.149: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.150: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT563




Figure 2.151: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.152: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT565




Figure 2.153: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.154: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT567




Figure 2.155: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.156: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.